Endo International (ENDPQ) 8-K 2 Jun 15 2014 FY Other Events Financial data

Document_And_Entity_Informatio

Document And Entity Information	12 Months Ended
	Dec. 31, 2014
Document And Entity Information [Abstract]
Document Type	8-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ENDP
Entity Registrant Name	ENDO INTERNATIONAL PLC
Entity Central Index Key	1593034
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash and cash equivalents	$408,753	$526,597
Restricted cash and cash equivalents	530,930	770,000
Marketable securities	815	0
Accounts receivable, net of allowance of $60 and $707 at December 31, 2014 and 2013, respectively	1,126,078	614,726
Inventories, net	423,321	324,327
Prepaid expenses and other current assets	38,680	34,407
Income taxes receivable	51,846	0
Deferred income taxes	561,974	255,433
Assets held for sale	1,937,864	2,113,134
Total current assets	5,080,261	4,638,624
MARKETABLE SECURITIES	1,506	2,979
PROPERTY, PLANT AND EQUIPMENT, NET	387,703	326,874
GOODWILL	2,899,587	565,994
OTHER INTANGIBLES, NET	2,333,193	947,466
DEFERRED INCOME TAXES	5,059	0
OTHER ASSETS	202,307	89,919
TOTAL ASSETS	10,909,616	6,571,856
CURRENT LIABILITIES:
Accounts payable	297,484	250,636
Accrued expenses	1,149,545	718,693
Current portion of legal settlement accrual	1,443,114	215,644
Current portion of long-term debt	155,937	414,929
Income taxes payable	0	3,089
Deferred income taxes	22	0
Liabilities related to assets held for sale	103,338	149,253
Total current liabilities	3,149,440	1,752,244
DEFERRED INCOME TAXES	677,740	259,092
LONG-TERM DEBT, LESS CURRENT PORTION, NET	4,202,356	3,323,844
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION, NET	262,781	508,482
OTHER LIABILITIES	209,086	142,978
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized; 4,000,000 issued	48	0
Ordinary shares, $0.0001 and $0.01 par value; 1,000,000,000 and 350,000,000 shares authorized; 153,912,985 and 144,413,074 shares issued; 153,912,985 and 115,354,393 shares outstanding at December 31, 2014 and December 31, 2013, respectively	15	1,444
Additional paid-in capital	3,093,867	1,166,375
(Accumulated deficit) retained earnings	-595,085	126,234
Accumulated other comprehensive loss	-124,088	-4,915
Treasury stock, zero and 29,058,681 shares at December 31, 2014 and December 31, 2013, respectively	0	-763,120
Total Endo Health Solutions Inc. stockholders’ equity	2,374,757	526,018
Noncontrolling interests	33,456	59,198
Total stockholders’ equity	2,408,213	585,216
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$10,909,616	$6,571,856

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$60	$707
Euro deferred shares, par value (in dollars per share)	$0.01
Euro deferred shares, shares authorized	4,000,000
Euro deferred shares, shares issued	4,000,000
Ordinary shares, par value (in dollars per share)	$0.00
Ordinary shares, shares authorized	1,000,000,000
Ordinary shares, shares issued	153,912,985
Ordinary shares, shares outstanding	153,912,985
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued		144,413,074
Common stock, shares outstanding		115,354,393
Treasury stock, shares	0	29,058,681

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
TOTAL REVENUES	$2,380,683	$2,124,681	$2,311,249
COSTS AND EXPENSES:
Cost of revenues	1,231,497	886,603	973,045
Selling, general and administrative	567,986	574,313	598,948
Research and development	112,708	97,465	161,365
Patent litigation settlement, net	0	0	85,123
Litigation-related and other contingencies, net	42,084	9,450	224,425
Asset impairment charges	22,542	32,011	72,551
Acquisition-related and integration items	77,384	7,614	18,432
OPERATING INCOME FROM CONTINUING OPERATIONS	326,482	517,225	177,360
INTEREST EXPENSE, NET	227,114	173,606	182,815
LOSS ON EXTINGUISHMENT OF DEBT	31,817	11,312	7,215
OTHER INCOME, NET	-32,324	-53,059	-621
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAX	99,875	385,366	-12,049
INCOME TAX	38,267	143,742	38,822
INCOME (LOSS) FROM CONTINUING OPERATIONS	61,608	241,624	-50,871
DISCONTINUED OPERATIONS, NET OF TAX	-779,792	-874,038	-637,150
CONSOLIDATED NET LOSS	-718,184	-632,414	-688,021
Less: Net income attributable to noncontrolling interests	3,135	52,925	52,316
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	($721,319)	($685,339)	($740,337)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations, basic (usd per share)	$0.42	$2.13	($0.44)
Discontinued operations, basic (usd per share)	($5.33)	($8.18)	($5.96)
Basic (usd per share)	($4.91)	($6.05)	($6.40)
Continuing operations, diluted (usd per share)	$0.40	$2.02	($0.44)
Discontinued operations, diluted (usd per share)	($5)	($7.74)	($5.96)
Diluted (usd per share)	($4.60)	($5.72)	($6.40)
WEIGHTED AVERAGE SHARES:
Basic (shares)	146,896	113,295	115,719
Diluted (shares)	156,730	119,829	115,719

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
CONSOLIDATED NET LOSS	($718,184)	($632,414)	($688,021)
Net unrealized (loss) gain on securities:
Unrealized (loss) gain arising during the period	-1,099	775	1,403
Less: reclassification adjustments for loss realized in net loss	17	0	0
Less: reclassification adjustments for loss realized in net loss	-1,082	775	1,403
Foreign currency translation (loss) gain	-121,389	714	2,164
Fair value adjustment on derivatives designated as cash flow hedges:
Fair value adjustment on derivatives designated as cash flow hedges arising during the period		546	-1,212
Less: reclassification adjustments for cash flow hedges settled and included in net loss	0	-148	279
Less: reclassification adjustments for cash flow hedges settled and included in net income (loss)	0	398	-933
OTHER COMPREHENSIVE (LOSS) INCOME	-122,471	1,887	2,634
CONSOLIDATED COMPREHENSIVE LOSS	-840,655	-630,527	-685,387
Less: Net income attributable to noncontrolling interests	3,135	52,925	52,316
Less: Other comprehensive (loss) income attributable to noncontrolling interests	-3,298	0	0
COMPREHENSIVE LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	($840,492)	($683,452)	($737,703)

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (USD $)	Total	Ordinary Shares	Euro Deferred Shares	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Total Endo Health Solutions Inc. Stockholders' Equity	Noncontrolling Interests
In Thousands, except Share data, unless otherwise specified
Stockholders' equity, beginning balance at Dec. 31, 2011	$2,039,591	$1,383		$952,325	$1,551,910	($9,436)	($518,492)	$1,977,690	$61,901
Shares, beginning balance at Dec. 31, 2011		138,337,002					21,178,122
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	-688,021				-740,337			-740,337	52,316
Other comprehensive income (loss)	2,634					2,634		2,634
Compensation related to stock-based awards	59,395			59,395				59,395
Forfeiture of restricted stock awards, shares		-19,624
Exercise of options, shares	853,794	853,794
Exercise of options	19,358	8		19,350				19,358
Tax benefits of stock awards	2,537			2,537				2,537
Ordinary shares issued, shares		869,710
Ordinary shares issued	478	9		469				478
Treasury stock acquired, shares							-8,304,330
Treasury stock acquired	-256,000						-256,000	-256,000
Issuance of ordinary shares from treasury, shares							235,425
Issuance of ordinary shares from treasury	6,062						6,062	6,062
Distributions to noncontrolling interests	-53,269								-53,269
Buy-out of noncontrolling interests, net	-598								-598
Other	1,039			1,039				1,039
Stockholders' equity, ending balance at Dec. 31, 2012	1,133,206	1,400		1,035,115	811,573	-6,802	-768,430	1,072,856	60,350
Shares, ending balance at Dec. 31, 2012		140,040,882					29,247,027
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	-632,414				-685,339			-685,339	52,925
Other comprehensive income (loss)	1,887					1,887		1,887
Compensation related to stock-based awards	38,998			38,998				38,998
Forfeiture of restricted stock awards, shares		-12,191
Exercise of options, shares	3,836,560	3,836,560
Exercise of options	97,129	39		97,090				97,129
Tax benefits of stock awards	4,265			4,265				4,265
Ordinary shares issued, shares		547,823
Ordinary shares issued	268	5		263				268
Tax withholding for restricted shares	-9,781			-9,781				-9,781
Issuance of ordinary shares from treasury, shares	188,374						188,346
Issuance of ordinary shares from treasury	5,310						5,310	5,310
Distributions to noncontrolling interests	-52,711								-52,711
Buy-out of noncontrolling interests, net	-1,366								-1,366
Other	425			425				425
Stockholders' equity, ending balance at Dec. 31, 2013	585,216	1,444		1,166,375	126,234	-4,915	-763,120	526,018	59,198
Shares, ending balance at Dec. 31, 2013		144,413,074					29,058,681
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	-718,184				-721,319			-721,319	3,135
Other comprehensive income (loss)	-122,471					-119,173		-119,173	-3,298
Compensation related to stock-based awards	32,671			32,671				32,671
Forfeiture of restricted stock awards, shares		-3,298
Exercise of options, shares	1,528,295	1,528,295
Exercise of options	41,392	4		41,388				41,392
Tax benefits of stock awards	33,531			33,531				33,531
Ordinary shares issued, shares		36,235,228
Ordinary shares issued	2,844,366	17		2,844,349				2,844,366
Euro deferred shares issued, shares			4,000,000
Euro deferred shares issued	55		55
Tax withholding for restricted shares	-25,081			-25,081				-25,081
Issuance of ordinary shares from treasury, shares	75,450
Distributions to noncontrolling interests	-5,291								-5,291
Buy-out of noncontrolling interests, net	-1,729								-1,729
Addition of Paladin noncontrolling interests due to acquisition	38,800								38,800
Removal of HealthTronics, Inc. noncontrolling interests due to disposition	-57,359								-57,359
Result of contribution of Endo Health Solutions Inc. to Endo International plc, shares		29,058,681					29,058,681
Result of contribution of Endo Health Solutions Inc. to Endo International plc	0	-1,450		-761,670			763,120
Repurchase of convertible senior subordinated notes due 2015, shares		798,367
Repurchase of convertible senior subordinated notes due 2015	-309,829			-309,829				-309,829
Settlement of common stock warrants	-284,454			-284,454				-284,454
Settlement of the hedge on convertible senior subordinated notes due 2015	356,265			356,265				356,265
Other	315		-7	322				315
Stockholders' equity, ending balance at Dec. 31, 2014	$2,408,213	$15	$48	$3,093,867	($595,085)	($124,088)	$0	$2,374,757	$33,456
Shares, ending balance at Dec. 31, 2014		153,912,985	4,000,000				0

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES:
Consolidated net loss	($718,184)	($632,414)	($688,021)
Adjustments to reconcile consolidated net loss to Net cash provided by operating activities:
Depreciation and amortization	331,651	255,663	285,524
Inventory step-up	65,582	0	880
Share-based compensation	32,671	38,998	59,395
Amortization of debt issuance costs and premium / discount	29,086	36,264	36,699
Provision for bad debts	165	3,495	3,402
Deferred income taxes	-275,123	-155,727	-193,960
Net loss on disposal of property, plant and equipment	2,626	2,571	50
Loss on extinguishment of debt	31,817	11,312	7,215
Asset impairment charges	22,542	680,198	768,467
Gain on sale of business and other assets	-8,780	-2,665	0
Changes in assets and liabilities which (used) provided cash:
Accounts receivable	-341,404	-80,195	40,395
Inventories	42,346	-29,286	-96,318
Prepaid and other assets	51,895	-22,509	18,942
Accounts payable	-96,361	-159,532	142,609
Accrued expenses	1,549,749	-167,107	424,340
Other liabilities	-302,251	487,625	-809
Income taxes payable/receivable	-80,251	31,826	-74,931
Net cash provided by operating activities	337,776	298,517	733,879
INVESTING ACTIVITIES:
Purchases of property, plant and equipment	-80,425	-96,483	-99,818
Proceeds from sale of property, plant and equipment	174	1,857	1,426
Acquisitions, net of cash acquired	-1,086,510	-3,645	-3,175
Proceeds from sale of marketable securities and investments	87,233	0	18,800
Proceeds from notes receivable	32,659	0	0
Increase in notes receivable	-35,400	0	0
Patent acquisition costs and license fees	-5,000	-12,000	-5,700
Proceeds from sale of business, net	54,521	8,150	0
Proceeds from / (payments to) settlement escrow	11,518	-11,518	0
Increase in restricted cash and cash equivalents	-633,173	-770,000	0
Decrease in restricted cash and cash equivalents	869,936	0	0
Other investing activities	12,614	0	0
Net cash used in investing activities	-771,853	-883,639	-88,467
FINANCING ACTIVITIES:
Proceeds from issuance of notes	750,000	700,000	0
Proceeds from issuance of term loans	1,525,000	0	0
Principal payments on term loans	-1,430,144	-152,032	-362,075
Principal payments on other indebtedness, net	-7,588	-3,447	-1,824
Repurchase of convertible senior subordinated notes due 2015	-587,803	0	0
Payments to settle ordinary share warrants	-284,454	0	0
Proceeds from the settlement of the hedge on convertible senior subordinated notes due 2015	356,265	0	0
Deferred financing fees	-62,715	-10,475	0
Payment for contingent consideration	0	-5,000	0
Tax benefits of share awards	35,188	12,017	4,949
Payments of tax withholding for restricted shares	-25,081	-9,781	0
Exercise of options	41,392	97,129	19,358
Payments related to the issuance of ordinary shares	-4,800	0	-256,000
Issuance of ordinary shares related to the employee stock purchase plan	4,617	5,310	6,062
Cash distributions to noncontrolling interests	-5,291	-52,711	-53,269
Cash buy-out of noncontrolling interests	-1,729	-1,485	-2,748
Net cash provided by (used in) financing activities	302,857	579,525	-645,547
Effect of foreign exchange rate	-4,037	1,692	431
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-135,257	-3,905	296
LESS: NET DECREASE IN CASH AND CASH EQUIVALENTS OF DISCONTINUED OPERATIONS	-17,413	-813	-2,749
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS	-117,844	-3,092	3,045
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	526,597	529,689	526,644
CASH AND CASH EQUIVALENTS, END OF PERIOD	408,753	526,597	529,689
SUPPLEMENTAL INFORMATION:
Cash paid for interest	159,492	128,452	152,097
Cash paid for income taxes	36,356	70,160	192,647
Cash paid into Qualified Settlement Funds for mesh legal settlements	585,165	54,500	0
Cash paid out of Qualified Settlement Funds for mesh legal settlements	111,454	42,982	0
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchases of property, plant and equipment financed by capital leases	4,784	497	1,373
Purchase of property, plant and equipment financed by direct financing arrangement	0	0	57,008
Accrual for purchases of property, plant and equipment	11,397	8,351	12,237
Acquisition financed by ordinary shares	2,844,279	0	0
Repurchase of convertible senior subordinated notes due 2015 financed by ordinary shares	$55,229	$0	$0

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1. DESCRIPTION OF BUSINESS
	The accompanying Consolidated Financial Statements of Endo International plc have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP). In prior periods, our Consolidated Financial Statements presented the accounts of Endo Health Solutions Inc., was incorporated under the laws of the State of Delaware on November 18, 1997, and all of its subsidiaries (EHSI). Endo International plc was incorporated in Ireland on October 31, 2013 as a private limited company and re-registered effective February 18, 2014 as a public limited company. It was established for the purpose of facilitating the business combination between EHSI and Paladin Labs Inc. (Paladin). On February 28, 2014, we became the successor registrant of EHSI and Paladin in connection with the consummation of certain transactions further described elsewhere in our Consolidated Financial Statements. In addition, on February 28, 2014, the shares of Endo International plc began trading on the NASDAQ under the symbol “ENDP,” the same symbol under which EHSI’s shares previously traded, and on the Toronto Stock Exchange under the symbol “ENL”. References throughout to “ordinary shares” refer to EHSI’s common shares, 350,000,000 authorized, par value $0.01 per share, prior to the consummation of the transactions and to Endo International plc’s ordinary shares, 1,000,000,000 authorized, par value $0.0001 per share, subsequent to the consummation of the transactions. In addition, on February 11, 2014 the Company issued 4,000,000 euro deferred shares of $0.01 each at par.
	References throughout to “Endo”, the “Company”, “we”, “our” or “us” refer to financial information and transactions of Endo Health Solutions Inc. prior to February 28, 2014 and Endo International plc thereafter.
	Endo International plc is an Ireland-domiciled, global specialty healthcare company focused on branded and generic pharmaceuticals. Our goal is to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of branded and generic drugs to meet patients’ needs.
	On February 3, 2014, we acquired Boca Pharmacal LLC (Boca), a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions. On May 19, 2014, we acquired worldwide rights to Sumavel® DosePro® (Sumavel) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. On July 24, 2014, the Company, together with its Endo Netherlands B.V. subsidiary (Endo Dutch B.V.), purchased the entirety of the representative shares of the capital stock of Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable (Somar), a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico. On August 6, 2014, our Generics International (US), Inc. subsidiary acquired DAVA Pharmaceuticals, Inc. (DAVA), a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals based in Fort Lee, New Jersey. On December 9, 2014, we acquired the rights to Natesto™ (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.
	On February 24, 2015, the Board of Directors approved a plan to sell the Company’s AMS business, which comprises the entirety of our former Devices segment. Subsequently, the Company entered into a definitive agreement to sell the Men’s Health and Prostate Health components of the AMS business to Boston Scientific Corporation. The Company is currently pursuing a sale of the Women’s Health component of the AMS business. In addition, we previously divested two operating divisions of HealthTronics, its image guided radiation therapy (IGRT) in 2011 and it’s anatomical pathology laboratory business in the third quarter of 2013. On December 28, 2013 our Board of Directors approved a plan to sell the remainder of the HealthTronics business, in its entirety. On February 3, 2014, we completed the sale of HealthTronics. Refer to Note 3. Discontinued Operations for additional information.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Consolidation and Basis of Presentation—The Consolidated Financial Statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. Certain prior period amounts have been reclassified to conform to the current period presentation.
	The Company owns majority controlling interests in certain entities. Additionally, prior to the sale of our HealthTronics business in February 2014, HealthTronics, Inc. owned interests in various partnerships and limited liability corporations where HealthTronics, Inc., as the general partner or managing member, exercised effective control. In accordance with the accounting consolidation principles, we consolidate various entities which neither we nor our subsidiaries own 100%. For additional information relating to the sale of HealthTronics, see Note 3. Discontinued Operations.
	Use of Estimates—The preparation of our Consolidated Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition and sales deductions for estimated chargebacks, rebates, sales incentives and allowances, certain royalties, distribution service fees, returns and allowances. Significant estimates and assumptions are also required when determining the fair value of certain financial instruments, the valuation of long-lived and indefinite-lived assets, income taxes, contingencies and share-based compensation. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Our estimates often are based on complex judgments, probabilities and assumptions that we believe to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by us, there may also be other estimates or assumptions that are reasonable.
	We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our Consolidated Financial Statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations.
	Customer, Product and Supplier Concentration—We primarily sell our products directly to a limited number of large pharmacy chains and through a limited number of wholesale drug distributors who, in turn, supply products to pharmacies, hospitals, governmental agencies and physicians. Total revenues from customers who accounted for 10% or more of our total consolidated revenues during the years ended December 31 are as follows:
		2014			2013		2012
	Cardinal Health, Inc.	21	%		26	%	30	%
	McKesson Corporation	31	%		32	%	32	%
	AmerisourceBergen Corporation	16	%		19	%	15	%
	Revenues from these customers are included within our U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals segments.
	The Company derives a majority of its total revenues from a limited number of products. Products that accounted for 10% or more of our total revenues during the years ended December 31 were as follows:
		2014			2013		2012
	Lidoderm®	7	%		28	%	41	%
	Opana® ER	8	%		11	%	13	%
	We have agreements with Novartis Consumer Health, Inc., Novartis AG, Teikoku Seiyaku Co., Ltd., Noramco, Inc., Grünenthal GmbH and Sharp Corporation for the manufacture and supply of a substantial portion of our existing pharmaceutical products. Additionally, we utilize UPS Supply Chain Solutions, Inc. for certain customer service support, warehouse and distribution services. See Note 14. Commitments and Contingencies for further information.
	Revenue Recognition—
	Pharmaceutical Products
	Our net pharmaceutical product sales consist of revenues from sales of our pharmaceutical products, less estimates for chargebacks, rebates, sales incentives and allowances, certain royalties, distribution service fees, returns and allowances as well as fees for services (collectively, revenue reserves which are classified as accrued expenses). Net pharmaceutical product sales also include sales of certain medical devices from our International Pharmaceuticals segment. We recognize revenue for product sales when title and risk of loss has passed to the customer, which is typically upon delivery to the customer, when estimated provisions for revenue reserves are reasonably determinable, and when collectability is reasonably assured. Revenue from the launch of a new or significantly unique product, for which we are unable to develop the requisite historical data on which to base estimates of returns and allowances due to the uniqueness of the therapeutic area or delivery technology as compared to other products in our portfolio and in the industry, may be deferred until such time that an estimate can be determined, all of the conditions above are met and when the product has achieved market acceptance, which is typically based on dispensed prescription data and other information obtained prior to and during the period following launch.
	Devices
	A portion of our revenue is generated from consigned inventory or from inventory with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to our customers providing there are no remaining performance obligations required from us or any matters requiring customer acceptance. In cases where we utilize distributors or ship product directly to the end user, we recognize revenue upon shipment provided all revenue recognition criteria have been met. We record estimated sales returns, discounts and rebates as a reduction of net sales in the period the related revenue is recognized.
	We provide incentives to customers, including volume based rebates. Customers are not required to provide documentation that would allow us to reasonably estimate the fair value of the benefit received and we do not receive an identifiable benefit in exchange for the consideration. Accordingly, the incentives are recorded as a reduction of revenue.
	Our AMS customers have rights of return for the occasional ordering or shipping error. We maintain an allowance for these returns and reduce reported revenue for expected returns from shipments during each reporting period. This allowance is based on historical and current trends in product returns.
	The operating results of this business segment are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	Other
	Product royalties received from third party collaboration partners and licensees of our products and patents are recorded as other revenues. Royalties are recognized as earned in accordance with the contract terms when royalties from third parties can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.
	Services
	Until it was sold on February 3, 2014, our HealthTronics business’ fees for urology and pathology services were recorded when the procedure was performed and were based on contracted rates. Management fees from our HealthTronics, Inc. limited partnerships were recorded monthly when earned. The operating results of this business segment are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	Sales Deductions—When we recognize net sales from the sale of our pharmaceutical products, we record an adjustment to revenue for estimated revenue reserves. These provisions are estimated based on historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our wholesale and indirect customers and other competitive factors. If the assumptions we used to calculate these adjustments do not appropriately reflect future activity, our financial position, results of operations and cash flows could be materially impacted.
	Research and Development—Expenditures for research and development are expensed as incurred. In addition to upfront and milestone payments, total R&D expenses include the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, as well as clinical trials, medical support of marketed products, other payments under third-party collaborations and contracts and other costs. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for research and development activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Upfront and milestone payments made to third parties in connection with agreements with third parties are generally expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are generally capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.
	Cash and Cash Equivalents—The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2014, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances. The Company maintains its cash deposits and cash equivalents with well-known and stable financial institutions.
	Restricted Cash and Cash Equivalents—Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted cash and cash equivalents in the Consolidated Balance Sheets. At December 31, 2014, restricted cash and cash equivalents totaled $530.9 million, of which $485.2 million is held in Qualified Settlement Funds for mesh product liability settlement agreements and $40.2 million is held in an escrow account, primarily for the purpose of guaranteeing amounts required to be paid to Litha Healthcare Group Limited’s (Litha) security holders in connection with acquisition of Litha’s remaining outstanding issued share capital. The restricted cash related to Qualified Settlement Funds are for payments related to the Company’s vaginal mesh liability. See Note 14. Commitments and Contingencies for further information relating to the vaginal mesh liability. At December 31, 2013, restricted cash and cash equivalents consisted of $700.0 million from the proceeds of the issuance of the New 2022 Notes and $70.0 million of additional cash. At December 31, 2013, the proceeds of the issuance of the New 2022 Notes and the additional $70.0 million were restricted and held in escrow and could not be utilized by the Company until the Paladin transaction closed.
	Marketable Securities—The Company has equity securities, which consist of investments in the stock of publicly traded companies. For additional information see Note 7. Fair Value Measurements.
	Accounts Receivable—Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information.
	Concentrations of Credit Risk—Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, marketable debt securities and accounts receivable. We invest our excess cash in high-quality, liquid money market instruments maintained by major U.S. banks and financial institutions. We have not experienced any losses on our cash equivalents.
	We perform ongoing credit evaluations of our customers and generally do not require collateral. We have no history of significant losses from uncollectible accounts. Approximately 76% and 78% of our trade accounts receivable balance represent amounts due from three customers at December 31, 2014 and 2013, respectively.
	We do not expect our current or future credit risk exposures to have a significant impact on our operations. However, there can be no assurance that our business will not experience any adverse impact from credit risk in the future.
	Inventories—Inventories consist of finished goods held for distribution, raw materials and work-in-process. Our inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other Assets in the Consolidated Balance Sheets.
	Property, plant and equipment—Property, plant and equipment is stated at cost less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction is in progress. Depreciation is computed over the estimated useful life of the related assets on a straight-line basis. Leasehold improvements and capital lease assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the terms of their respective leases. Depreciation is not recorded on assets held for sale. Gains and losses on disposals are included in Other income, net in the Consolidated Statements of Operations.
	Depreciation is based on the following estimated useful lives, as of December 31, 2014:
		Range of Useful Lives, from:
	Buildings	8 years		to	45 years
	Machinery and equipment	2 years		to	20 years
	Leasehold improvements	2 years		to	9 years
	Computer equipment and software	2 years		to	10 years
	Assets under capital lease	Shorter of useful life or lease term
	Furniture and fixtures	2 years		to	10 years
	Computer Software—The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and amortized beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
	Lease Accounting—The Company accounts for operating lease transactions by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.
	Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated in a manner similar to other Property, plant and equipment.
	Certain construction projects may be accounted for as direct financing arrangements, whereby the Company records, over the construction period, the full cost of the asset in Property, plant and equipment, net in the Consolidated Balance Sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by the Company, and is amortized over the expected lease term through monthly rental payments using an effective interest method. Assets recorded under direct financing arrangements are depreciated over the lease term.
	License Rights—The cost of licenses are either expensed immediately or, if capitalized, are stated at cost, less accumulated amortization and are amortized using the straight-line method over their estimated useful lives ranging from 3 years to 15 years, with a weighted average useful life of approximately 9 years. We determine amortization periods for licenses based on our assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the expected launch date of the product, the strength of the intellectual property protection of the product and various other competitive, developmental and regulatory issues, and contractual terms. Amortization expense is not recorded on assets held for sale.
	Customer Relationships—Acquired customer relationships are recorded at fair value upon acquisition. All customer relationship assets relate to our AMS business and are classified as Assets held for sale in the Consolidated Balance Sheets. Amortization expense is not recorded on assets held for sale.
	Trade names—Acquired trade names are recorded at fair value upon acquisition and, if deemed to have definite lives, are amortized using estimated useful lives ranging from 12 years to 15 years for our intangibles relating to continuing operations, with a weighted average useful life of approximately 15 years. We determine amortization periods for trade names based on our assessment of various factors impacting estimated useful lives and cash flows from the acquired assets. Such factors include the strength of the trade name and our plans regarding the future use of the trade name. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.
	Developed Technology—Acquired developed technology is recorded at fair value upon acquisition and amortized using estimated useful lives ranging from 3 years to 20 years for our intangibles relating to continuing operations, with a weighted average useful life of approximately 13 years. We determine amortization periods for developed technology based on our assessment of various factors impacting estimated useful lives and cash flows of the acquired assets. Such factors include the strength of the intellectual property protection of the product and various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale. The value of these assets is subject to continuing scientific, medical and marketplace uncertainty.
	Long-Lived Asset Impairment Testing—Long-lived assets, which include property, plant and equipment and definite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying amount of the asset exceeds the undiscounted future cash flows generated by that asset and the carrying amount is not considered recoverable, an impairment exists. An impairment loss is measured as the excess of the asset’s carrying amount over its fair value. An impairment loss is recognized in net income in the period that the impairment occurs.
	In-Process Research and Development Assets (IPR&D)—The fair value of IPR&D acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Future cash flows are predominately based on the net income forecast of each project, consistent with historical pricing, margins and expense levels of similar products. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying patent. In determining the fair value of each research project, expected cash flows are adjusted for the technical and regulatory risk of completion.
	IPR&D is initially capitalized and considered indefinite-lived intangible assets subject to annual impairment reviews. The reviews, which occur annually or more frequently upon the occurrence of certain events, requires the determination of the fair value of the respective intangible assets. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are amortized over the expected useful lives.
	Goodwill—Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis, as of October 1st of each year or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment model permits, and we utilize, a two-step method for determining goodwill impairment. In the first step, we determine the fair value of our reporting units using an appropriate valuation methodology. If the net book value of a reporting unit exceeds its fair value, we would then perform the second step of the impairment test which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations. Any residual fair value is allocated to goodwill. An impairment charge is recognized only when the implied fair value of our reporting unit’s goodwill is less than its carrying amount.
	Contingencies—The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Contingent accruals are recorded with a corresponding charge to Litigation-related and other contingencies, net in the Consolidated Statements of Operations when the Company determines that a loss is both probable and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our assessments involve significant judgment regarding future events. The Company records a receivable from its product liability insurance carriers only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable.
	Convertible Senior Subordinated Notes—We accounted for the issuance of our 1.75% Convertible Senior Subordinated Notes due April 2015 (the Convertible Notes) in accordance with the guidance regarding the accounting for convertible debt instruments that may be settled in cash upon conversion, which among other items, specifies that contracts issued or held by an entity that are both (1) indexed to the entities own ordinary shares and (2) classified in shareholders’ equity in its statement of financial position are not considered to be derivative financial instruments if the appropriate provisions are met. Accordingly, we have recorded the Convertible Notes as debt in the Consolidated Balance Sheets.
	Convertible Notes Hedge & Warrants—Concurrent with the issuance of the Convertible Notes we entered into privately negotiated ordinary share call options with affiliates of the initial purchasers. In addition, we sold warrants to affiliates of certain of the initial purchasers. In addition to entering into the convertible note hedge transaction and the warrant transaction, we entered into a privately negotiated, accelerated share repurchase agreement with the same counterparty, as part of our broader share repurchase program described in Note 16. Shareholders' Equity. We accounted for the call options, warrants, and accelerated share repurchase agreement in accordance with the guidance regarding the accounting derivative financial instruments indexed to, and potentially settled in, a company’s own stock. The call options, warrants, and accelerated share repurchase agreement meet the requirements to be accounted for as equity instruments. The cost of the call options and the proceeds related to the sale of the warrants are included in Additional paid-in capital in the Consolidated Balance Sheets.
	Treasury Stock—Treasury stock consists of shares of Endo International plc that have been issued but subsequently reacquired. We account for treasury stock purchases under the cost method. In accordance with the cost method, we account for the entire cost of acquiring our ordinary shares as treasury stock, which is a contra equity account. When these shares are reissued, we use an average cost method for determining cost. Proceeds in excess of cost are then credited to Additional paid-in capital in the Consolidated Balance Sheets.
	Advertising Costs—Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations and amounted to $28.1 million, $31.6 million and $36.0 million for the years ended December 31, 2014, 2013 and 2012, respectively.
Cost of Revenues—Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. It includes purchasing and receiving costs, direct and indirect costs to manufacture products, including direct materials, direct labor, and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods. Cost of revenues also includes royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation, amortization of intangible assets, warehousing costs, freight charges, costs to operate our equipment, and other shipping and handling activity.
Share-Based Compensation—The Company accounts for its share-based compensation plans in accordance with FASB Codification Topic 718, Stock Compensation. Accordingly, share-based compensation for employees and non-employee directors is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs.
Foreign Currency Translation—The financial statements for operations outside the U.S. are maintained primarily in their local currency. All assets and liabilities of our international subsidiaries are translated to U.S. dollars at year-end exchange rates, while elements of the Consolidated Statements of Operations are translated at average exchange rates in effect during the year. Translation adjustments arising from the use of differing exchange rates are included in Accumulated other comprehensive income (loss) in shareholders’ equity with the exception of inter-company balances not considered permanently invested which are included in Other income, net in the Consolidated Statements of Operations. Gains and losses on foreign currency transactions are also included in Other income, net.
Income Taxes—Provisions for income taxes are calculated on reported pre-tax income based on current tax laws, statutory tax rates and available tax incentives and planning opportunities in various jurisdictions in which we operate. Such provisions differ from the amounts currently receivable or payable because certain items of income and expense are recognized in different time periods for financial reporting purposes than for income tax purposes. We recognize deferred taxes by the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for differences between the financial statement and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Significant judgment is required in determining income tax provisions and evaluating tax positions. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The factors used to assess the likelihood of realization are the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings.
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Comprehensive Income—Comprehensive income includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.
Segment Information— The Company operates in three reportable segments. These segments are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals and (3) International Pharmaceuticals. A summary of our total revenues to external customers and adjusted income before income tax for each of our segments is found in Note 6. Segment Results.
Recent Accounting Pronouncements
In April 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of an Entity” (ASU 2014-08). ASU 2014-08 changes the requirements for reporting discontinued operations by limiting discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The disclosure requirements for discontinued operations under ASU 2014-08 will be expanded in order to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. ASU 2014-08 is effective on a prospective basis for (1) all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years, and (2) all businesses that are classified as held for sale on acquisition that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years. We have applied the provisions of ASU 2014-08 to our AMS business. Refer to Note 3. Discontinued Operations.
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim reporting periods within that reporting period. Early adoption is not permitted. Accordingly, the Company will adopt this ASU on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this ASU. The Company is currently evaluating the impact of ASU 2014-09 on the Company’s consolidated results of operations and financial position.
In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (ASU 2014-15). This ASU states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company plans to adopt ASU 2014-15 in conjunction with the December 31, 2016 financial statements and will comply with the disclosure requirements of the standard in the Form 10-K for the period ended December 31, 2016.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 3. DISCONTINUED OPERATIONS
	American Medical Systems
	On February 24, 2015, the Board of Directors approved a plan to sell the Company’s AMS business, which comprises the entirety of our former Devices segment. Subsequently, the Company entered into a definitive agreement to sell the Men’s Health and Prostate Health components of the AMS business to Boston Scientific Corporation (Boston Scientific) for up to $1.65 billion, with $1.60 billion in upfront cash. The Company is also eligible to receive a potential milestone payment of $50.0 million in cash conditioned on Boston Scientific achieving certain product revenue milestones in the Men’s Health and Prostate Health components in 2016. In addition, Boston Scientific will pay $60.0 million in exchange for 60,000 shares of Series B Non-Voting Preferred Stock issued by American Medical Systems Holdings, Inc. The preferred stock entitles the holder to dividends payable quarterly at an initial annual rate of 7.25%, which will increase by 0.25% each year on January 1, from 2018 until the rate equals 11.50%. While the preferred stock remains outstanding, American Medical Systems Holdings, Inc. will be subject to certain affirmative and negative covenants, including an obligation to maintain assets in excess of the liquidation preference of the preferred stock, and restrictions on the sale of assets and the incurrence of certain indebtedness. The preferred stock matures and becomes mandatorily redeemable in 2035.
	The transaction with Boston Scientific is expected to close in the third quarter of 2015, subject to customary conditions, including the expiration or termination of any applicable waiting periods under applicable competition laws. In addition, the Company is currently pursuing a sale of the Women’s Health component of the AMS business.
	The majority of the assets and liabilities of the AMS business, previously known as the Devices segment, are classified as held for sale in the Consolidated Balance Sheets. Certain of AMS’s assets and liabilities, primarily with respect to its product liability accrual for all known pending and estimated future claims related to vaginal mesh cases, the related Qualified Settlement Funds and certain intangible and fixed assets, are not classified as held for sale based on management’s current expectation that these assets and liabilities will remain with the Company subsequent to sale. Depreciation and amortization expense are not recorded on assets held for sale. The operating results of this business are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. While the Company is retaining the liability for all known pending and estimated future claims related to vaginal mesh cases related to products sold prior to the sale date, the Company is pursuing the sale of the underlying vaginal mesh products to a third party and thus the litigation expense and legal defense costs specifically attributable to the vaginal mesh cases has been included in Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	As described further in Note 10. Goodwill and Other Intangibles, as part of the 2014 goodwill impairment test, we determined that a market approach was appropriate as the primary valuation methodology for our AMS reporting unit based on bids related to expressions of interest from third parties for our AMS business, which began during the third quarter of 2014. The results of our 2014 Step I analyses showed the fair value of the AMS business unit exceeded its respective carrying amount.
	The results of the 2013 Step I analysis for the AMS reporting unit showed that the fair values of that reporting unit was lower than its carrying amount, thus requiring a Step II analysis for the reporting unit. The declines in the fair value, as well as fair value changes for other assets and liabilities in the Step II goodwill impairment test, resulted in an implied fair value of goodwill below the carrying amount of the goodwill for the reporting unit. Accordingly, we recorded combined pre-tax non-cash goodwill impairment charges in the Consolidated Statements of Operations totaling $481.0 million in 2013.
	The result of the 2012 Step I analysis for the AMS reporting unit showed that the fair value of that reporting unit was lower than its respective carrying amount, thus requiring a Step II analysis for the reporting unit. The decline in the fair value, as well as fair value changes for other assets and liabilities in the Step II goodwill impairment test, resulted in an implied fair value of goodwill below the carrying amount of the goodwill for the reporting unit. Accordingly, we recorded a pre-tax non-cash goodwill impairment charge in the Consolidated Statements of Operations totaling $507.5 million in 2012.
	A summary of significant other intangible asset impairment charges for the AMS business for the three years ended December 31, 2014 is included below.
	As a result of the 2013 Step II analysis, we also determined that the carrying amounts of certain AMS IPR&D intangible assets were impaired. This determination was based primarily on lower than initially expected revenue and profitability levels over a sustained period of time and downward revisions to management’s short-term and long-term forecasts. Accordingly, during 2013 we recorded pre-tax non-cash impairment charges of $12.0 million to impair the IPR&D assets, representing the difference between the fair values and the carrying amounts. Of this $12.0 million impairment charge, approximately $6.0 million was related to assets included as continuing operations in the Consolidated Balance Sheets and was recorded as Asset impairment charges in the Consolidated Statements of Operations.
	As a result of the 2012 Step II analysis, we also determined that the carrying amounts of the women's health developed technology intangible asset and one of the AMS IPR&D intangible assets were impaired. This determination was based primarily on lower than initially expected revenue and profitability levels over a sustained period of time and downward revisions to management's short-term and long-term forecasts for the AMS women's health product line. Accordingly, we recorded a pre-tax non-cash impairment charge of $128.5 million to impair the women's health developed technology intangible asset in its entirety.
	The following table provides the operating results of the Discontinued operations of AMS, net of tax for the three years ended December 31 (in thousands):
		2014			2013			2012
	Revenue	$	496,505		$	492,226		$	504,487
	Litigation-related expense and other contingencies, net	1,273,358			474,792			92,000
	Loss from discontinued operations before income taxes	(1,225,576		)	(944,933		)	(718,374		)
	Income taxes	(440,107		)	(167,809		)	(75,237		)
	Discontinued operations, net of tax	$	(785,469	)	$	(777,124	)	$	(643,137	)
	The following table provides the components of Assets and Liabilities held for sale as of December 31, 2014 and 2013 (in thousands):
		December 31, 2014			December 31, 2013
	Current assets	$	165,075		$	168,760
	Property, plant and equipment	41,122			45,203
	Goodwill	862,960			806,838
	Other intangibles, net	861,174			925,460
	Other assets	7,533			6,616
	Assets held for sale	$	1,937,864		$	1,952,877
	Current liabilities	$	53,143		$	62,110
	Deferred income taxes	46,538			51,671
	Other liabilities	3,657			3,901
	Liabilities held for sale	$	103,338		$	117,682
	The following table provides the Depreciation and amortization and Purchases of property, plant and equipment of AMS for the three years ended December 31 (in thousands):
		2014			2013			2012
	Cash flows from discontinued operating activities:
	Net loss	$	(785,469	)	$	(777,124	)	$	(643,137	)
	Depreciation and amortization	70,275			72,003			84,089
	Cash flows from discontinued investing activities:
	Purchase of property, plant and equipment	$	(4,423	)	$	(3,517	)	$	(5,271	)
	HealthTronics
	On December 28, 2013, the Board approved a plan to sell the HealthTronics business and the Company entered into a definitive agreement to sell the business on January 9, 2014 to Altaris Capital Partners LLC for an upfront cash payment of $85.0 million, subject to cash and other working capital adjustments. As of December 31, 2014, we are entitled to receive additional cash payments of $4.7 million from the purchaser of HealthTronics. In addition, as of December 31, 2014, EHSI has rights to additional cash payments of up to $30.0 million based on the operating performance of HealthTronics through December 31, 2015, for total potential consideration of up to $119.7 million. The sale was completed on February 3, 2014. Additional cash payments, if any, will be recorded when earned.
	As previously disclosed, prior to the sale, at September 30, 2013, the Company had determined that a sale of the HealthTronics business was more-likely-than-not to occur over the next twelve months. Accordingly, the Company initiated an interim goodwill impairment analysis of the HealthTronics reporting units’ goodwill balances as of September 30, 2013. The fair value of the Urology Services and HealthTronics Information Technology Solutions (HITS) reporting units were estimated using a number of factors including the fair value implied by the then ongoing sales process and previously prepared discounted cash flow analyses. As a result of this analysis, the Company determined that the net book value of both our Urology Services reporting unit and our HITS reporting unit exceeded their estimated fair value. The Company prepared a preliminary analysis to estimate the amount of an impairment charge as of September 30, 2013 and determined that an impairment was probable and reasonably estimable. The preliminary fair value assessments were performed by the Company taking into consideration a number of factors including the preliminary results of a hypothetical purchase price allocation. As a result of the preliminary analysis, the Company recorded a combined estimated goodwill impairment charge of $38.0 million during the three months ended September 30, 2013, representing the difference between the estimated implied fair value of the HealthTronics reporting units’ goodwill and their respective net book values. The Company finalized the impairment analysis in the fourth quarter of 2013 when it recorded charges of $118.9 million to write down the book value of the reporting units’ assets to fair value less costs to sell. Subsequently, during the year ended December 31, 2014, the Company has recorded a net gain of approximately $3.6 million, representing the carrying amount of the assets sold less the amount of the net proceeds, including the $4.7 million described above.
	In addition, the results of the Company’s 2012 Step I analyses for the Anatomical Pathology Services and HITS reporting units showed that the fair values of those reporting units were lower than their respective carrying amounts, thus requiring a Step II analysis for each reporting unit. The declines in these fair values, as well as fair value changes for other assets and liabilities in the Step II goodwill impairment test, resulted in an implied fair value of goodwill below the carrying amount of the goodwill for these reporting units. Accordingly, we recorded combined pre-tax non-cash goodwill impairment charges in the Consolidated Statements of Operations totaling $49.9 million in 2012.
	Until it was sold on February 3, 2014, the assets of this business, previously known as the HealthTronics segment, and related liabilities were classified as held for sale in the Consolidated Balance Sheet. Depreciation and amortization expense were not recorded on assets held for sale. The operating results of this business are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. Financial results are only related to disposed of or to-be-disposed of businesses.
	The following table provides the operating results of Discontinued operations of HealthTronics, net of tax for the three years ended December 31(in thousands):
		2014			2013			2012
	Revenue	$	14,443		$	207,194		$	211,627
	Income (loss) from discontinued operations before income taxes	$	6,434		$	(119,690	)	$	(11,160	)
	Income taxes	757			(22,776		)	(17,147		)
	Discontinued operations, net of tax	$	5,677		$	(96,914	)	$	5,987
	There were no Assets and Liabilities held for sale relating to HealthTronics included in the Consolidated Balance Sheet as of December 31, 2014. The following table provides the components of Assets and Liabilities held for sale as of December 31, 2013 (in thousands):
		31-Dec-13
	Current assets	$	69,131
	Property, plant and equipment	23,461
	Goodwill and other intangibles, net	58,761
	Other assets	8,904
	Assets held for sale	$	160,257
	Current liabilities	$	27,656
	Long term debt, less current portion, net	3,354
	Other liabilities	561
	Liabilities held for sale	$	31,571
	The table above does not include noncontrolling interests related to HealthTronics of $59.2 million as of December 31, 2013.
	The operating, investing and financing cash flows from the HealthTronics business are presented in a single reconciling line item in the Consolidated Statement of Cash Flows.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring	NOTE 4. RESTRUCTURING
	June 2013 Restructuring Initiative
	On June 4, 2013, the Board approved certain strategic, operational and organizational steps for the Company and its subsidiaries to take to refocus its operations and enhance shareholder value. These actions were the result of a comprehensive assessment of the Company’s strengths and challenges, its cost structure and execution capabilities, and its most promising opportunities to drive future cash flow and earnings growth. The cost reduction initiatives included a reduction in headcount of approximately 15% worldwide, streamlining of general and administrative expenses, optimizing commercial spend and refocusing research and development efforts.
	As a result of the June 2013 restructuring initiative, the Company incurred restructuring expenses of $2.1 million during the year ended December 31, 2014, consisting of $1.2 million of employee severance and other benefit-related costs and $0.9 million of other costs associated with the restructuring. During the year ended December 31, 2013, the Company incurred restructuring expenses of $56.3 million, consisting of $41.4 million of employee severance and other benefit-related costs, $12.0 million of other costs associated with the restructuring, mainly contract termination fees and $2.8 million of asset impairment charges. The Company does not anticipate there will be additional material pre-tax restructuring expenses related to this initiative. The majority of these restructuring costs, with the exception of the costs related to AMS and HealthTronics, are included in Selling, general and administrative expense in the Consolidated Statements of Operations. The operating results of AMS and HealthTronics are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	A summary of expenses related to the June 2013 restructuring initiatives is included below by reportable segment and for corporate unallocated for the year ended December 31, 2013 (in thousands):
		Employee Severance and Other Benefit-Related Costs			Asset Impairment Charges			Other Restructuring Costs			Total
	U.S. Branded Pharmaceuticals	$	22,847		$	2,849		$	8,780		$	34,476
	U.S. Generic Pharmaceuticals	262			—			1,142			1,404
	Discontinued operations (NOTE 3)	9,905			—			2,044			11,949
	Corporate unallocated	8,421			—			—			8,421
	Total	$	41,435		$	2,849		$	11,966		$	56,250
	A summary of the liability balance related to the June 2013 restructuring initiative is included below for the years ended December 31, 2014 and December 31, 2013 (in thousands):
		Employee Severance and Other Benefit-Related Costs			Other Restructuring Costs			Total
	Liability balance as of December 31, 2012	$	—		$	—		$	—
	Expenses	41,435			11,966			53,401
	Cash distributions	(34,056		)	(6,076		)	(40,132		)
	Other non-cash adjustments	—			(971		)	(971		)
	Liability balance as of December 31, 2013	$	7,379		$	4,919		$	12,298
	Expenses	$	1,224		$	880		$	2,104
	Cash distributions	(7,320		)	(4,453		)	(11,773		)
	Other non-cash adjustments	—			(1,191		)	(1,191		)
	Liability balance as of December 31, 2014	$	1,283		$	155		$	1,438
	Other Restructuring Initiatives
	During the last three years, the Company and certain of its subsidiaries undertook certain other restructuring initiatives that were individually not material to the Company’s Consolidated Financial Statements for any of the periods presented. On an aggregate basis, the Company recorded charges related to these initiatives totaling $21.2 million for the year ended December 31, 2014, which primarily consisted of employee severance and other benefit-related costs. The Company recorded charges related to these initiatives totaling $10.3 million during the year ended December 31, 2013, which primarily related to employee severance and other benefit-related costs, accelerated depreciation and asset impairment charges. Additionally, the Company recognized lease-exit costs of $7.8 million during the first quarter of 2013 upon the cease use dates of our Chadds Ford, Pennsylvania and Westbury, New York properties, consisting of our remaining obligations under the respective lease agreements. During the year ended December 31, 2012, the Company recorded $43.6 million related to these initiatives, primarily related to employee severance and other benefit-related costs. The majority of these costs are included in Selling, general and administrative expense in the Consolidated Statements of Operations.
	The liability related to these initiatives totaled $15.6 million and $16.1 million at December 31, 2014 and 2013, respectively. The majority of this liability is included in Accrued expenses in the Consolidated Balance Sheets. The change in the liability relates primarily to cash payments made during 2014, partially offset by the recognition of the expenses mentioned in the preceding paragraph.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions	NOTE 5. ACQUISITIONS
	For each of the acquisitions described below, the estimated fair values of the net assets acquired below are provisional as of December 31, 2014 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements. Accordingly, the measurement of the assets acquired and liabilities assumed may change upon finalization of the Company’s valuations and completion of the purchase price allocations, all of which are expected to occur no later than one year from the respective acquisition dates.
	Paladin Labs Inc. Acquisition
	On February 28, 2014 (the Paladin Acquisition Date) EHSI acquired all of the shares of Paladin and a subsidiary of ours merged with and into EHSI, with EHSI surviving the merger. As a result of these transactions, the former shareholders of EHSI and Paladin became the shareholders of Endo International plc, a public limited company organized under the laws of Ireland, and both EHSI and Paladin became our indirect wholly-owned subsidiaries.
	Under the terms of the transaction, former Paladin shareholders received 1.6331 shares of Endo International plc stock, or approximately 35.5 million shares, and C$1.16 in cash, for total consideration of $2.87 billion as of February 28, 2014. On the Paladin Acquisition Date, each then current EHSI shareholder received one ordinary share of Endo International plc for each share of EHSI common stock owned upon closing. Immediately following the closing of the transaction, former EHSI shareholders owned approximately 79% of Endo International plc, and former Paladin shareholders owned approximately 21%.
	The acquisition consideration was as follows (in thousands of U.S. dollars, except for per share amounts):
	Number of Paladin shares paid through the delivery of Endo International ordinary shares	20,765
	Exchange ratio	1.6331
	Number of ordinary shares of Endo International—as exchanged*	33,912
	Endo International ordinary share price on February 28, 2014	$	80
	Fair value of ordinary shares of Endo International issued to Paladin Shareholders*				$	2,712,956
	Number of Paladin shares paid in cash	20,765
	Per share cash consideration for Paladin shares (1)	$	1.09
	Cash distribution to Paladin shareholders*				22,647
	Fair value of the vested portion of Paladin stock options outstanding—1.3 million at February 28, 2014 (2)				131,323
	Total acquisition consideration				$	2,866,926
	__________
	*	Amounts do not recalculate due to rounding.
	-1	Represents the cash consideration per the arrangement agreement of C$1.16 per Paladin share translated into U.S. dollars utilizing an exchange rate of $0.9402.
	-2	Represents the fair value of vested Paladin stock option awards attributed to pre-combination services that were outstanding on the Paladin Acquisition Date and settled on a cash-less exercise basis for Endo International plc shares.
	Paladin is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring and in-licensing innovative pharmaceutical products for the Canadian and world markets. Paladin’s key products serve growing therapeutic areas including attention deficit hyperactivity disorder (ADHD), pain, urology and allergy. In addition to its Canadian operations, Paladin owns a controlling interest in Laboratorios Paladin de Mexico S.A. in Mexico and in publicly traded Litha Healthcare Group Limited (Litha) in South Africa.
	Paladin’s stable and growing cash flows and strong Canadian franchise complement Endo’s existing portfolio and further diversify Endo’s pharmaceutical product mix and geographic reach. The Company believes the transaction will generate operational and tax synergies and will create a financial platform to facilitate organic growth with broader options for future strategic activity.
	While the Paladin acquisition was primarily equity based, Endo also made changes to its existing debt structure to complete the transaction, as further described in Note 13. Debt.
	The operating results of Paladin from and including February 28, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of Paladin, effective February 28, 2014.
	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the Paladin Acquisition Date (in thousands):
		February 28, 2014 (As initially reported)			Measurement period adjustments			February 28, 2014 (As adjusted)
	Cash and cash equivalents	$	113,571		$	—		$	113,571
	Marketable securities	89,420			—			89,420
	Accounts receivable	93,832			3,262			97,094
	Inventories	62,095			1,498			63,593
	Prepaid expenses and other current assets	32,605			9			32,614
	Deferred income tax assets, current	11,719			1,423			13,142
	Property, plant and equipment	7,299			4			7,303
	Intangible assets	676,000			(1,752		)	674,248
	Other assets	56,289			1,255			57,544
	Total identifiable assets	$	1,142,830		$	5,699		$	1,148,529
	Accounts payable and accrued expenses	$	124,321		$	7,099		$	131,420
	Income taxes payable	22,524			934			23,458
	Deferred income taxes	160,620			(22,967		)	137,653
	Debt	23,826			—			23,826
	Other liabilities	9,578			30,890			40,468
	Total liabilities assumed	$	340,869		$	15,956		$	356,825
	Net identifiable assets acquired	$	801,961		$	(10,257	)	$	791,704
	Noncontrolling interests	$	(69,600	)	$	30,800		$	(38,800	)
	Goodwill	2,134,565			(20,543		)	2,114,022
	Net assets acquired	$	2,866,926		$	—		$	2,866,926
	During the third quarter of 2014, the Company divested its Canadian rights to Oralair, an intangible asset acquired during the Paladin acquisition, for total proceeds of approximately $4.2 million. See Note 10. Goodwill and Other Intangibles for the impact of the sale on the gross intangible assets of the Company.
	The estimated fair value of the Paladin assets acquired and liabilities assumed are provisional as of December 31, 2014 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements, particularly with respect to certain acquired equity and cost method investments, property, plant and equipment, intangible assets, contingent assets and liabilities, deferred income taxes and noncontrolling interests. Accordingly, the measurement of the Paladin assets acquired and liabilities assumed may change significantly upon finalization of the Company’s valuations and completion of the purchase price allocation, both of which are expected to occur no later than one year from the acquisition date.
	The Company expects multiple reporting units to benefit, directly or indirectly, from the synergies arising from the Paladin acquisition. As a result, as of December 31, 2014, the Company has provisionally assigned the goodwill arising from the Paladin acquisition to multiple reporting units across each of its reportable segments. This assignment was based on the relative incremental benefit expected to be realized by each impacted reporting unit. The Company is continuing to assess the amount of goodwill assigned to each reporting unit and the underlying allocation methodology used to assign this goodwill. See Note 10. Goodwill and Other Intangibles for the preliminary allocation of Paladin-related goodwill by reportable segment.
	The valuation of the intangible assets acquired and related amortization periods are as follows:
		Valuation			Amortization
		(in millions)			Period
					(in years)
	Developed Technology:
	Canada Base Prescription	$	410		12
	Canada OTC	50			11
	Canada Other	74.2			11
	Litha	70			12
	Licenses not renewed	4.5			3
	Total	$	608.7
	In Process Research & Development (IPR&D):
	Serelaxin	$	55		n/a
	Other	10.5			n/a
	Total	$	65.5
Total other intangible assets	$	674.2
The preliminary fair values of the developed technology and IPR&D assets were estimated using a discounted present value income approach. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company used cash flows discounted at rates ranging from 9.5% to 15.5%, which were considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions. This analysis is preliminary and is subject to further adjustment as additional information becomes available.
The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, expected corporate synergies, the assembled workforce of Paladin and other factors. The goodwill is not deductible for income tax purposes.
Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets.
The Company recognized acquisition-related transaction costs associated with the Paladin acquisition during the year ended December 31, 2014 totaling $27.5 million. These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Consolidated Statements of Operations.
The amounts of Paladin Revenue and Net income attributable to Endo International plc included in the Company’s Consolidated Statements of Operations from February 28, 2014 to December 31, 2014 are as follows (in thousands, except per share data):
Revenue	$	224,806
Net income attributable to Endo International plc	$	26,966
Basic net income per share	$	0.18
Diluted net income per share	$	0.17
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Paladin had occurred on January 1, 2013 for the years ended December 31, 2014 and 2013. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2013, nor are they indicative of any future results.
	Year Ended December 31, 2014			Year Ended December 31, 2013
Unaudited pro forma consolidated results (in thousands, except per share data):
Revenue	$	2,423,683		$	2,392,687
Net loss attributable to Endo International plc	$	(727,961	)	$	(574,407	)
Basic net loss per share	$	(4.96	)	$	(5.07	)
Diluted net loss per share	$	(4.64	)	$	(4.79	)
These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Paladin to reflect factually supportable adjustments that give effect to events that are directly attributable to the Paladin acquisition assuming the Paladin acquisition had occurred January 1, 2013. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition which increased the expense by $8.2 million for the year ended December 31, 2013, and decreased the expense by $4.1 million for the year ended December 31, 2014. In addition, the adjustments include additional intangible amortization, net of tax, that would have been charged assuming the Company’s estimated fair value of the intangible assets, which increased the expense by $14.6 million for the year ended December 31, 2013. An adjustment to the amortization expense for the year ended December 31, 2014 increased the expense by $2.8 million.
The Company has determined that U.S. shareholders of Endo will generally recognize gain (but not loss) on the Endo shareholders’ exchange of EHSI common stock for Endo International plc ordinary shares in the merger (Endo Share Exchange). This determination was based on various factors, including the upward movement of the EHSI stock price following signing of the arrangement agreement and the aggregate estimated tax basis of the Endo shareholders in the EHSI common stock at the time of the Endo Share Exchange. Due to these factors the conditions necessary to prevent the application of Section 367(a) to the merger were not satisfied, and, as a result, the Endo Share Exchange are a taxable transaction for U.S. federal income tax purposes effective February 28, 2014 whereby U.S. shareholders of Endo will generally recognize gain (but not loss) on the Endo Share Exchange. With respect to each U.S. shareholder, such gain will generally equal the excess of the fair market value of the Endo International plc ordinary shares received over such holder’s adjusted tax basis in the shares of EHSI common stock exchanged therefor. The Company accrued approximately $54.3 million of expense related to the reimbursement of directors’ and certain employees’ excise tax liabilities pursuant to Section 4985 of the Internal Revenue Code, substantially all of which was advanced in December 2014. This reimbursement was approved by shareholders at a special meeting to vote upon the Paladin transaction.
Boca Pharmacal LLC Acquisition
On February 3, 2014, the Company acquired Boca Pharmacal LLC (Boca) for approximately $236.6 million in cash. Boca is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.
The preliminary fair values of the net identifiable assets acquired totaled approximately $212.3 million, resulting in goodwill of approximately $24.3 million, which was assigned to our U.S. Generic Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Boca acquisition includes approximately $140.9 million of identifiable intangible assets, including $112.3 million of developed technology to be amortized over an average life of approximately 11 years and $28.6 million of IPR&D.
The operating results of Boca from and including February 3, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of Boca, effective February 3, 2014.
Pro forma results of operations have not been presented because the effect of the Boca acquisition was not material.
Sumavel® DosePro®
On May 19, 2014, the Company’s Endo Pharmaceuticals Inc. (EPI) subsidiary acquired the worldwide rights to Sumavel® DosePro® (Sumavel) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. The Company is accounting for this transaction as a business combination in accordance with the relevant accounting literature.
EPI acquired the product for consideration of $93.8 million, consisting of an upfront payment of $89.7 million and contingent cash consideration with an acquisition-date fair value of $4.1 million. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. In addition, the Company provided Zogenix, Inc. with a $7.0 million non-interest bearing loan due 2023 for working capital needs and it assumed an existing third-party royalty obligation on net sales. Sumavel® is a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches.
The preliminary fair values of the net identifiable assets acquired totaled approximately $93.8 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Sumavel® acquisition includes approximately $90.0 million of identifiable developed technology intangible assets to be amortized over an average life of approximately 13 years.
The operating results of Sumavel® from and including May 19, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of Sumavel, effective May 19, 2014.
Pro forma results of operations have not been presented because the effect of the Sumavel® acquisition was not material.
Grupo Farmacéutico Somar Acquisition
On July 24, 2014, the Company, together with its Endo Netherlands B.V. subsidiary (Endo Dutch B.V.), acquired the representative shares of the capital stock of Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable (Somar), a leading privately-owned specialty pharmaceuticals company based in Mexico City, for $270.1 million in cash consideration, subject to a customary post-closing net working capital adjustment. Somar generated revenues of approximately $100.0 million in 2013.
The preliminary fair values of the net identifiable assets acquired totaled approximately $184.4 million, resulting in goodwill of approximately $85.7 million, which was assigned to our International Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Somar acquisition includes approximately $169.3 million of identifiable intangible assets, including $149.3 million to be amortized over an average life of approximately 12 years and $20.0 million of IPR&D.
The operating results of Somar from and including July 24, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of Somar, effective July 24, 2014.
Pro forma results of operations have not been presented because the effect of the Somar acquisition was not material.
DAVA Pharmaceuticals, Inc. Acquisition
On August 6, 2014 (the DAVA Acquisition Date), the Company’s Generics International (US), Inc. acquired DAVA Pharmaceuticals, Inc. (DAVA), a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals based in Fort Lee, New Jersey, for consideration of $595.3 million. The consideration consisted of cash consideration of $590.2 million, subject to a customary post-closing net working capital adjustment, and contingent cash consideration with an acquisition-date fair value of $5.1 million. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. DAVA’s strategically-focused generics portfolio includes thirteen on-market products in a variety of therapeutic categories.
The operating results of DAVA from and including August 6, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of DAVA, effective August 6, 2014.
Pro forma results of operations have not been presented because the effect of the DAVA acquisition was not material.
The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the DAVA Acquisition Date (in thousands):
	August 6, 2014 (As initially reported)			Measurement period adjustments			August 6, 2014 (As adjusted)
Cash and cash equivalents	$	533		$	—		$	533
Accounts receivable	15,842			2,246			18,088
Inventories	120,626			(47,400		)	73,226
Prepaid expenses and other current assets	2,672			—			2,672
Property, plant and equipment	2,659			—			2,659
Intangible assets	439,623			75,277			514,900
Other assets	21,029			—			21,029
Total identifiable assets	$	602,984		$	30,123		$	633,107
Accounts payable and accrued expenses	$	17,585		$	6,892		$	24,477
Deferred income taxes	195,915			10,357			206,272
Other liabilities	21,139			—			21,139
Total liabilities assumed	$	234,639		$	17,249		$	251,888
Net identifiable assets acquired	$	368,345		$	12,874		$	381,219
Goodwill	226,683			(12,574		)	214,109
Net assets acquired	$	595,028		$	300		$	595,328
The preliminary fair values of the net identifiable assets acquired totaled approximately $381.2 million, resulting in goodwill of approximately $214.1 million, which was assigned to our U.S. Generic Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the DAVA acquisition includes approximately $514.9 million of identifiable intangible assets, including $455.3 million of developed technology to be amortized over an average life of approximately 12 years and $59.6 million of IPR&D.
Natesto™
On December 9, 2014, the Company’s EPI subsidiary acquired the rights to Natesto™ (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto™, which was approved by the U.S. Food and Drug Administration (FDA) in May of 2014. Endo intends to launch the product through its Endo Pharmaceuticals Inc. (EPI) subsidiary in early 2015. The Company is accounting for this transaction as a business combination in accordance with the relevant accounting literature.
EPI acquired the product for consideration of $61.0 million, consisting of an upfront payment of $25.0 million, prepaid inventory of $5.0 million and contingent cash consideration with an acquisition-date fair value of $31.0 million. See Note 7. Fair Value Measurements for further discussion of this contingent consideration.
The preliminary fair values of the net identifiable assets acquired totaled approximately $61.0 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Natesto™ acquisition includes approximately $56.0 million of developed technology to be amortized over 10 years.
The results of Natesto™ from and including December 9, 2014 are included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2014. The Consolidated Balance Sheets as of December 31, 2014 reflect the acquisition of Natesto™, effective December 9, 2014.
Pro forma results of operations have not been presented because the effect of the Natesto™ acquisition was not material.

Segment_Results

Segment Results	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Results	NOTE 6. SEGMENT RESULTS
	Concurrent with the February 28, 2014 acquisition of Paladin, the Company changed the names of its reportable segments. This change to our segments had no impact on the Company’s Consolidated Financial Statements for all periods presented. In addition, the International Pharmaceuticals segment was added, which is comprised of the operations of the acquired Paladin and Somar businesses. As further described in Note 3. Discontinued Operations, the operating results of the HealthTronics and AMS businesses are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	The three remaining reportable business segments in which the Company now operates are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals, and (3) International Pharmaceuticals. These segments reflect the level at which executive management regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
	We evaluate segment performance based on each segment’s adjusted income (loss) from continuing operations before income tax, which we define as income (loss) from continuing operations before income tax before certain upfront and milestone payments to partners, acquisition-related and integration items, cost reduction and integration-related initiatives, asset impairment charges, amortization of intangible assets related to marketed products, inventory step-up recorded as part of our acquisitions, non-cash interest expense, litigation-related and other contingent matters and certain other items that the Company believes do not reflect its core operating performance.
	Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated”. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segment less these unallocated corporate costs.
	U.S. Branded Pharmaceuticals
	Our U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as our urology, endocrinology and oncology products. The marketed products that are included in this segment include Lidoderm®, Opana® ER, Voltaren® Gel, Percocet®, Frova®, Fortesta® Gel, Supprelin® LA, Valstar®, Vantas®, Sumavel® DosePro®, Aveed® and Natesto™.
	U.S. Generic Pharmaceuticals
	Our U.S. Generic Pharmaceuticals segment consists of products primarily focused in pain management through a differentiated portfolio of controlled substances and liquids that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. The product offerings of this segment include products in the pain management, urology, CNS disorders, immunosuppression, oncology, women’s health and hypertension markets, among others. Additionally, in May 2014, we launched an authorized generic lidocaine patch 5% (referred to as Lidoderm® authorized generic).
	International Pharmaceuticals
	Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products and certain medical devices for the Canadian, Mexican, South African and world markets, which we acquired from Paladin and Somar. Paladin’s key products serve growing therapeutic areas including ADHD, pain, urology and allergy. Somar develops, manufactures, and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives.
	The following represents selected information for the Company’s reportable segments for the years ended December 31 (in thousands):
		2014			2013			2012
	Net revenues to external customers:
	U.S. Branded Pharmaceuticals	$	969,437		$	1,394,015		$	1,677,984
	U.S. Generic Pharmaceuticals	1,140,821			730,666			633,265
	International Pharmaceuticals (1)	270,425			—			—
	Total net revenues to external customers	$	2,380,683		$	2,124,681		$	2,311,249
	Adjusted income (loss) from continuing operations before income tax:
	U.S. Branded Pharmaceuticals	$	529,507		$	783,927		$	906,839
	U.S. Generic Pharmaceuticals	464,029			193,643			171,418
	International Pharmaceuticals	80,683			—			—
	__________
	-1	Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
	There were no material revenues from external customers attributed to an individual foreign country during the years ended December 31, 2014, 2013 or 2012. There were no material tangible long-lived assets attributed to an individual foreign country as of December 31, 2014 or 2013.
	The table below provides reconciliations of our segment adjusted income from continuing operations before income tax to our consolidated income (loss) from continuing operations before income tax, which is determined in accordance with U.S. GAAP, for the years ended December 31 (in thousands):
		2014			2013			2012
	Total segment adjusted income from continuing operations before income tax:	$	1,074,219		$	977,570		$	1,078,257
	Corporate unallocated costs	(355,417		)	(315,743		)	(328,633		)
	Upfront and milestone payments to partners	(51,774		)	(29,703		)	(60,778		)
	Asset impairment charges	(22,542		)	(32,011		)	(72,551		)
	Acquisition-related and integration items (1)	(77,384		)	(7,614		)	(18,432		)
	Separation benefits and other cost reduction initiatives (2)	(25,760		)	(91,530		)	(23,489		)
	Excise tax (3)	(54,300		)	—			—
	Amortization of intangible assets	(218,712		)	(123,547		)	(146,898		)
	Inventory step-up	(65,582		)	—			—
	Non-cash interest expense related to the 1.75% Convertible Senior Subordinated Notes	(12,192		)	(22,742		)	(20,762		)
	Loss on extinguishment of debt	(31,817		)	(11,312		)	(7,215		)
	Watson litigation settlement income, net	—			50,400			—
	Accrual for payment to Impax Laboratories Inc. related to sales of Opana® ER	—			—			(102,000		)
	Patent litigation settlement items, net	—			—			(85,123		)
	Certain litigation-related charges, net (4)	(42,084		)	(9,450		)	(224,425		)
	Charge related to the non-recoverability of certain non-trade receivables	(10,000		)	—			—
	Net gain on sale of certain early-stage drug discovery and development assets	5,200			—			—
	Foreign currency impact related to the remeasurement of intercompany debt instruments	13,153			—			—
	Charge for an additional year of the branded prescription drug fee in accordance with IRS regulations issued in the third quarter of 2014	(24,972		)	—			—
	Other, net	(161		)	1,048			—
	Total consolidated income (loss) from continuing operations before income tax	$	99,875		$	385,366		$	(12,049	)
	__________
	-1	Acquisition-related and integration-items include costs directly associated with the closing of certain acquisitions, changes in the fair value of contingent consideration and the costs of integration activities related to both current and prior period acquisitions.
	-2	Separation benefits and other cost reduction initiatives include employee separation costs of $14.4 million, $35.2 million and $20.0 million in 2014, 2013 and 2012, respectively. Contract termination fees of $5.8 million in 2013 are also included in this amount. The amount of separation benefits and other cost reduction initiatives in 2013 includes an expense recorded upon the cease use date of our Chadds Ford, Pennsylvania and Westbury, New York properties in the first quarter of 2013, representing the liability for our remaining obligations under the respective lease agreements of $7.2 million. These expenses were primarily recorded as Selling, general and administrative and Research and development expense in our Consolidated Statements of Operations. The amounts in this table exclude amounts related to discontinued operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.
	-3	This amount represents charges related to the expense for the reimbursement of directors’ and certain employees’ excise tax liabilities pursuant to Section 4985 of the Internal Revenue Code.
	-4	These amounts include charges for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.
	The following represents additional selected financial information for our reportable segments for the years ended December 31 (in thousands):
		2014			2013			2012
	Depreciation expense:
	U.S. Branded Pharmaceuticals	$	16,209		$	19,828		$	15,540
	U.S. Generic Pharmaceuticals	16,751			13,354			12,343
	International Pharmaceuticals	1,856			—			—
	Corporate unallocated	7,849			8,354			5,033
	Total depreciation expense	$	42,665		$	41,536		$	32,916
		2014			2013			2012
	Amortization expense:
	U.S. Branded Pharmaceuticals	$	78,890		$	80,223		$	105,974
U.S. Generic Pharmaceuticals	95,042			43,924			41,524
International Pharmaceuticals	44,780			—			$	—
Total amortization expense	$	218,712		$	124,147		$	147,498
Interest income and expense are considered corporate items and included in Corporate unallocated. Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 7. FAIR VALUE MEASUREMENTS
	Financial Instruments
	The financial instruments recorded in our Consolidated Balance Sheets include cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds are structured to maintain the fund’s net asset value at $1.00 per unit, which assists in providing adequate liquidity upon demand by the holder. Money market funds pay dividends that generally reflect short-term interest rates. Thus, only the dividend yield fluctuates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds), accounts receivable, accounts payable and accrued expenses approximate their fair values.
	Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
	•	Level 1—Quoted prices in active markets for identical assets or liabilities.
	•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Marketable Securities
	Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the fair value hierarchy, as defined above. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in the Consolidated Balance Sheets at December 31, 2014 and December 31, 2013.
	At the time of purchase, we classify our marketable securities as either available-for-sale securities or trading securities, depending on our intent at that time. Available-for-sale and trading securities are carried at fair value with unrealized holding gains and losses recorded within other comprehensive income or net income, respectively. The Company reviews unrealized losses associated with available-for-sale securities to determine the classification as a “temporary” or “other-than-temporary” impairment. A temporary impairment results in an unrealized loss being recorded in other comprehensive income. An impairment that is viewed as other-than-temporary is recognized in net income. The Company considers various factors in determining the classification, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the issuer or investee, and the Company’s ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.
	Loans Receivable
	Our loans receivable at December 31, 2014 relate primarily to loans totaling $16.3 million to our joint venture owned through our Litha subsidiary. The joint venture investment is further described below. The majority of this amount is secured by certain of the assets of our joint venture. The fair values of these loans were based on anticipated cash flows, which approximate the carrying amount, and were classified in Level 2 measurements in the fair value hierarchy. These loans are included in Other assets in our Consolidated Balance Sheet at December 31, 2014.
	Equity and Cost Method Investments
	We have various investments which we account for using the equity or cost method of accounting, including a $31.4 million joint venture investment in the Biologicals and Vaccines Institute of Southern Africa (Pty) Limited, owned through our Litha subsidiary, which is accounted for as an equity method investment. The fair value of the equity method and cost method investments is not readily available nor have we estimated the fair value of these investments and disclosure is not required. The Company is not aware of any identified events or changes in circumstances that would have a significant adverse effect on the carrying value of any of our equity or cost method investments included in Other assets in our Consolidated Balance Sheets at December 31, 2014 and December 31, 2013.
	Acquisition-Related Contingent Consideration
	Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. See Recurring Fair Value Measurements below for additional information on the fair value methodology used for the acquisition-related contingent consideration.
	Voltaren® Gel Royalties due to Novartis
	The initial fair value of the Minimum Voltaren® Gel royalties due to Novartis were determined using an income approach (present value technique) taking into consideration the level and timing of expected cash flows and an assumed discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The liability is currently being accreted up to the expected minimum payments, less payments made to date. We believe the carrying amount of this minimum royalty guarantee at December 31, 2014 and December 31, 2013 represents a reasonable approximation of the price that would be paid to transfer the liability in an orderly transaction between market participants at the measurement date. Accordingly, the carrying value approximates fair value as of December 31, 2014 and December 31, 2013.
	Recurring Fair Value Measurements
	The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013 were as follows (in thousands):
		Fair Value Measurements at Reporting Date using:
	December 31, 2014	Quoted Prices in		Significant Other			Significant			Total
		Active Markets		Observable			Unobservable
		for Identical		Inputs (Level 2)			Inputs (Level 3)
		Assets (Level 1)
	Assets:
	Money market funds	$	279,327	$	—		$	—		$	279,327
	Equity securities	2,321		$	—		—			2,321
	Total	$	281,648	$	—		$	—		$	281,648
	Liabilities:
	Acquisition-related contingent consideration—short-term	$	—	$	—		$	4,282		$	4,282
	Acquisition-related contingent consideration—long-term	—		—			41,723			41,723
	Total	$	—	$	—		$	46,005		$	46,005
	At December 31, 2014, money market funds include $124.4 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 14. Commitments and Contingencies for further discussion of our product liability cases.
		Fair Value Measurements at Reporting Date using:
	December 31, 2013	Quoted Prices in		Significant Other			Significant			Total
		Active Markets		Observable			Unobservable
		for Identical		Inputs (Level 2)			Inputs (Level 3)
		Assets (Level 1)
	Assets:
	Money market funds	$	843,390	$	—		$	—		$	843,390
	Equity securities	2,979		—			—			2,979
	Total	$	846,369	$	—		$	—		$	846,369
	Liabilities:
	Acquisition-related contingent consideration—short-term	$	—	$	—		$	3,878		$	3,878
	Acquisition-related contingent consideration—long-term	—		—			869			869
	Total	$	—	$	—		$	4,747		$	4,747
	At December 31, 2013, money market funds include $700.0 million from the proceeds of the issuance of the New 2022 Notes and $70.0 million of capitalization by EHSI. This cash was restricted until the Paladin transaction closed.
	Acquisition-Related Contingent Consideration
	On November 30, 2010 (the Qualitest Pharmaceuticals Acquisition Date), the Company acquired Generics International (US Parent), Inc. (doing business as Qualitest Pharmaceuticals), which was party to an asset purchase agreement with Teva Pharmaceutical Industries Ltd (Teva) (the Teva Agreement). Pursuant to this agreement, Qualitest Pharmaceuticals purchased certain pipeline generic products from Teva and could be obligated to pay consideration to Teva upon the achievement of certain future regulatory milestones (the Teva Contingent Consideration).
	The current range of the undiscounted amounts the Company could be obligated to pay in future periods under the Teva Agreement is between zero and $7.5 million after giving effect to the first quarter 2013 payment. The Company is accounting for the Teva Contingent Consideration in the same manner as if it had entered into that arrangement with respect to its acquisition of Qualitest Pharmaceuticals. Accordingly, the fair value was estimated based on a probability-weighted discounted cash flow model (income approach). The resultant probability-weighted cash flows were then discounted using a discount rate of U.S. Prime plus 300 basis points. Using this valuation technique, the fair value of the contractual obligation to pay the Teva Contingent Consideration was determined to be approximately $5.2 million at December 31, 2014 and $4.7 million at December 31, 2013. The increase in the balance primarily relates to changes in the fair value of the liability, primarily reflecting changes to the present value assumptions associated with our valuation model.
	During the second quarter of 2014, in connection with our acquisition of Sumavel®, we entered into an agreement to make contingent cash consideration payments to the former owner of Sumavel® of between zero and $20.0 million, based on certain factors relating primarily to the financial performance of Sumavel®. At the acquisition date, we estimated the fair value of this obligation to be $4.1 million based on a probability-weighted discounted cash flow model (income approach). Using this valuation technique, the fair value of the contractual obligation to pay the Sumavel® Contingent Consideration was determined to be approximately $4.7 million at December 31, 2014. The increase in the balance primarily relates to changes in the fair value of the liability, primarily reflecting changes to the present value assumptions associated with our valuation model.
	In connection with our acquisition of DAVA, we agreed to make cash consideration payments of up to $25.0 million contingent on the achievement of certain sales-based milestones. At the DAVA Acquisition date, we estimated the fair value of this obligation to be $5.1 million based on a probability-weighted discounted cash flow model (income approach). Using this valuation technique, the fair value of the contractual obligation to pay the DAVA® Contingent Consideration was determined to be approximately $5.1 million at December 31, 2014.
	In connection with the acquisition of Natesto™, we entered into an agreement to make contingent cash consideration payments to the former owners of Natesto™ based on certain potential clinical and commercial milestones of up to $165.0 million as well as royalties based on a percentage of potential future sales of Natesto™. At the Natesto™ acquisition date, we estimated the fair value of this obligation to be $31.0 million based on a probability-weighted discounted cash flow model (income approach). Using this valuation technique, the fair value of the contractual obligation to pay the Natesto™ Contingent Consideration was determined to be approximately $31.0 million at December 31, 2014.
	Amounts recorded for the short-term and long-term portions of acquisition related contingent consideration are included in Accrued expenses and Other liabilities, respectively, in the Consolidated Balance Sheets.
	Fair Value Measurements Using Significant Unobservable Inputs
	The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2014 and 2013 (in thousands):
		2014		2013
	Beginning of period	$	4,747	$	8,924
	Amounts acquired	40,224		—
	Amounts settled	—		(5,000		)
	Transfers (in) and/or out of Level 3	—		—
	Changes in fair value recorded in earnings	1,034		823
	End of period	$	46,005	$	4,747
The following is a summary of available-for-sale securities held by the Company at December 31, 2014 and December 31, 2013 (in thousands):
	Available-for-sale
	Amortized		Gross			Gross			Fair Value
	Cost		Unrealized			Unrealized
			Gains			(Losses)
December 31, 2014
Money market funds	$	279,327	$	—		$	—		$	279,327
Total included in cash and cash equivalents	$	154,959	$	—		$	—		$	154,959
Total included in restricted cash and cash equivalents	$	124,368	$	—		$	—		$	124,368
Equity securities	$	805	$	10		$	—		$	815
Total other short-term available-for-sale securities	$	805	$	10		$	—		$	815
Equity securities	$	1,766	$	—		$	(260	)	$	1,506
Long-term available-for-sale securities	$	1,766	$	—		$	(260	)	$	1,506
	Available-for-sale
	Amortized		Gross			Gross			Fair Value
	Cost		Unrealized			Unrealized
			Gains			(Losses)
December 31, 2013
Money market funds	$	843,390	$	—		$	—		$	843,390
Total included in cash and cash equivalents	$	73,390	$	—		$	—		$	73,390
Total included in restricted cash and cash equivalents	$	770,000	$	—		$	—		$	770,000
Equity securities	$	1,766	$	1,213		$	—		$	2,979
Long-term available-for-sale securities	$	1,766	$	1,213		$	—		$	2,979
Nonrecurring Fair Value Measurements
The Company’s financial assets measured at fair value on a nonrecurring basis during the year ended December 31, 2014 were as follows (in thousands):
	Fair Value Measurements at Reporting Date using:								Total Income (Expense) for the Year Ended December 31, 2014
	Quoted Prices in		Significant Other			Significant
	Active Markets		Observable Inputs			Unobservable Inputs
	for Identical Assets		(Level 2)			(Level 3)
	(Level 1)
Assets:
Certain other intangible assets	$	—	$	—		$	3,300		$	(18,200	)
Property, plant and equipment (See Note 9)	—		—			—			(4,342		)
	$	—	$	—		$	3,300		$	(22,542	)
Liabilities:
Minimum Voltaren® Gel royalties due to Novartis	$	—	$	—		$	37,500		$	—
Total	$	—	$	—		$	37,500		$	—
The Company’s financial assets, excluding assets held for sale, measured at fair value on a nonrecurring basis during the year ended December 31, 2013 were as follows (in thousands):
	Fair Value Measurements at Measurement Date using:								Total Expense for the Year Ended December 31, 2013
	Quoted Prices in		Significant Other			Significant
	Active Markets		Observable Inputs			Unobservable Inputs
	for Identical Assets		(Level 2)			(Level 3)
	(Level 1)
Assets:
AMS IPR&D intangible asset	$	—	$	—		$	8,000		$	(6,000	)
Qualitest IPR&D intangible assets	—		—			—			(17,000		)
Epicept intangible asset	—		—			—			(1,500		)
Property, plant and equipment (See Note 9)	—		—			—			(7,511		)
Total	$	—	$	—		$	8,000		$	(32,011	)
Liabilities:
Minimum Voltaren® Gel royalties due to Novartis	$	—	$	—		$	21,451		$	—
Total	$	—	$	—		$	21,451		$	—
See Note 10. Goodwill and Other Intangibles for a discussion of goodwill and intangible asset impairment charges related to our continuing operations, including an intangible asset associated with our AMS business which is not classified as held for sale based on management’s current expectation that this asset will remain with the Company subsequent to sale. Additionally, during the year ended December 31, 2013, goodwill and other intangible assets associated with our AMS and HealthTronics businesses, which are classified as held for sale in the Consolidated Balance Sheets, were measured at fair value using Level 3 inputs. The results of these fair value measurements are not included in the preceding table. As a result of these nonrecurring fair value measurements, we recorded an aggregate related pre-tax asset impairment charges of $648.2 million. Refer to Note 3. Discontinued Operations for further discussion.
The nonrecurring fair value measurements described above were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	NOTE 8. INVENTORIES
	Inventories consist of the following at December 31, 2014 and December 31, 2013 (in thousands):
		December 31, 2014		December 31, 2013
	Raw materials	$	118,431	$	89,640
	Work-in-process	43,290		45,713
	Finished goods	261,600		188,974
	Total	$	423,321	$	324,327

Property_Plant_And_Equipment

Property, Plant And Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant And Equipment	NOTE 9. PROPERTY, PLANT AND EQUIPMENT
		Land and Buildings			Machinery and Equipment			Leasehold Improve-			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc-			Total
								ments												tion
		(In thousands)
	Cost:
	At January 1, 2014	$	191,141		$	83,431		$	22,323		$	73,057		$	5,012		$	4,743		$	69,497		$	449,204
	Additions	19,012			9,199			1,157			38,675			4,784			159			10,659			83,645
	Additions due to acquisitions	16,409			5,057			1,581			3,149			—			618			277			27,091
	Disposals/transfers/impairments/other	—			(5,175		)	(8,691		)	(25,789		)	(3,714		)	(2,208		)	(572		)	(46,149		)
	Effect of currency translation	(2,070		)	(613		)	(205		)	(108		)	—			(94		)	—			(3,090		)
	At December 31, 2014	$	224,492		$	91,899		$	16,165		$	88,984		$	6,082		$	3,218		$	79,861		$	510,701
	Accumulated Depreciation:
	At January 1, 2014	$	(17,388	)	$	(30,983	)	$	(15,625	)	$	(49,939	)	$	(3,357	)	$	(2,027	)	$	(3,011	)	$	(122,330	)
	Additions	(13,381		)	(11,599		)	(553		)	(14,360		)	(1,697		)	(1,075		)	—			(42,665		)
	Disposals/transfers/impairments/other	—			6,052			8,118			22,159			3,234			2,025			—			41,588
	Effect of currency translation	113			131			26			97			—			42			—			409
	At December 31, 2014	$	(30,656	)	$	(36,399	)	$	(8,034	)	$	(42,043	)	$	(1,820	)	$	(1,035	)	$	(3,011	)	$	(122,998	)
	Net Book Amount:
	At December 31, 2014	$	193,836		$	55,500		$	8,131		$	46,941		$	4,262		$	2,183		$	76,850		$	387,703
	At December 31, 2013	$	173,753		$	52,448		$	6,698		$	23,118		$	1,655		$	2,716		$	66,486		$	326,874
	Depreciation expense, including expense related to assets under capital lease, was $42.7 million, $41.5 million and $32.9 million for the year ended December 31, 2014, 2013 and 2012, respectively.
	During the years ended December 31, 2014, 2013 and 2012, the Company recorded impairment charges totaling $4.3 million, $7.5 million and $5.7 million, respectively, to completely write off certain miscellaneous property, plant and equipment amounts that were taken out of service. These charges were related to our ongoing efforts to improve our operating efficiency and to consolidate certain locations, including our generics research and development operations and our corporate headquarters. These charges are included in the Asset impairment charges line item in our Consolidated Statement of Operations.

Goodwill_And_Other_Intangibles

Goodwill And Other Intangibles	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	NOTE 10. GOODWILL AND OTHER INTANGIBLES
	Goodwill
	Changes in the carrying amount of our goodwill for the year ended December 31, 2014 were as follows (in thousands):
		U.S. Branded Pharmaceuticals			U.S. Generic Pharmaceuticals			International Pharmaceuticals			Total Consolidated
	Balance as of December 31, 2013:
	Goodwill	$	290,793		$	275,201		$	—		$	565,994
	Accumulated impairment losses	—			—			—			—
		$	290,793		$	275,201		$	—		$	565,994
	Goodwill acquired during the period	841,139			796,436			738,862			2,376,437
	Effect of currency translation	—			—			(42,844		)	(42,844		)
	Balance as of December 31, 2014:
	Goodwill	1,131,932			1,071,637			696,018			2,899,587
	Accumulated impairment losses	—			—			—			—
		$	1,131,932		$	1,071,637		$	696,018		$	2,899,587
	On February 24, 2015, the Board of Directors approved a plan to sell the Company’s AMS business. At this time, goodwill related to our Devices segment of $863.0 million and $806.8 million as of December 31, 2014 and 2013, respectively, net of impairment, became part of the disposal group and is included in Assets held for sale in the Consolidated Balance Sheets. The change in the goodwill balance from December 31, 2013 to December 31, 2014 was related to an increase of goodwill relating to acquisitions of approximately $62.0 million offset by a decrease relating to the effects of currency translation of approximately $5.8 million.
	Other Intangible Assets
	The following is a summary of other intangibles held by the Company at December 31, 2014 and December 31, 2013 (in thousands):
	Cost basis:	Balance as of December 31, 2013			Acquisitions			Impairments			Other			Effect of Currency Translation			Balance as of December 31, 2014
					-1			-2			-3
	Indefinite-lived intangibles:
	In-process research and development	$	67,400		$	173,700		$	(5,900	)	$	(45,000	)	$	(5,602	)	$	184,598
	Total indefinite-lived intangibles	$	67,400		$	173,700		$	(5,900	)	$	(45,000	)	$	(5,602	)	$	184,598
	Definite-lived intangibles:
	Licenses (weighted average life of 9 years)	$	587,127		$	—		$	—		$	77,240		$	—		$	664,367
	Tradenames (weighted average life of 15 years)	20,000			1,500			—			—			(185		)	21,315
	Developed technology (weighted average life of 13 years)	838,901			1,470,172			(23,500		)	5,812			(48,169		)	2,243,216
	Total definite-lived intangibles (weighted average life of 12 years)	$	1,446,028		$	1,471,672		$	(23,500	)	$	83,052		$	(48,354	)	$	2,928,898
	Total other intangibles	$	1,513,428		$	1,645,372		$	(29,400	)	$	38,052		$	(53,956	)	$	3,113,496
	Accumulated amortization:	Balance as of December 31, 2013			Amortization			Impairments			Other			Effect of Currency Translation			Balance as of December 31, 2014
								-2			-3
	Indefinite-lived intangibles:
	In-process research and development	$	—		$	—		$	—		$	—		$	—		$	—
	Total indefinite-lived intangibles	$	—		$	—		$	—		$	—		$	—		$	—
	Definite-lived intangibles:
	Licenses	$	(357,439	)	$	(68,974	)	$	—		$	—		$	—		$	(426,413	)
	Tradenames	(4,088		)	(1,378		)	—			—			4			(5,462		)
	Developed technology	(204,435		)	(148,360		)	3,190			—			1,177			(348,428		)
	Total definite-lived intangibles	$	(565,962	)	$	(218,712	)	$	3,190		$	—		$	1,181		$	(780,303	)
	Total other intangibles	$	(565,962	)	$	(218,712	)	$	3,190		$	—		$	1,181		$	(780,303	)
	Net other intangibles	$	947,466														$	2,333,193
	__________
	-1	Includes intangible assets acquired in connection with the acquisitions of Boca, Paladin, Sumavel® DosePro®, Somar, DAVA and Natesto™. See Note 5. Acquisitions for further information.
	-2	We assessed the value of certain other in-process research and development assets and determined that approximately $5.9 million was impaired. The $23.5 million impairment relates to the write-off of a definite-lived license intangible asset related to Opana® ER. See further information below under the caption “Impairments.”
	-3	On March 6, 2014, we announced that the FDA approved Aveed® for the treatment of hypogonadism in adult men. Upon approval, the Company reclassified the intangible asset, with a balance of $35.0 million, from IPR&D to Licenses. At this time, the Company also capitalized an additional milestone payment of $5.0 million related to the approval of Aveed®. See Note 11. License and Collaboration Agreements for further information. Pursuant to the Company’s Voltaren® Gel Agreement with Novartis, we renewed the agreement for an additional one-year period during 2014, and as a result, we capitalized an intangible asset valued at $37.5 million. See Note 11. License and Collaboration Agreements for further information. During the third quarter of 2014, certain IPR&D assets totaling $10.0 million were put into service. During the third quarter of 2014, the Company divested its Canadian rights to Oralair, an intangible asset acquired during the Paladin acquisition, for total proceeds of approximately $4.2 million.
	Amortization expense for the years ended December 31, 2014, 2013 and 2012 totaled $218.7 million, $124.1 million and $147.5 million, respectively. Estimated amortization of intangibles for the five years subsequent to December 31, 2014 is as follows (in thousands):
	2015	$	253,391
	2016	$	203,218
	2017	$	194,225
	2018	$	193,959
	2019	$	178,670
	Changes in the gross carrying amount of our other intangibles for the year ended December 31, 2014 were as follows (in thousands):
		Gross
		Carrying
		Amount
	December 31, 2013	$	1,513,428
	Aveed® approval milestone	5,000
	Paladin acquisition	674,248
	Boca acquisition	140,900
	Sumavel acquisition	90,024
	Somar acquisition	169,300
	DAVA acquisition	514,900
	Natesto™ acquisition	56,000
	Intangible assets sold	(4,448		)
	Voltaren® Gel license extension	37,500
Opana® ER license write-off	(23,500		)
Other in-process research and development asset impairment	(5,900		)
Effect of currency translation	(53,956		)
December 31, 2014	$	3,113,496
The December 31, 2013 amounts above related to both the gross amount and related accumulated amortization for license intangible assets within the Other Intangible Assets summary and the total other intangible gross amount within the Gross Carrying Amount roll-forward have been revised from amounts previously disclosed within our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission on March 3, 2014. The purpose of this revision was to remove approximately $47.1 million from both the gross amount and corresponding accumulated amortization for intangible assets that were fully amortized as of December 31, 2013. These adjustments had no impact on the reported net other intangible assets and the revision did not impact the Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Comprehensive (Loss) Income or Consolidated Statements of Cash Flows as of and for the year ended December 31, 2013.
Impairments
Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired.
The assets and liabilities of the HealthTronics business are classified as held for sale in the Consolidated Balance Sheets as of December 31, 2013, and the assets and liabilities of the AMS business are classified as held for sale in the Consolidated Balance Sheets for all periods presented. The operating results of these businesses are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, and for a discussion of significant asset impairment charges related to these businesses, see Note 3. Discontinued Operations.
Endo has historically concluded that an income approach using a discounted cash flow model was an appropriate valuation methodology to determine each reporting unit’s fair value for goodwill impairment testing and each asset’s fair value for indefinite-lived intangible asset impairment testing. This conclusion was based upon market conditions, and, in some cases, a lack of comparable market transactions for similar assets. In connection with our October 1, 2014 annual goodwill and indefinite-lived intangible assets impairment test, we utilized a similar valuation methodology, except for the testing of our AMS and Litha reporting units. For these reporting units, we relied primarily on a market approach but also tested their respective fair values using a discounted cash flow model.
Our Litha reporting unit represents our ownership stake in Litha, a company traded publicly on the Johannesburg Stock Exchange. For this reporting unit, our conclusion to use a market approach was based on the availability of fair value information resulting from the value implied by our buy-out of the remaining noncontrolling interest of Litha, which was approved by Litha shareholders on December 18, 2014. This transaction is further described in Note 22. Subsequent Events.
Our discounted cash flow models are highly reliant on various assumptions, including estimates of future cash flow (including long-term growth rates), discount rate, and expectations about variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. Where an income approach was utilized, the discount rates applied to the estimated cash flows for our October 1, 2014, 2013 and 2012 annual goodwill and indefinite-lived intangible assets impairment test ranged from 8.5% to 15.5%, from 9.5% to 14.5% and from 9.5% to 10.0%, respectively, depending on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use.
In order to assess the reasonableness of the calculated fair values of our reporting units, we also compare the sum of the reporting units’ fair values to Endo’s market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair values over the market capitalization) or an implied control discount (the excess sum of total invested capital over the sum of the reporting unit’s fair values). The Company evaluates the implied control premium or discount by comparing it to control premiums or discounts of recent comparable market transactions, as applicable. If the control premium or discount is not reasonable in light of comparable recent transactions, or recent movements in the Company’s share price, we reevaluate the fair value estimates of the reporting units by adjusting discount rates and/or other assumptions. This re-evaluation could correlate to different implied fair values for certain or all of the Company’s reporting units. The results of our 2014 Step I analyses showed the fair values of each of our reporting units exceeded their respective carrying amounts.
Results of 2013 Annual Impairment Testing
The results of our 2013 Step I analyses showed that the fair values of the Pain, UEO and Generics reporting units exceeded their respective carrying amounts. The excess of fair value over carrying amount for the UEO and Generics reporting units as of October 1, 2013 was $904.7 million and $1.6 billion, respectively, which was more than 100% of each reporting unit’s carrying amount.
The Pain reporting unit had a negative book value as of October 1, 2013. Accordingly, we also considered other qualitative and quantitative factors to determine whether the goodwill associated with this reporting unit was more likely than not impaired. The factors we considered included market dynamics regarding the current product portfolio, the likelihood of technical, regulatory, and commercial success for certain pipeline products, and the estimated fair value of the Pain reporting unit’s intangible assets. Based on these considerations, the Company concluded it was more likely than not that the goodwill associated with this reporting unit was not impaired as of October 1, 2013.
Results of 2012 Annual Impairment Testing
The results of our 2012 Step I analyses showed that the fair values of the Pain, UEO and Generics reporting units exceeded their respective carrying amounts. The excess of fair value over carrying amount for each of these reporting units as of October 1, 2012 ranged from approximately 70% to more than 100% of carrying amount or $355.8 million to $1.5 billion, respectively.
The results of the analysis for the Urology Services reporting unit, which held $139.9 million of goodwill as of October 1, 2012, showed fair value that exceeded its carrying amount by 8% or $16.4 million.
A summary of significant other intangible asset impairment charges by reportable segment for the three years ended December 31, 2014 is included below.
U.S. Branded Pharmaceuticals Segment
As part of the 2014 year-end financial close and reporting process, the Company concluded that an impairment assessment was required to evaluate the recoverability of a definite-lived license intangible asset related to Opana® ER. After performing these assessments, we recorded a pre-tax non-cash impairment charge of $12.3 million, representing the remaining carrying amount of this asset.
Pursuant to the Sanctura XR® Amended and Restated License, Commercialization and Supply Agreement with Allergan USA, Inc. (Allergan), the Company's Endo Pharmaceuticals Solutions Inc. (EPSI) subsidiary receives royalties based on net sales of Sanctura XR® made by Allergan. Following a lengthy patent litigation which began in 2009, the court ultimately found the patents covering Allergan’s Sanctura XR® (trospium chloride) extended-release capsules were invalid in June 2012. As part of our first quarter 2012 financial close and reporting process, the Company concluded that an impairment assessment was required to evaluate the recoverability of the indefinite-lived intangible asset. The Company assessed the recoverability of this asset and determined the fair value of the Sanctura XR® intangible asset to be $21.6 million at March 31, 2012. Accordingly, the Company recorded a pre-tax non-cash impairment charge of $40.0 million in March 2012, representing the difference between the carrying amount of the intangible asset and its estimated fair value at March 31, 2012.
In October 2012, Watson announced that it had received FDA approval for its generic version of Sanctura XR® and that it intended to begin shipping its product immediately. As a result, the Company reevaluated the recoverability of the asset and determined that an impairment existed. The fair value of the Sanctura XR® intangible asset was determined to be $5.0 million at September 30, 2012. Accordingly, the Company recorded an additional pre-tax non-cash impairment charge of $11.2 million in September 2012. The remaining net book value was amortized in its entirety by December 31, 2012, commensurate with the expected rate of erosion due to generic competition.
U.S. Generic Pharmaceuticals Segment
As part of our annual definite-lived intangible asset impairment review process for 2013, the Company determined that the fair values of certain Qualitest IPR&D assets were less than the respective carrying amounts. Accordingly, in the fourth quarter of 2013, we recorded a pre-tax non-cash impairment charge of $17.0 million representing the full carrying amount of the assets.
Former Devices Segment
As discussed in Note 3. Discontinued Operations, as a result of the 2013 Step II analysis, we determined that the carrying amounts of certain AMS IPR&D intangible assets were impaired. This determination was based primarily on lower than initially expected revenue and profitability levels over a sustained period of time and downward revisions to management’s short-term and long-term forecasts. Accordingly, during 2013 we recorded pre-tax non-cash impairment charges of $12.0 million to impair the IPR&D assets, representing the difference between the fair values and the carrying amounts. Of this $12.0 million impairment charge, approximately $6.0 million was related to assets included in assets held for sale in the Consolidated Balance Sheets and was recorded as Discontinued operations, net of tax in the Consolidated Statements of Operations.

License_And_Collaboration_Agre

License And Collaboration Agreements	12 Months Ended
	Dec. 31, 2014
License And Collaboration Agreements [Abstract]
License and Collaboration Agreements	NOTE 11. LICENSE AND COLLABORATION AGREEMENTS
	Commercial Products
	Novartis AG and Novartis Consumer Health, Inc.
	On March 4, 2008, EPI entered into a License and Supply Agreement (the Voltaren® Gel Agreement) with and among Novartis AG and Novartis Consumer Health, Inc. (Novartis) to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren® Gel (Voltaren® Gel or the Licensed Product). Voltaren® Gel received regulatory approval in October 2007 from the FDA, becoming the first topical prescription treatment for use in treating pain associated with osteoarthritis and the first new product approved in the U.S. for osteoarthritis since 2001. Voltaren® Gel was granted marketing exclusivity in the U.S. as a prescription medicine until October 2010.
	Under the terms of the Voltaren® Gel Agreement, which had an initial term of five years, EPI made an upfront cash payment of $85.0 million. EPI agreed to pay royalties to Novartis on annual Net Sales of the Licensed Product, subject to certain thresholds as defined in the Voltaren® Gel Agreement. In addition, EPI agreed to make certain guaranteed minimum annual royalty payments of $30.0 million per year payable in the 4th and 5th year of the Voltaren® Gel Agreement, which could be reduced under certain circumstances, including Novartis’s failure to supply the Licensed Product, subject to certain limitations including the launch of a generic to the Licensed Product in the U.S. These guaranteed minimum royalties were creditable against royalty payments on an annual basis such that EPI’s obligation with respect to each year is to pay the greater of (i) royalties payable based on annual net sales of the Licensed Product or (ii) the guaranteed minimum royalty for such Voltaren® Gel Agreement year. Novartis is also eligible to receive a one-time milestone payment of $25.0 million if annual net sales of Voltaren® Gel exceed $300.0 million in the U.S. To date, annual net sales have not exceeded this threshold and, therefore, this milestone payment has not been paid.
	The $85.0 million upfront payment and the present value of the guaranteed minimum royalties was initially capitalized as an intangible asset in the amount of $129.0 million, representing the fair value of the exclusive license to market Voltaren® Gel over the initial contract term. We amortized this intangible asset into Cost of revenues over an estimated five-year useful life. Due to Novartis’s failure to supply Voltaren® Gel during the first quarter of 2012 resulting from the shutdown of its Lincoln, Nebraska manufacturing facility, EPI was not obligated to make any first quarter 2012 royalty payment, including the $7.5 million minimum royalty. Accordingly, during the first quarter of 2012, we recorded a reduction to the associated liability and a decrease in the intangible asset. Voltaren® Gel royalties incurred during the years ended December 31, 2014, 2013 and 2012 were $30.0 million, $30.0 million and $21.6 million, respectively, representing either a percentage of actual net sales of Voltaren® Gel or minimum royalties pursuant to the Voltaren® Gel Agreement.
	EPI is solely responsible to commercialize the Licensed Product during the term of the Voltaren® Gel Agreement. With respect to each year during the term of the Voltaren® Gel Agreement, subject to certain limitations, EPI is required to incur a minimum amount of annual advertising and promotional expenses (A&P Expenditures) on the commercialization of the Licensed Product, which may be reduced under certain circumstances including Novartis’s failure to supply the Licensed Product. In addition, EPI is required to perform a minimum number of face-to-face one-on-one discussions with physicians and other healthcare practitioners (Details) for the purpose of promoting the Licensed Product within its approved indication during each year of the Voltaren® Gel Agreement, which may be reduced under certain circumstances including Novartis’s failure to supply the Licensed Product. Further, during the term of the Voltaren® Gel Agreement, EPI will share in the costs of certain clinical studies and development activities initiated at the request of the FDA or as considered appropriate by Novartis and EPI. On December 31, 2012, EPI and Novartis entered into an amendment to the Voltaren® Gel Agreement (the Voltaren® Gel Amendment) which reduced the minimum number of Details required to be conducted by EPI and the minimum amount of annual advertising and promotional expenses required to be spent by EPI on the commercialization of Voltaren® Gel during each remaining year of the Voltaren® Gel Agreement.
	During the fourth Voltaren® Gel Agreement Year beginning on July 1, 2011 and extending through June 30, 2012, EPI agreed to spend 13% of prior year sales or approximately $16.0 million on A&P Expenditures. During the fifth Voltaren® Gel Agreement Year beginning on July 1, 2013 and extending through June 30, 2014, EPI agreed to spend approximately $5.9 million on A&P Expenditures. During the period beginning on July 1, 2014 and extending through June 30, 2015, EPI agreed to spend approximately $8.4 million on A&P Expenditures. In subsequent Agreement Years, the minimum A&P Expenditures set forth in the Voltaren® Gel Agreement are determined based on a percentage of net sales of Voltaren® Gel, which may be reduced under certain circumstances, including Novartis’s failure to supply Voltaren® Gel.
	Amounts incurred for such A&P Expenditures were $5.5 million, $8.1 million and $9.4 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	During the term of the Voltaren® Gel Agreement, EPI has agreed to purchase all of its requirements for the Licensed Product from Novartis. The price was fixed for the first year and subject to annual changes based upon changes in the producer price index and raw materials. The Voltaren® Gel Amendment reduced the supply price of Voltaren® Gel otherwise payable under the Agreement.
	Novartis has the exclusive right, at its sole discretion, to effect a switch of the Licensed Product from a prescription product to an over-the-counter (OTC) product in the U.S. (an OTC Switch) by filing an amendment or supplement to the Licensed Product New Drug Application or taking any other action necessary or advisable in connection therewith to effect the OTC Switch, and thereafter to commercialize such OTC product. Novartis is obligated to notify EPI if it submits a filing to the FDA in respect of an OTC equivalent product. In the event that Novartis gains approval of an OTC equivalent product that results in the Licensed Product being declassified as a prescription product, then Novartis will make certain royalty payments to EPI on net sales of such OTC equivalent product in the U.S. by Novartis, its affiliates and their respective licensees or sublicensees as set forth in the Voltaren® Gel Agreement. As a condition to the payment of any and all such royalties, net sales of the Licensed Product in the U.S. must have exceeded a certain threshold prior to the launch of the OTC equivalent product by Novartis or its affiliates.
	The initial term of the Voltaren® Gel Agreement expired on June 30, 2013. In December 2012, pursuant to the provisions of the Voltaren® Gel Agreement which had provided EPI with an option to extend the term of the agreement for two successive one year terms, the term was renewed for an additional one-year period. As a result, we capitalized, as an intangible asset, $21.3 million representing the present value of the guaranteed minimum royalties we expected to pay to Novartis AG over the renewal term.
	The subsequent terms of the Voltaren® Gel Agreement expired on June 30, 2014, and June 30, 2015, respectively. In both December 2013 and 2014, pursuant to the provisions of the Voltaren® Gel Agreement which had provided EPI with an option to extend the term of the agreement for a one year term, the term was renewed for an additional one-year period. As a result, we capitalized, as an intangible asset, $21.5 million in 2013 and $37.5 million in 2014, representing the present value of guaranteed minimum royalties we expected or currently expect to pay to Novartis AG.
	The Voltaren® Gel Agreement will remain in place unless either (i) EPI provides written notice of non-renewal to the other party at least six months prior to the expiration of the first renewal term or any renewal term thereafter, (ii) Novartis provides written notice of non-renewal to the other party at least six months prior to the expiration of the third renewal term or any renewal term thereafter, or (iii) the Voltaren® Gel Agreement is otherwise terminated in accordance with its terms. Upon extension, EPI is again obligated to make certain guaranteed minimum annual royalty payments of $30.0 million per year during each successive one-year renewal term, subject to certain limitations including the launch of a generic to the Licensed Product in the U.S. These guaranteed minimum annual royalty payments may be reduced under certain circumstances, including Novartis’s failure to supply the Licensed Product. These guaranteed minimum royalties will be creditable against royalty payments on an annual basis such that EPI’s obligation with respect to each year is to pay the greater of (i) royalties payable based on annual net sales of the Licensed Product or (ii) the guaranteed minimum royalty for such Voltaren® Gel Agreement year.
	Among other standard and customary termination rights granted under the Voltaren® Gel Agreement, the Voltaren® Gel Agreement can be terminated by either party upon reasonable written notice and if either party has committed a material breach that has not been remedied within 90 days from the giving of written notice. EPI may terminate the Voltaren® Gel Agreement by written notice upon the occurrence of several events, including the launch in the U.S. of a generic to the Licensed Product. Novartis may terminate the Voltaren® Gel Agreement upon reasonable written notice (1) if EPI fails to deliver a set percentage of the minimum Details in a certain six-month period under the Voltaren® Gel Agreement; or (2) on or after the launch in the U.S. of an OTC equivalent product by Novartis, its affiliates or any third party that does not result in the declassification of the Licensed Product as a prescription product, following which net sales in a six-month period under the Voltaren® Gel Agreement are less than a certain defined dollar amount.
	Vernalis Development Limited
	In July 2004, we entered into a License Agreement with Vernalis Development Limited (Vernalis) under which Vernalis agreed to license, exclusively to us, rights to market frovatriptan succinate (Frova®) in North America (the Vernalis License Agreement). Frova® was launched June 2002 in the U.S. and indicated for the acute treatment of migraine headaches in adults. Under the terms of the Vernalis License Agreement, we paid Vernalis an upfront fee of $30.0 million and annual $15.0 million payments each in 2005 and 2006. We capitalized the $30.0 million up-front payment and the present value of the two $15.0 million anniversary payments. We are amortizing this intangible asset into Cost of revenues on a straight-line basis over its estimated life.
	In addition, Vernalis could receive milestone payments for the achievement of defined annual net sales targets. These sales milestone payments increase based on increasing net sales targets ranging from a milestone of $10.0 million on $200.0 million in net sales to a milestone of $75.0 million on $1.2 billion in net sales. These sales milestones could total up to $255.0 million if all of the defined net sales targets are achieved. Beginning on January 1, 2007, we began paying royalties to Vernalis based on the net sales of Frova®. The term of the license agreement is for the shorter of the time (i) that there are valid claims on the Vernalis patents covering Frova® or there is market exclusivity granted by a regulatory authority, whichever is longer, or (ii) until the date on which a generic version of Frova® is first offered, but in no event longer than 20 years. We can terminate the license agreement under certain circumstances, including upon one years’ written notice. In July 2007, Vernalis and Endo entered into an Amendment (Amendment No. 3) to the License Agreement dated July 14, 2004. Under Amendment No. 3, Vernalis granted an exclusive license to Endo to make, have made, use, commercialize and have commercialized Frova® in Canada, under the Canadian Trademark.
	In February 2008, we entered into Amendment No. 4 to the Vernalis License Agreement (Amendment No. 4). In addition to amending certain specific terms and conditions of the License Agreement, Amendment No. 4 sets forth an annual minimum net sales threshold such that no royalties will be due on annual U.S. net sales of Frova® less than $85.0 million. Prior to this amendment, royalties were payable by us to Vernalis on all net sales of Frova® in the U.S. Now, once the annual minimum net sales amount is reached, royalty payments will be due only on the portion of annual net sales that exceed the $85.0 million threshold. To date, annual net sales have not exceeded the $85.0 million threshold and, therefore, no royalties have been paid.
	On August 15, 2011, the parties amended the Vernalis License Agreement (Amendment No. 5). Pursuant to Amendment No. 5, Vernalis assigned to the Company certain patents which were previously exclusively licensed by the Company. Amendment No. 5 did not alter the financial arrangement between the parties.
	The Population Council
	The Company markets certain of its products utilizing the hydrogel polymer technology pursuant to an agreement between Indevus (now, Endo Pharmaceuticals Solutions Inc.) and The Population Council. Unless earlier terminated by either party in the event of a material breach by the other party, the term of the agreement is the shorter of 25 years from October 1997 or until the date on which The Population Council receives approximately $40.0 million in payments from the Company. To date, we have made payments of $14.8 million to the Population Council. The Company is required to pay to The Population Council 3% of its net sales of Vantas® and any polymer implant containing a luteinizing hormone-releasing hormone (LHRH) analog. We are also obligated to pay royalties to The Population Council ranging from 0.5% of net sales to 4% of net sales under certain conditions. In addition, we are obligated to pay the Population Council 30% of certain profits and payments received in certain territories by the Company from the licensing of Vantas® or any other polymer implant containing an LHRH analog and 5% for other implants.
	Strakan International Limited
	In August 2009, we entered into a License and Supply Agreement with Strakan International Limited, a subsidiary of ProStrakan Group plc. (ProStrakan), which was subsequently acquired by Kyowa Hakko Kirin Co. Ltd., for the exclusive right to commercialize Fortesta® Gel in the U.S. (the ProStrakan Agreement). Fortesta® Gel is a patented 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. A metered dose delivery system permits accurate dose adjustment to increase the ability to individualize patient treatment. Under the terms of the ProStrakan Agreement, Endo paid ProStrakan an up-front cash payment of $10.0 million, which was recorded as Research and development expense.
	The Company received FDA approval for Fortesta® Gel in December 2010, which triggered a one-time approval milestone to ProStrakan for $12.5 million. The approval milestone was recorded as an intangible asset and is being amortized into Cost of revenues on a straight-line basis over its estimated useful life. An additional milestone payment of $7.5 million was triggered during the second quarter of 2011 pursuant to the terms of the ProStrakan Agreement, at which time it was recorded to Cost of revenues. ProStrakan could potentially receive up to approximately $160.0 million in additional payments linked to the achievement of future commercial milestones related to Fortesta® Gel.
	ProStrakan will exclusively supply Fortesta® Gel to Endo at a supply price based on a percentage of annual net sales subject to a minimum floor price as defined in the ProStrakan Agreement. Endo may terminate the ProStrakan Agreement upon six months’ prior written notice at no cost to the Company.
	Grünenthal GmbH
	In December 2007, we entered into a License, Development and Supply Agreement (the Grünenthal Agreement) with Grünenthal for the exclusive clinical development and commercialization rights in Canada and the U.S. for an oral formulation of Opana® ER, which is designed to be crush-resistant. Under the terms of the Grünenthal Agreement, we paid approximately $4.9 million for the successful completion of a clinical milestone in 2010, which was recorded as Research and development expense. In December 2011, the FDA approved a formulation of Opana® ER designed to be crush-resistant, which is called Opana® ER.
	In the fourth quarter of 2011, the Company capitalized a one-time approval milestone to Grünenthal for $4.9 million. We are amortizing this intangible asset into Cost of revenues over its estimated useful life. We made an additional payment of $4.9 million in August 2012 related to a commercial milestone which was recorded as Cost of revenues. In the fourth quarter of 2013, the Company recorded an additional $10.4 million as Cost of Revenues related to a commercial milestone. Additional amounts of approximately 53.9 million euros (approximately $65.1 million at December 31, 2014) may become due upon achievement of additional future predetermined regulatory and commercial milestones. Endo will also make payments to Grünenthal based on net sales of any such product or products commercialized under this agreement, including the formulation of Opana® ER approved by the FDA in December 2011.
	Effective December 19, 2012, EPI and Grünenthal amended the Grünenthal Agreement whereby EPI became responsible for planning of packaging of finished product and certain other routine packaging quality obligations and Grünenthal agreed to reimburse EPI for the third-party costs incurred related to packaging as well as pay EPI a periodic packaging fee. The amendment also changed certain of the terms with respect to the floor price required to be paid by EPI in consideration for product supplied by Grünenthal. On February 18, 2014, EPI and Grünenthal amended the Grünenthal Agreement to define the responsibilities of the parties for certain additional clinical work to be performed for Opana ER.
	BayerSchering
	In July 2005, Indevus (now, Endo Pharmaceuticals Solutions Inc. or EPSI) licensed exclusive U.S. rights from Schering AG, Germany, now BayerSchering Pharma AG (BayerSchering) to market a long-acting injectable testosterone preparation for the treatment of male hypogonadism that we refer to as Aveed® (the BayerSchering Agreement). EPSI was responsible for the development and commercialization of Aveed® in the U.S. BayerSchering is responsible for manufacturing and supplying EPSI with finished product. As part of the BayerSchering Agreement, Indevus agreed to pay to BayerSchering up to $30.0 million in up-front, regulatory milestone, and commercialization milestone payments, including a $5.0 million payment due upon approval by the FDA to market Aveed®. Indevus also agreed to pay to BayerSchering 25% of net sales of Aveed® to cover both the cost of finished product and royalties. The BayerSchering Agreement expires ten years from the first commercial sale of Aveed®.
	In October 2006, Indevus entered into a supply agreement with BayerSchering pursuant to which BayerSchering agreed to manufacture and supply Indevus with all of its requirements for Aveed® for a supply price based on net sales of Aveed®. The supply price is applied against the 25% of net sales owed to BayerSchering pursuant to the BayerSchering Agreement. Either party may also terminate the BayerSchering Agreement in the event of a material breach by the other party.
	On March 6, 2014, we announced that the FDA approved Aveed® for the treatment of hypogonadism in adult men, which is associated with a deficiency or absence of the male hormone testosterone. Aveed® became available in early March. Upon approval, EPSI made the aforementioned milestone payment of $5.0 million to BayerSchering. The approval milestone was recorded as an intangible asset and is being amortized into Cost of revenues on a straight-line basis over its estimated useful life. In the future, EPSI could be obligated to pay milestones of up to approximately $17.5 million based on continued market exclusivity of Aveed® or upon certain future sales milestones.
	Products in Development
	Impax Laboratories, Inc.
	In June 2010, the Company entered into a Development and Co-Promotion Agreement (the Impax Development Agreement) with Impax Laboratories, Inc. (Impax), whereby the Company was granted a royalty-free license for the co-exclusive rights to co-promote a next generation Parkinson’s disease product. Under the terms of the Impax Development Agreement, Endo paid Impax an upfront payment of $10.0 million in 2010, which was recorded as Research and development expense. The Company could be obligated to pay up to approximately $30.0 million in additional payments linked to the achievement of future clinical, regulatory, and commercial milestones related to the development product. Prior to the completion of Phase III trials, Endo may only terminate the Impax Development Agreement upon a material breach.
	Hydron Technologies, Inc.
	In November 1989, GP Strategies Corporation (GP Strategies), then known as National Patent Development Corporation, entered into an agreement (the Hydron Agreement) with Dento-Med Industries, Inc., now known as Hydron Technologies, Inc. In June 2000, Valera Pharmaceuticals, Inc. (Valera, now a wholly-owned, indirect subsidiary of the Company known as Endo Pharmaceuticals Valera Inc.) entered into a contribution agreement with GP Strategies, pursuant to which Valera acquired the assets of GP Strategies’ drug delivery business, including all intellectual property, and all of GP Strategies’ rights under the Hydron Agreement, and certain other agreements with The Population Council and Shire US, Inc.
	Pursuant to the Hydron Agreement, the Company has the exclusive right to manufacture, sell and distribute any prescription drug or medical device and certain other products made with the hydrogel polymer technology. Hydron Technologies retained an exclusive, worldwide license to manufacture, market or use products composed of, or produced with the use of, the hydrogel polymer technology in certain consumer and oral health fields. Neither party is prohibited from manufacturing, exploiting, using or transferring the rights to any new non-prescription drug product containing the hydrogel polymer technology, subject to certain exceptions, for limited exclusivity periods. Subject to certain conditions and exceptions, the Company is obligated to supply certain types of polymer to Hydron Technologies and Hydron Technologies is obligated to purchase such products from the Company. Under the Hydron Agreement, the Company also had the title to the Hydron® trademark. Recently, the Company decided to stop using the Hydron® trademark and transferred the title to such trademark to Hydron Technologies pursuant to the Hydron Agreement. This agreement continues indefinitely, unless terminated earlier by the parties. Each party may owe royalties up to 5% to the other party on certain products under certain conditions.
	BioDelivery Sciences International, Inc.
	In January 2012, EPI signed a worldwide license and development agreement (the BioDelivery Agreement) with BioDelivery Sciences International, Inc. (BioDelivery) for the exclusive rights to develop and commercialize Belbuca™ (buprenorphine HCl) Buccal Film. The drug is a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, which incorporates a bioerodible mucoadhesive (BEMA®) technology. The NDA for Belbuca™ was submitted on December 23, 2014 and accepted by the U.S. Food and Drug Administration (FDA) in February 2015.
	EPI made an upfront payment to BioDelivery for $30.0 million, which was expensed as Research and development in the first quarter of 2012. During the first quarter of 2012, $15.0 million of additional costs were incurred related to the achievement of certain regulatory milestones and were recorded as Research and development expense. EPI paid this amount in the second quarter of 2012. Pursuant to its rights under the terms of the BioDelivery Agreement, BioDelivery elected in November 2013 to have a portion of the Belbuca™ development costs, above a certain amount, paid by EPI. Any such amounts paid by EPI shall be credited against future milestone payments, as defined in the BioDelivery Agreement.
	During each of the first, second, and fourth quarters of 2014, $10.0 million of milestones were incurred related to the achievement of certain clinical milestones, resulting in a total of $30.0 million recorded as Research and development expense during 2014. If Belbuca™ is approved, EPI will be obligated to pay additional regulatory milestones of $50.0 million. In addition, EPI will pay royalties based on net sales of the drug and could be obligated to pay additional commercial milestones of up to approximately $55.0 million.
	EPI may terminate the BioDelivery Agreement at any time upon six months’ written notice. Unless terminated earlier, the BioDelivery Agreement shall expire, on a country-by-country basis, upon the later to occur of 10 years from the date of first commercial sale in a particular country or the date on which the last valid claim of the applicable BioDelivery patents in a particular country has expired or been invalidated or found unenforceable.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued Expenses	NOTE 12. ACCRUED EXPENSES
	Accrued expenses are comprised of the following for each of the years ended December 31, (in thousands):
		2014		2013
	Chargebacks	$	217,402	$	118,014
	Returns and allowances	174,940		104,699
	Rebates	497,362		336,084
	Other sales deductions	25,380		12,897
	Other	234,461		146,999
	Total	$	1,149,545	$	718,693

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Instruments [Abstract]
Debt	NOTE 13. DEBT
	The following table presents the carrying amounts and estimated fair values of the Company’s total indebtedness at December 31, 2014 and December 31, 2013 (in thousands):
		December 31, 2014					December 31, 2013
		Carrying			Fair Value		Carrying			Fair Value
		Amount					Amount
	1.75% Convertible Senior Subordinated Notes due 2015	$	98,818				$	379,500
	Unamortized discount on 1.75% Convertible Senior Subordinated Notes due 2015	(1,759		)			(34,079		)
	1.75% Convertible Senior Subordinated Notes due 2015, net	$	97,059		$	98,317	$	345,421		$	372,481
	7.00% Senior Notes due 2019	499,875			522,813		500,000			536,563
	7.00% Senior Notes due 2020	$	400,000				$	400,000
	Unamortized initial purchaser’s discount	(2,338		)			(2,800		)
	7.00% Senior Notes due 2020, net	$	397,662		422,250		$	397,200		430,500
	7.25% Senior Notes due 2022	400,000			429,278		400,000			431,750
	5.75% Senior Notes due 2022	700,000			707,000		700,000			703,500
	5.375% Senior Notes due 2023	750,000			735,469		—			—
	Term Loan A Facility Due 2019	1,069,063			1,062,889		—			—
	Term Loan B Facility Due 2021	421,812			409,685		—			—
	Term Loan A Facility Due 2018	—			—		1,335,469			1,335,345
	Term Loan B Facility Due 2018	—			—		60,550			60,686
	Other debt	22,822			22,886		133			133
	Total long-term debt, net	$	4,358,293		$	4,410,587	$	3,738,773		$	3,870,958
	Less current portion, net	155,937			154,226		414,929			441,989
	Total long-term debt, less current portion, net	$	4,202,356		$	4,256,361	$	3,323,844		$	3,428,969
	The fair value of our 1.75% Convertible Senior Subordinated Notes is based on an income approach, which incorporates certain inputs and assumptions, including scheduled coupon and principal payments, the inherent conversion and put features in the notes and share price volatility assumptions based on historic volatility of the Company’s ordinary shares and other factors. These fair value measurements are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy.
	The fair values of the various term loan facilities and senior notes were based on market quotes and transactions proximate to the valuation date. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.
	Credit Facility
	Upon closing of the Paladin acquisition on February 28, 2014, certain subsidiaries of the Company entered into a credit facility with Deutsche Bank AG New York Branch and Royal Bank of Canada and certain other lenders, which replaced Endo’s prior credit facility. The prior credit facility was terminated and canceled, with the outstanding indebtedness of $1.4 billion repaid and all liens terminated and released. The initial borrowings under the new credit facility consisted of a five-year senior secured term loan A facility of $1.1 billion (the 2014 Term Loan A Facility), a seven-year senior secured term loan B facility of $425.0 million (the 2014 Term Loan B Facility), and a five-year revolving credit facility with an initial borrowing capacity of up to $750.0 million (the 2014 Revolving Credit Facility and, together with the 2014 Term Loan A Facility and the 2014 Term Loan B Facility, the 2014 Credit Facility). Substantially all of the 2014 Revolving Credit Facility is available at December 31, 2014. The 2014 Credit Facility was issued to refinance certain of our existing indebtedness and for general corporate purposes, including acquisitions.
	The 2014 Credit Facility contains an uncommitted expansion provision which permits up to $1.0 billion (or an unlimited amount if the secured leverage ratio, as defined in the agreement governing the 2014 Credit Facility, is less than or equal to 2.75x) of additional revolving or term loan commitments from one or more lenders.
	Under the 2014 Credit Facility, $50.0 million is available for letters of credit and up to $50.0 million is available for swing line loans on same-day notice, both of which may be increased to up to $75.0 million, subject to consents as described in the agreement governing the 2014 Credit Facility. The borrowers’ obligations under the 2014 Credit Facility are guaranteed by all of borrowers’ direct and indirect wholly-owned material restricted subsidiaries and secured by substantially all of the borrowers’ assets and those of the guarantors.
	The 2014 Credit Facility contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on capital expenditures, asset sales, mergers and acquisitions, indebtedness, liens, dividends, investments and transactions with the Company’s affiliates. As of December 31, 2014, we are in compliance with all such covenants.
	Under the 2014 Credit Facility, borrowings incur interest at an amount equal to a rate calculated based on the type of borrowing and the Company’s leverage ratio, as defined in the underlying agreement. For the 2014 Term Loan A Facility and 2014 Revolving Credit Facility, the Company could elect to pay interest based on an adjusted London Inter-Bank Offer Rate (LIBOR) plus between 1.50% and 2.25% or an alternate base rate, as defined in the underlying agreement, plus between 0.50% and 1.25%. For the 2014 Term Loan B Facility, the Company could elect to pay interest based on an adjusted LIBOR (with a floor of 0.75%) plus 2.50% or an alternate base rate plus 1.50%. The Company will pay a commitment fee of between 30 to 50 basis points, payable quarterly, on the average daily unused amount of the 2014 Revolving Credit Facility.
	In connection with our entering into the 2014 Credit Facility, we incurred new debt issuance costs of approximately $27.8 million. In accordance with the applicable accounting guidance for debt modifications and extinguishments, $26.7 million of these costs were deferred to be amortized over the term of the 2014 Credit Facility and included in Other assets in our Consolidated Balance Sheets. The remaining debt issuance costs of $1.1 million and previously deferred debt issuance costs of $8.6 million associated with the prior credit facility were charged to expense. These expenses were included in the Consolidated Statements of Operations as a Loss on extinguishment of debt.
	As a result of the closing of the Paladin acquisition, the Company assumed approximately $23.8 million of previously existing debt entered into by Paladin’s subsidiary, Litha.
	On March 26, 2013, we made a prepayment of $100.0 million on our prior term loan B facility. Approximately $2.2 million of the remaining unamortized financing costs was written off in connection with this prepayment and included in the Consolidated Statements of Operations as a Loss on extinguishment of debt.
	Prior to the termination of our prior credit facility on February 28, 2014, we entered into an amendment and restatement agreement on March 26, 2013, pursuant to which we amended and restated our then existing credit facility to extend its term by approximately two years and modify its covenants to provide us with greater financial and operating flexibility. The amended and restated agreement extended the maturity dates of our $500.0 million revolving credit facility and our term loan A facility which, at the time of the amendment and restatement, had a remaining principal balance of $1.4 billion, to March 15, 2018. The amended and restated agreement kept in place our term loan B facility, which had a maturity date of June 17, 2018 and, at the time of the amendment and restatement, had a remaining principal balance of $60.6 million. In connection with this transaction, we incurred new debt issuance costs of approximately $8.1 million, $7.6 million of which were deferred to be amortized over the term of the facility and included in Other assets in our Consolidated Balance Sheets. The remaining $0.5 million and previously deferred debt issuance costs of $8.6 million associated with the prior credit facility were charged to expense upon the amendment and restatement. These expenses were included in the Consolidated Statements of Operations as a Loss on extinguishment of debt.
	In February 2012, we made a prepayment of $205.0 million on our then existing term loan B facility. We made additional prepayments of $33.0 million and $39.7 million in July 2012 and September 2012, respectively. In connection with these prepayments, approximately $7.2 million of the remaining unamortized financing costs associated with this facility were written off and included in the Consolidated Statements of Operations as a Loss on extinguishment of debt.
	7.00% Senior Notes Due 2019
	2019 EHSI Notes
	On June 8, 2011, EHSI issued $500.0 million in aggregate principal amount of 7.00% senior notes due 2019 (the Original 2019 EHSI Notes) at an issue price of par. The Original 2019 EHSI Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. On November 30, 2011, all of the Original 2019 EHSI Notes were properly tendered and not withdrawn in an exchange for new notes (the 2019 EHSI Notes) having identical terms that had been registered under the Securities Act of 1933, as amended. Additionally, on May 6, 2014, $481.9 million of the 2019 EHSI Notes were exchanged for new notes issued by Endo Finance LLC and Endo Finco Inc. (collectively, the Endo Finance Issuers). In connection with the exchange offer, the holders who tendered their 2019 EHSI Notes consented to (i) deleting substantially all the restrictive covenants in the indenture governing the 2019 EHSI Notes, (ii) modifying the covenants regarding mergers and consolidations and (iii) eliminating certain events of default. A total of $18.0 million of the existing 2019 EHSI Notes remained outstanding subsequent to the exchange.
	2019 Endo Finance Notes
	On May 6, 2014, the Endo Finance Issuers issued approximately $481.9 million in aggregate principal amount of 7.00% senior notes due 2019 (the 2019 Endo Finance Notes; collectively with the 2019 EHSI Notes, the 2019 Notes) in exchange for approximately $481.9 million aggregate principal amount of 2019 EHSI Notes. The 2019 Endo Finance Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
	Also on May 6, 2014, the Endo Finance Issuers and the guarantors of the 2019 Endo Finance Notes entered into a registration rights agreement under which they will be required to use their commercially reasonable efforts to (i) file with the SEC by March 31, 2015 an exchange offer registration statement pursuant to which they will offer, in exchange for the 2019 Endo Finance Notes, new notes having terms substantially identical in all material respects to those of the 2019 Endo Finance Notes (except the new notes will not contain terms with respect to transfer restrictions) (the A/B Exchange Offer), (ii) complete the A/B Exchange Offer by July 31, 2015 or, under specified circumstances, (iii) file a shelf registration statement with the SEC covering resales of the 2019 Endo Finance Notes. The Endo Finance Issuers may be required to pay additional interest if they fail to comply with the registration and exchange requirements set forth in the registration rights agreement.
	2019 Notes in General
	The 2019 Notes are senior unsecured obligations of the issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2019 Notes is payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2012. The 2019 Notes will mature on July 15, 2019, subject to earlier repurchase or redemption in accordance with the terms of the 2019 Notes indentures incorporated by reference herein.
	On or after July 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2019 Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From July 15, 2015 to and including July 14, 2016	103.5	%
	From July 15, 2016 to and including July 14, 2017	101.75	%
	From July 15, 2017 and thereafter	100	%
	In addition, at any time prior to July 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2019 Notes at a specified redemption price set forth in the indentures, plus accrued and unpaid interest and additional interest, if any. If certain of the issuers experience certain change of control events, they must offer to repurchase the 2019 Notes at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
	The 2019 Notes indentures contain covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate, or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2019 Notes receiving investment grade credit ratings.
	7.00% Senior Notes Due 2020
	2020 EHSI Notes
	In November 2010, EHSI issued $400.0 million in aggregate principal amount of 7.00% senior notes due 2020 (the Original 2020 EHSI Notes) at an issue price of 99.105%. The Original 2020 EHSI Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. On November 30, 2011, all of the Original 2020 EHSI Notes were properly tendered and not withdrawn in an exchange for new notes (the 2020 EHSI Notes) having identical terms that had been registered under the Securities Act of 1933, as amended. Additionally, on May 6, 2014, $393.0 million of the 2020 EHSI Notes were exchanged for new notes issued by the Endo Finance Issuers. In connection with the exchange offer, the holders who tendered their 2020 EHSI Notes consented to (i) deleting substantially all the restrictive covenants in the indenture governing the 2020 EHSI Notes, (ii) modifying the covenants regarding mergers and consolidations and (iii) eliminating certain events of default. A total of $7.0 million of the existing 2020 EHSI Notes remained outstanding subsequent to the exchange.
	2020 Endo Finance Notes
	On May 6, 2014, the Endo Finance Issuers issued approximately $393.0 million in aggregate principal amount of 7.00% senior notes due 2020 (the 2020 Endo Finance Notes; collectively with the 2020 EHSI Notes, the 2020 Notes) in exchange for approximately $393.0 million aggregate principal amount of 2020 EHSI Notes. The 2020 Endo Finance Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
	Also on May 6, 2014, the Endo Finance Issuers and the guarantors of the 2020 Endo Finance Notes entered into a registration rights agreement under which they will be required to use their commercially reasonable efforts to (i) file with the SEC by March 31, 2015 an exchange offer registration statement pursuant to which they will offer, in exchange for the 2020 Endo Finance Notes, new notes having terms substantially identical in all material respects to those of the 2020 Endo Finance Notes (except the new notes will not contain terms with respect to transfer restrictions) (the A/B Exchange Offer), (ii) complete the A/B Exchange Offer by July 31, 2015 or, under specified circumstances, (iii) file a shelf registration statement with the SEC covering resales of the 2020 Endo Finance Notes. The Endo Finance Issuers may be required to pay additional interest if they fail to comply with the registration and exchange requirements set forth in the registration rights agreement.
	2020 Notes in General
	The 2020 Notes are senior unsecured obligations of the issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2020 Notes is payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2011. The 2020 Notes will mature on December 15, 2020, subject to earlier repurchase or redemption in accordance with the terms of the 2020 Notes indentures incorporated by reference herein.
	On or after December 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2020 Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on December 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From December 15, 2015 to and including December 14, 2016	103.5	%
From December 15, 2016 to and including December 14, 2017	102.333	%
From December 15, 2017 to and including December 14, 2018	101.167	%
From December 15, 2018 and thereafter	100	%
In addition, at any time prior to December 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2020 Notes at a specified redemption price set forth in the 2020 Notes indentures, plus accrued and unpaid interest and additional interest, if any. If certain of the issuers experience certain change of control events, they must offer to repurchase the 2020 Notes at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
The 2020 Notes indentures contain covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate, or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2020 Notes receiving investment grade credit ratings.
7.25% Senior Notes Due 2022
2022 EHSI Notes—7.25%
On June 8, 2011, EHSI issued $400.0 million in aggregate principal amount of 7.25% senior notes due 2022 (the Original 2022 EHSI Notes—7.25%) at an issue price of par. The Original 2022 EHSI Notes—7.25% were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. On November 30, 2011, all of the Original 2022 EHSI Notes—7.25% were properly tendered and not withdrawn in an exchange for new notes (the 2022 EHSI Notes—7.25%) having identical terms that had been registered under the Securities Act of 1933, as amended. Additionally, on May 6, 2014, $396.3 million of the 2022 EHSI Notes—7.25% were exchanged for new notes issued by the Endo Finance Issuers. In connection with the exchange offer, the holders who tendered their 2022 EHSI Notes—7.25% consented to (i) deleting substantially all the restrictive covenants in the indenture governing the 2022 EHSI Notes—7.25%, (ii) modifying the covenants regarding mergers and consolidations and (iii) eliminating certain events of default. A total of $3.7 million of the existing 2022 EHSI Notes—7.25% remained outstanding subsequent to the exchange.
The aggregate consent payment paid in connection with the May 6, 2014 exchange offers and consent solicitations for each of the senior notes described above was approximately $11.7 million, which was recorded as debt issuance costs and included in Other assets in our Consolidated Balance Sheets. In connection with these transactions, we also charged $5.3 million to expense related to fees paid to third parties related to the exchange offers. This amount was included in the Consolidated Statements of Operations as a Loss on extinguishment of debt.
2022 Endo Finance Notes—7.25%
On May 6, 2014, the Endo Finance Issuers issued approximately $396.3 million in aggregate principal amount of 7.25% senior notes due 2022 (the 2022 Endo Finance Notes—7.25%; collectively with the 2022 EHSI Notes—7.25%, the 2022 Notes—7.25%) in exchange for approximately $396.3 million aggregate principal amount of 2022 EHSI Notes—7.25%. The 2022 Endo Finance Notes—7.25% were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Also on May 6, 2014, the Endo Finance Issuers and the guarantors of the 2022 Endo Finance Notes—7.25% entered into a registration rights agreement under which they will be required to use their commercially reasonable efforts to (i) file with the SEC by March 31, 2015 an exchange offer registration statement pursuant to which they will offer, in exchange for the 2022 Endo Finance Notes—7.25%, new notes having terms substantially identical in all material respects to those of the 2022 Endo Finance Notes—7.25% (except the new notes will not contain terms with respect to transfer restrictions) (the A/B Exchange Offer), (ii) complete the A/B Exchange Offer by July 31, 2015 or, under specified circumstances, (iii) file a shelf registration statement with the SEC covering resales of the 2022 Endo Finance Notes—7.25%. The Endo Finance Issuers may be required to pay additional interest if they fail to comply with the registration and exchange requirements set forth in the registration rights agreement.
2022 Notes—7.25% in General
The 2022 Notes—7.25% are senior unsecured obligations of the issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2022 Notes—7.25% is payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2012. The 2022 Notes—7.25% will mature on January 15, 2022, subject to earlier repurchase or redemption in accordance with the terms of the 2022 Notes—7.25% indentures incorporated by reference herein.
On or after July 15, 2016, the issuers may on any one or more occasions redeem all or a part of the 2022 Notes—7.25% at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
Payment Dates (between indicated dates)	Redemption
	Percentage
From July 15, 2016 to and including July 14, 2017	103.625	%
From July 15, 2017 to and including July 14, 2018	102.417	%
From July 15, 2018 to and including July 14, 2019	101.208	%
From July 15, 2019 and thereafter	100	%
In addition, at any time prior to July 15, 2016, the issuers may on any one or more occasions redeem all or a part of the 2022 Notes—7.25% at a specified redemption price set forth in the 2022 Notes—7.25% indentures, plus accrued and unpaid interest and additional interest, if any. If certain of the issuers experience certain change of control events, they must offer to repurchase the 2022 Notes—7.25% at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
The 2022 Notes—7.25% indentures contain covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate, or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2022 Notes—7.25% receiving investment grade credit ratings.
5.75% Senior Notes Due 2022
On December 19, 2013, Endo Finance Co. issued $700.0 million in aggregate principal amount of 5.75% senior notes due 2022 (the 2022 Notes—5.75%). The 2022 Notes—5.75% indenture was amended and restated on February 28, 2014, at which time Endo Finance LLC became the issuer and Endo Finco Inc. became co-obligor. The 2022 Notes—5.75% were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
The 2022 Notes—5.75% are senior unsecured obligations of the Endo Finance Issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2022 Notes—5.75% is payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2014. The 2022 Notes—5.75% will mature on January 15, 2022, subject to earlier repurchase or redemption in accordance with the terms of the 2022 Notes—5.75% indenture incorporated by reference herein.
Costs associated with this offering, including costs related to investment bankers, of $12.8 million were deferred to be amortized over the term of the 2022 Notes—5.75% and included in Other assets in our Consolidated Balance Sheets. Prior to the closing of the Paladin acquisition, proceeds from the 2022 Notes—5.75% were restricted and held in escrow and could not be utilized by the Company. This amount was included in Restricted cash and cash equivalents in our Consolidated Balance Sheets at December 31, 2014.
On or after January 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2022 Notes—5.75%, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on January 15 of the years indicated below:
Payment Dates (between indicated dates)	Redemption
	Percentage
From January 15, 2017 to and including January 14, 2018	104.313	%
From January 15, 2018 to and including January 14, 2019	102.875	%
From January 15, 2019 to and including January 14, 2020	101.438	%
From January 15, 2020 and thereafter	100	%
In addition, at any time prior to January 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2022 Notes—5.75% at a specified redemption price set forth in the indenture, plus accrued and unpaid interest and additional interest, if any. In addition, prior to January 15, 2017 the Endo Finance Issuers may redeem up to 35% of the aggregate principal amount of the 2022 Notes—5.75% with the net cash proceeds from specified equity offerings at a redemption price equal to 105.750% of the aggregate principal amount of the 2022 Notes—5.75% redeemed, plus accrued and unpaid interest. If Endo Limited experiences certain change of control events, the Endo Finance Issuers must offer to repurchase the 2022 Notes—5.75% at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
The 2022 Notes—5.75% indenture contains covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate, or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2022 Notes—5.75% receiving investment grade credit ratings.
5.375% Senior Notes Due 2023
On June 30, 2014, the Endo Finance Issuers issued $750.0 million in aggregate principal amount of 5.375% senior notes due 2023 (the 2023 Notes). The 2023 Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
The 2023 Notes are senior unsecured obligations of the Endo Finance Issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2023 Notes is payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2015. The 2023 Notes will mature on January 15, 2023, subject to earlier repurchase or redemption in accordance with the terms of the 2023 Notes indenture incorporated by reference herein.
Costs associated with this offering, including costs related to investment bankers, of $12.6 million were deferred to be amortized over the term of the 2023 Notes and included in Other assets in our Consolidated Balance Sheets. The 2023 Notes were issued for general corporate purposes, which included acquisitions, including the acquisition of DAVA.
On or after July 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2023 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
Payment Dates (between indicated dates)	Redemption
	Percentage
From July 15, 2017 to and including July 14, 2018	104.031	%
From July 15, 2018 to and including July 14, 2019	102.688	%
From July 15, 2019 to and including July 14, 2020	101.344	%
From July 15, 2020 and thereafter	100	%
In addition, at any time prior to July 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2023 Notes at a specified redemption price set forth in the indenture, plus accrued and unpaid interest and additional interest, if any. In addition, prior to January 15, 2017 the Endo Finance Issuers may redeem up to 35% of the aggregate principal amount of the 2023 Notes with the net cash proceeds from specified equity offerings at a redemption price equal to 105.375% of the aggregate principal amount of the 2023 Notes redeemed, plus accrued and unpaid interest. If Endo Limited experiences certain change of control events, the Endo Finance Issuers must offer to repurchase the 2023 Notes at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
The 2023 Notes indenture contains covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate, or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2023 Notes receiving investment grade credit ratings.
Also on June 30, 2014, the Endo Finance Issuers and the guarantors of the 2023 Notes entered into a registration rights agreement under which they will be required to use their commercially reasonable efforts to (i) file with the SEC by July 31, 2015 an exchange offer registration statement pursuant to which they will offer, in exchange for the 2023 Notes, new notes having terms substantially identical in all material respects to those of the 2023 Notes (except the new notes will not contain terms with respect to transfer restrictions) (the A/B Exchange Offer), (ii) complete the A/B Exchange Offer by July 31, 2015 or, under specified circumstances, (iii) file a shelf registration statement with the SEC covering resales of the 2023 Notes. The Endo Finance Issuers may be required to pay additional interest if they fail to comply with the registration and exchange requirements set forth in the registration rights agreement.
1.75% Convertible Senior Subordinated Notes Due 2015
At December 31, 2014, our indebtedness included 1.75% Convertible Senior Subordinated Notes due April 15, 2015 (the Convertible Notes). In May 2014, we repurchased approximately $240.7 million aggregate principal amount of the Convertible Notes for approximately $548.2 million, including accrued interest. In addition, in July 2014 we repurchased approximately $40.0 million aggregate principal amount of the Convertible Notes for approximately $95.2 million, which included the issuance of 798,367 ordinary shares valued at approximately $55.2 million. The combined repurchases during 2014 reduced the outstanding principal amount of the Convertible Notes to approximately $98.8 million. In connection with the May 2014 and July 2014 repurchases, we charged $14.8 million and $2.0 million, respectively, to expense, representing the differences between the fair value of the repurchased debt components and their carrying amount, as well as third-party costs related to the transactions. The expenses were included in the Consolidated Statements of Operations as a Loss on extinguishment of debt. Additionally, we recorded a combined decrease to Additional paid-in capital in the amount of $365.0 million, representing the fair value of the equity component of the repurchased Convertible Notes.
Holders of the Convertible Notes were initially entitled to convert their Convertible Notes into cash and/or shares of EHSI’s common stock. Under the supplemental indenture entered into in connection with the Paladin acquisition, the Convertible Notes became exchangeable into cash and/or ordinary shares, and we became a co-obligor with respect to the Convertible Notes. We and EHSI are permitted to deliver cash, ordinary shares or a combination of cash and ordinary shares, at our election, to satisfy any future conversions of the Convertible Notes.
The Convertible Notes became convertible at the option of holders beginning October 1, 2013. The conversion right was triggered on September 17, 2013, when the closing sale price of the Company’s ordinary shares on the NASDAQ Stock Exchange exceeded $37.96 (130% of the conversion price of $29.20) for the 20th trading day in the 30 consecutive trading days ending on September 30, 2013 and the remaining balance of the Convertible Notes remains convertible at December 31, 2014. We have elected to settle the remaining principal amount of any conversion consideration in cash. Holders of the remaining Convertible Notes may surrender their notes for conversion at any time prior to the close of business on the second business day immediately preceding the stated maturity date. In the event that holders exercise the right to convert their Convertible Notes, the Company will write-off a ratable portion of the associated debt issuance costs. The Company has included the Convertible Notes in the current portion of long-term debt in its Consolidated Balance Sheets as of December 31, 2014 and, because the conversion right was triggered on September 17, 2013, as of December 31, 2013.
Concurrently with the issuance of the Convertible Notes, EHSI entered into a privately negotiated convertible note hedge transaction with affiliates of the initial purchasers. Pursuant to the hedge transaction EHSI purchased approximately 13.0 million ordinary share call options intended to reduce the potential dilution to our ordinary shares upon conversion of the Convertible Notes by effectively increasing, after taking into account the sold warrants discussed below, the initial conversion price of the Convertible Notes to $40.00 per share, representing a 61.1% conversion premium over the closing price of our ordinary shares on April 9, 2008 of $24.85 per share. The call options allowed us to purchase up to approximately 13.0 million of our ordinary shares at an initial strike price of $29.20 per share. The call options expire on April 15, 2015 and must be net-share settled. The cost of the call option was approximately $107.6 million. In addition, EHSI sold warrants to affiliates of certain of the initial purchasers whereby they have the option to purchase up to approximately 13.0 million of our ordinary shares at an initial strike price of $40.00 per share. The warrants expire on various dates from July 14, 2015 through October 6, 2015 and must be net-share settled. EHSI received approximately $50.4 million in cash proceeds from the sale of these warrants. The warrant transaction could have a dilutive effect on our net income per share to the extent that the price of our ordinary shares exceeds the strike price of the warrants at exercise.
In connection with the May 2014 and July 2014 Convertible Notes repurchase activity, we entered into agreements with the note hedge counterparty to settle a portion of the call options and warrants. In connection with these agreements, as part of the May 2014 and July 2014 repurchases, we settled call options representing the right to purchase approximately 8.2 million and 1.4 million ordinary shares, respectively, for total cash consideration paid by the counterparty of $302.1 million and $54.2 million, respectively, which were recorded as increases to Additional paid-in capital. The remaining call options, which allow us to purchase up to approximately an additional 3.4 million of our ordinary shares at a strike price of $29.20 per share, expire on April 15, 2015 and must be net-share settled. In connection with these agreements, as part of the May 2014 and July 2014 repurchases, we also settled approximately 8.2 million and 1.4 million, respectively, of warrants for cash consideration paid by EHSI of $242.2 million and $42.3 million, respectively, which were recorded as reductions to Additional paid-in capital. Subsequent to these transactions, the holders of the remaining warrants have the option to purchase up to approximately 3.4 million of our ordinary shares at strike price of $40.00 per share. The remaining warrants expire on various dates from July 14, 2015 through October 6, 2015 and must be net-share settled. The remaining warrants have a dilutive effect on our net income per share to the extent that the price of our ordinary shares exceeds the strike price of the warrants at exercise.
As discussed in Note 20. Net (Loss) Income Per Share, in periods in which our ordinary shares price exceeds the conversion price of the Convertible Notes or the strike price of the warrants, we include the effects of the additional shares that may be issued in our diluted net loss per share calculation using the treasury stock method.
Maturities
Maturities on long-term debt for each of the next 5 years as of December 31, 2014 are as follows (in thousands):
	December 31,
	2014
2015	$	157,695
2016	$	82,229
2017	$	109,946
2018	$	155,500
2019	$	1,191,625

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	NOTE 14. COMMITMENTS AND CONTINGENCIES
	Manufacturing, Supply and Other Service Agreements
	Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging and labeling services. The most significant of these agreements are with Novartis Consumer Health, Inc. and Novartis AG (collectively, Novartis), Teikoku Seiyaku Co., Ltd., Noramco, Inc., Grünenthal GmbH, Sharp Corporation and UPS Supply Chain Solutions, Inc. If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for their products or services needed to conduct their business, it could have a material adverse effect on our business, financial condition, results of operations and cash flows.
	In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.
	Novartis License and Supply Agreement
	Pursuant to the March 2008 Voltaren® Gel License and Supply Agreement (the Voltaren® Gel Agreement) with Novartis AG and Novartis Consumer Health, Inc. EPI has agreed to purchase from Novartis all of its requirements for Voltaren® Gel during the entire term of the Voltaren® Gel Agreement. The price of product purchased under the Voltaren® Gel Agreement is fixed for the first year and subject to annual changes based upon changes in the producer price index and raw materials. Amounts purchased pursuant to the Voltaren® Gel Agreement were $55.0 million, $50.2 million and $34.0 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Teikoku Seiyaku Co., Ltd.
	Under the terms of EPI’s agreement (the Teikoku Agreement) with Teikoku Seiyaku Co. Ltd. (Teikoku), a Japanese manufacturer, Teikoku manufactures Lidoderm® at its two Japanese facilities, located on adjacent properties, for commercial sale by EPI in the U.S. EPI also has an option to extend the supply area to other territories. EPI amended the Teikoku agreement on April 24, 2007, January 6, 2010, November 1, 2010 and February 25, 2015 (together, the Amended Agreement). The material components of the Amended Agreement are as follows:
	•	EPI agreed to issue firm purchase orders for a minimum number of patches per year through 2017, representing the noncancelable portion of the Amended Agreement. There is a lower minimum purchase requirement in effect subsequent to 2017. EPI has met its minimum purchase requirement for 2014.
	•	Teikoku agreed to fix the supply price of Lidoderm® for a period of time after which the price will be adjusted at future dates certain based on a price index defined in the Amended Agreement.
	•	Following cessation of EPI’s obligation to pay royalties to Hind Healthcare Inc. (Hind) under the Sole and Exclusive License Agreement dated as of November 23, 1998, as amended, between Hind and EPI (the Hind Agreement), EPI began to pay to Teikoku annual royalties based on annual net sales of Lidoderm®.
	•	The Amended Agreement will not expire until December 31, 2021, unless terminated in accordance with its terms. After December 31, 2021, the Amended Agreement shall be automatically renewed on the first day of January each year unless terminated in accordance with its terms.
	•	Either party may terminate the Amended Agreement, following a 45-day cure period, in the event that EPI fails to issue firm purchase orders for the annual minimum quantity for each year after 2017.
	•	EPI is the exclusive licensee for any authorized generic for Lidoderm® until the later of August 15, 2017 or the date of the first commercial sale of the second non-Teikoku generic version of Lidoderm®.
	Amounts purchased pursuant to the Teikoku Agreement, as amended, were $45.1 million, $167.0 million and $179.5 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	On November 23, 2011, EPI’s obligation to pay royalties to Hind under the Hind Agreement ceased. Accordingly, on November 23, 2011, pursuant to the terms of the Teikoku Agreement, EPI began to incur royalties to Teikoku based on annual net sales of Lidoderm®. The royalty rate is 6% of branded Lidoderm® net sales. During the years ended December 31, 2014, 2013 and 2012, we recorded $19.1 million, $35.0 million and $55.7 million for these royalties to Teikoku, respectively. These amounts were included in our Consolidated Statements of Operations as Cost of revenues. At December 31, 2014, $19.1 million is recorded as a royalty payable and included in Accounts payable in the accompanying Consolidated Balance Sheets.
	Noramco, Inc.
	Under the terms of our agreement (the Noramco Agreement) with Noramco, Inc. (Noramco), Noramco manufactured and supplied to us certain narcotic active drug substances, in bulk form, and raw materials for inclusion in our controlled substance pharmaceutical products. There were no minimum annual purchase commitments under the Noramco Agreement. However, we were required to purchase a fixed percentage of our annual requirements of each narcotic active drug substance covered by the Noramco Agreement from Noramco. The purchase price for these substances was equal to a fixed amount, adjusted on an annual basis. Originally, the Noramco Agreement was to expire on December 31, 2011, with automatic renewal provisions for unlimited successive one-year periods. In September 2011, we extended the Noramco Agreement through early 2012. On April 27, 2012, we entered into a new supply agreement with Noramco (the 2012 Noramco Agreement). Under the terms of this supply agreement, Noramco manufactures and supplies to us certain narcotic active drug substances, in bulk form, for inclusion in our controlled substance pharmaceutical products. There are no minimum annual purchase commitments under the 2012 Noramco Agreement. However, we are required to purchase from Noramco a fixed percentage of our annual requirements of each narcotic active drug substance covered by the 2012 Noramco Agreement. The purchase price for these substances is equal to a fixed amount, adjusted on an annual basis based on volume. The term of the 2012 Noramco Agreement is for four years with automatic renewal provisions for unlimited successive one-year periods. The Noramco Agreement may be terminated at any time upon mutual written agreement between the parties or by either party in certain circumstances upon providing sufficient written notice to the other party.
	Amounts purchased from Noramco were $76.0 million, $66.1 million and $52.9 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Grünenthal GmbH
	Under the terms of EPI’s December 2007 License, Development and Supply Agreement with Grünenthal (the Grünenthal Agreement), Grünenthal agreed to manufacture and supply to EPI a crush-resistant formulation of Opana® ER based on a supply price equal to a certain percentage of net sales of Opana® ER, subject to a floor price. In the first quarter of 2012, we began production of the crush-resistant formulation of Opana® ER at a third party manufacturing facility managed by Grünenthal. The Grünenthal Agreement will expire on the later of (i) the 15th anniversary of the date of first commercial sale of the product, (ii) the expiration of the last issued patent in the territory claiming or covering products or (iii) the expiration of exclusivity granted by the FDA for the last product developed under the Grünenthal Agreement. Either party may terminate the Grünenthal Agreement in certain circumstances upon providing sufficient written notice to the other party. Effective December 19, 2012, EPI and Grünenthal amended the Grünenthal Agreement whereby EPI became responsible for the planning of packaging of finished product and certain other routine packaging quality obligations and Grünenthal agreed to reimburse EPI for the third-party costs incurred related to packaging as well as pay EPI a periodic packaging fee. The amendment also changed certain of the terms with respect to the floor price required to be paid by EPI in consideration for product supplied by Grünenthal.
	EPI’s license and supply payments made to Grünenthal pursuant to the Grünenthal Agreement are recorded in Cost of revenues in our Consolidated Financial Statements and must be paid in U.S. dollars within 45 days after each calendar quarter. We incurred $32.9 million, $35.3 million and $35.7 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Sharp Corporation
	Under the terms of our agreement (the Sharp Agreement) with Sharp Corporation (Sharp), a U.S. manufacturer, Sharp performs certain packaging and labeling services for Endo, including the packaging and labeling of Lidoderm® at its facilities in Allentown, Pennsylvania and Conshohocken, Pennsylvania, for commercial sale by us in the U.S. Effective June 1, 2012, the parties amended the Sharp Agreement to include several new products that Sharp will package and label. These products include our formulation of Opana® ER designed to be crush-resistant, Vantas®, Supprelin® LA, Valstar® and several SKUs of generic prednisone and methylprednisolone. The Sharp Agreement is effective until March 2015 and is subject to renewal for additional one-year periods upon mutual agreement by both parties. Endo has the right to terminate the Sharp Agreement at any time upon 90 days’ written notice to Sharp.
	Amounts purchased pursuant to the Sharp agreement were $2.0 million, $7.8 million and $9.5 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Ventiv Commercial Services, LLC
	On December 27, 2011, EPI entered into a Sales and Promotional Services Agreement (the Ventiv Agreement) with Ventiv Commercial Services, LLC (Ventiv), effective as of December 30, 2011. Under the terms of the Ventiv Agreement, Ventiv provided to EPI certain sales and promotional services through a contracted field force, collectively referred to as the Ventiv Field Force. The Ventiv Field Force promoted Voltaren® Gel, Lidoderm®, Frova®, Opana® ER, Fortesta® Gel and any additional products added by EPI. The sales representatives were required to perform face-to-face, one-on-one discussions with physicians and other healthcare practitioners promoting these products.
	EPI paid to Ventiv a monthly fixed fee during the term of the Ventiv Agreement based on a budget that had been approved by both EPI and Ventiv. During the term of the Ventiv Agreement, Ventiv was also eligible to earn, in addition to the fixed management fee, an at-risk management fee. This at-risk management fee was payable upon the achievement of certain performance metrics mutually agreed upon by the parties.
	On September 26, 2012, the Ventiv Agreement was amended to decrease the size of the Ventiv Field Force and the fees payable to Ventiv. On May 31, 2013, EPI terminated the Ventiv Agreement, effective July 1, 2013. The termination did not give rise to any early termination fees or penalties.
	There were no expenses incurred with respect to Ventiv for the year ended December 31, 2014. The expenses incurred with respect to Ventiv were $15.1 million and $37.2 million for the years ended December 31, 2013 and 2012, respectively. These amounts were included within Selling, general and administrative expense in the accompanying Consolidated Statements of Operations.
	UPS Supply Chain Solutions
	Under the terms of this agreement, EPI utilizes UPS Supply Chain Solutions (UPS) to provide customer service support and warehouse, freight and distribution services for certain of its products in the U.S. The initial term of the agreement extends through March 31, 2015. The agreement may be terminated by either EPI or UPS (1) without cause upon prior written notice to the other party; (2) with cause in the event of an uncured material breach by the other party; and (3) if the other party become insolvent or bankrupt. In the event of termination of services provided under the Warehouse Distribution Services Schedule to the agreement (i) by EPI without cause or (ii) by UPS due to EPI’s breach, failure by EPI to make payments when due, or EPI’s insolvency, EPI would be required to pay UPS certain termination costs. Such termination costs would not be material to the Company’s Consolidated Statements of Operations. On February 21, 2012, EPI amended this agreement to provide for a reduced pricing structure, which includes new monthly fees, new variable fees and new termination fees. On August 16, 2013, EPI further amended this agreement to add another mode of transport permissible under the agreement.
	General
	In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a materially adverse effect on our business, financial condition, results of operations and cash flows.
	Milestones and Royalties
	See Note 11. License and Collaboration Agreements for a complete description of future milestone and royalty commitments pursuant to our acquisitions, license and collaboration agreements.
	Legal Proceedings
	We and certain of our subsidiaries are involved in various claims, legal proceedings and governmental investigations that arise from time to time in the ordinary course of our business, including relating to product liability, intellectual property, regulatory compliance and commercial matters. While we cannot predict the outcome of these ongoing legal proceedings and we and our subsidiaries intend to defend vigorously our and their position, an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows.
	As of December 31, 2014, the Company’s reserve for loss contingencies totaled approximately $1.71 billion, of which $1.66 billion relates to the Company’s product liability accrual for all known pending and estimated future claims related to vaginal mesh cases. The increase in our reserve reflects management’s ongoing assessment of our entire liability portfolio, including the vaginal mesh cases. During 2014, the Company announced that it had reached master settlement agreements with several of the leading plaintiffs’ law firms to resolve claims relating to vaginal mesh products sold by the Company’s AMS subsidiary. The agreements were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. Although the Company believes there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.
	Product Liability
	We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various federal and state courts, as well as in Canada and other countries outside the United States, alleging personal injury resulting from the use of certain of our products and the products of our subsidiaries. These matters are described in more detail below.
	The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage. The Company and its subsidiaries intend to contest vigorously all such disputes with respect to their insurance coverage and to enforce their rights under the terms of these insurance policies, and accordingly, the Company will record receivables with respect to amounts due under these policies, only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under the Company’s product liability insurance policies will be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.
	Vaginal Mesh Cases. On October 20, 2008, the FDA issued a Public Health Notification regarding potential complications associated with transvaginal placement of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The notification provides recommendations and encourages physicians to seek specialized training in mesh procedures, to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications.
	In July 2011, the FDA issued an update to the October 2008 Public Health Notification regarding mesh to further advise the public and the medical community of the potential complications associated with transvaginal placement of surgical mesh to treat POP and SUI. In this July 2011 update, the FDA maintained that adverse events are not rare, as previously reported, and questioned the relative effectiveness of transvaginal mesh as a treatment for POP as compared to non-mesh surgical repair. The July 2011 notification continued to encourage physicians to seek specialized training in mesh procedures, to consider and to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications. The FDA also convened an advisory panel which met on September 8-9, 2011 to further address the safety and effectiveness of transvaginal surgical mesh used to treat POP and SUI. At the conclusion of the meetings, the advisory panel recommended reclassifying transvaginal mesh products used to treat POP to Class III devices (premarket approval) and recommended that manufacturers of these products be required to conduct additional post-market surveillance studies. The advisory panel recommended that transvaginal surgical mesh products used to treat SUI remain as Class II devices. Regarding retropubic and transobturator (TOT) slings, the advisory panel recommended that no additional post-market surveillance studies are necessary. Regarding mini-slings, the advisory panel recommended premarket studies for new devices and additional post-market surveillance studies.
	On January 3, 2012, the FDA ordered manufacturers of transvaginal surgical mesh used for POP and of single incision mini-slings for urinary incontinence, such as our subsidiary AMS, to conduct post-market safety studies and to monitor adverse event rates relating to the use of these products. AMS received a total of nineteen class-wide post-market study orders regarding its pelvic floor repair and mini-sling products; however, the FDA agreed to place sixteen of these study orders on hold for a variety of reasons. Three of these post-market study orders remain active and AMS is continuing the process of complying with these orders. In these orders, the FDA also noted that it is still considering the recommendation of the September 9, 2011 advisory committee that urogynecological surgical mesh for transvaginal repair of POP be reclassified from Class II to Class III.
	On April 29, 2014, the FDA issued a statement proposing to reclassify surgical mesh for transvaginal pelvic organ prolapse repair from Class II to Class III. Further, the FDA proposed to reclassify urogynecologic surgical mesh instrumentation from Class I to Class II, and to establish special controls for surgical instrumentation for use with urogynecologic surgical mesh. The FDA stated that it was proposing these changes based on the tentative determination that general controls by themselves are insufficient to provide reasonable assurance of the safety and effectiveness of these devices. Although this proposal was subject to a 90-day comment period, to date the FDA has not taken further action regarding these proposals.
	Since 2008, AMS, and more recently, in certain cases the Company or certain of its subsidiaries, have been named as defendants in multiple lawsuits in various state courts, a multidistrict litigation (MDL) in the Southern District of West Virginia (MDL No. 2325), as well as in Canada, and other countries outside the United States alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. Plaintiffs in these suits allege various personal injuries including chronic pain, incontinence and inability to control bowel function and permanent deformities.
	As of December 31, 2014, AMS and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) regarding settling up to approximately 45,400 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs, which were executed at various times from June 14, 2013 through December 31, 2014, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault by the Company or AMS. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of Qualified Settlement Funds (QSFs) into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation thresholds requiring participation by the majority of claims represented by each law firm. If certain participation thresholds are not met, then AMS will have the right to terminate the settlement with that law firm. In addition, one agreement gives AMS a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in Qualified Settlement Funds are included in Restricted cash and cash equivalents in the December 31, 2014 Consolidating Balance Sheet.
	Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and a dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant shall represent and warrant that liens, assignment rights, or other claims that are identified in the claims administration process have been or will be satisfied by the individual claimant. The amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlement shall be kept confidential by all parties and their counsel.
	The following table presents the changes in the vaginal mesh Qualified Settlement Funds and product liability balance during the year ended December 31, 2014 (in thousands):
		Qualified Settlement Funds			Product Liability
	Balance as of December 31, 2013	$	11,518		$	520,000
	Additional charges	—			1,273,358
	Cash distributions to Qualified Settlement Funds	585,165			—
	Cash distributions to settle disputes from Qualified Settlement Funds	(111,454		)	(111,454		)
	Cash distributions to settle disputes	—			(26,709		)
	Balance as of December 31, 2014	$	485,229		$	1,655,195
	While the Company is retaining the liability for all known pending and estimated future claims related to vaginal mesh cases related to products sold prior to the sale date, the Company is pursuing the sale of the underlying vaginal mesh products to a third party and thus the litigation expense and legal defense costs specifically attributable to the vaginal mesh cases has been included in Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	Our estimated liability includes a reduction factor of approximately 20% applied to the maximum number of potentially eligible claims resulting in a liability that is lower than the maximum payouts under the MSAs. This reduction factor is based on our estimate of likely duplicative claims and claims that will not ultimately obtain recovery under the MSAs or otherwise.
	Approximately $1.39 billion of the total liability amount shown above is classified as Current portion of legal settlement accrual, with the remainder classified as Long-term legal settlement accrual, less current portion, net in the December 31, 2014 Consolidating Balance Sheet. The $1.39 billion consists of two components: the maximum contractual 2015 cash payments called for under the MSAs and the Qualified Settlement Funds balance of $485.2 million. The maximum contractual 2015 cash payments does not include the reduction factor described above. AMS expects to fund the payments under all settlement agreements by December 31, 2017. As the funds are disbursed out of the Qualified Settlement Funds from time to time, the product liability accrual will be reduced accordingly with a corresponding reduction to Restricted cash and cash equivalents. In addition, the Company may pay cash distributions to settle disputes separate from the Qualified Settlement Funds, which will also decrease the product liability accrual but will not decrease Restricted cash and cash equivalents.
	AMS and the Company intend to contest vigorously all currently remaining pending cases and any future cases that may be brought, if any, and to continue to explore other options as appropriate in the best interests of the Company and AMS. However, it is not possible at this time to determine with certainty the ultimate outcome of these matters or the effect of potential future claims. We will continue to monitor each related legal claim and adjust the accrual for new information and further developments. It is possible that the outcomes of such cases could result in additional losses that could have a material adverse effect on our business, financial condition, results of operations and cash flows.
	In addition, we have been contacted regarding a civil investigation that has been initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and have subsequently received additional subpoenas from other states. We are cooperating fully with this investigation. At this time, we cannot predict or determine the outcome of this investigation or reasonably estimate the amount or range of amounts of fines or penalties, if any, that might result from a settlement or an adverse outcome from this investigation.
	MCP Cases. Qualitest, and in certain cases the Company or certain of its subsidiaries, along with several other pharmaceutical manufacturers, have been named as defendants in numerous lawsuits in various federal and state courts alleging personal injury resulting from the use of the prescription medicine metoclopramide. Plaintiffs in these suits allege various personal injuries including tardive dyskinesia, other movement disorders and death. Qualitest and the Company intend to contest all of these cases vigorously and to explore other options as appropriate in the best interests of the Company and Qualitest.
	Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any additional litigation will be brought against the Company or its subsidiaries. As of February 20, 2015, approximately 600 MCP cases, some of which may have been filed on behalf of multiple plaintiffs, are currently pending against Qualitest and/or the Company or certain of its subsidiaries.
The Company and its subsidiaries have reached an agreement with certain plaintiffs’ counsel in an effort to reach resolution of substantially all of these pending MCP cases. The agreement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by the Company or any of its subsidiaries. An essential element of these settlements will be participation by the majority of plaintiffs involved in pending litigation. If certain participation thresholds are not met, the Company will have the right to terminate the agreements.
Distribution of funds to any individual plaintiff will be conditioned upon, among other things a full release and a dismissal with prejudice of the entire action or claim as to the Company and/or each of its subsidiaries. Prior to receiving an award, an individual claimant shall represent and warrant that liens, assignment rights, or other claims that are identified in the claims administration process have been or will be satisfied by the individual claimant. The amount of settlement awards to participating plaintiffs, claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlement shall be kept confidential by all parties and their counsel. The cost of this settlement has been incorporated into the increase in our legal loss contingency reserve.
Propoxyphene Cases. Qualitest and, in certain cases, the Company or certain of its subsidiaries, along with several other pharmaceutical manufacturers, have been named as defendants in numerous lawsuits originally filed in various federal and state courts alleging personal injury resulting from the use of prescription pain medicines containing propoxyphene. Plaintiffs in these suits allege various personal injuries including cardiac impairment, damage and death. In August 2011, a multidistrict litigation (MDL) was formed, and certain transferable cases pending in federal court were coordinated in the Eastern District of Kentucky as part of MDL No. 2226. On March 5, 2012 and June 22, 2012, pursuant to a standing show cause order, the MDL Judge dismissed with prejudice certain claims against generic manufacturers, including Qualitest and the Company. Certain plaintiffs appealed those decisions to the U.S. Court of Appeals for the Sixth Circuit. On June 27, 2014, the Sixth Circuit affirmed the dismissal of the cases that had been pending as part of a consolidated appeal. In November 2012, additional cases were filed in various California state courts. While many of these cases were initially remanded and pending in a state court coordinated proceeding in Los Angeles, the Ninth Circuit sitting en banc has reversed these remands, finding federal subject matter jurisdiction. As a result, these actions have been returned to the federal courts to which they were initially removed. On November 18, 2014, additional multi-plaintiff cases were filed in state court in Oklahoma. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any additional litigation will be brought against the Company or its subsidiaries, but Qualitest and the Company intend to contest the litigation vigorously and to explore all options as appropriate in the best interests of Qualitest and the Company. As of February 20, 2015, approximately 47 propoxyphene cases, some of which may have been filed on behalf of multiple plaintiffs, are currently pending against Qualitest and/or the Company. The Company and its subsidiaries are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter.
Testosterone Cases. EPI, and in certain cases the Company or certain of its subsidiaries, including its new subsidiary Auxilium Pharmaceuticals, Inc., along with other pharmaceutical manufacturers, have been named as defendants in lawsuits alleging personal injury resulting from the use of prescription medications containing testosterone, including Fortesta® Gel and Delatestryl®. Plaintiffs in these suits allege various personal injuries including pulmonary embolism, stroke, and other vascular and/or cardiac injuries. In June 2014, an MDL was formed to include claims involving all testosterone replacement therapies filed against EPI and other manufacturers of such products, and certain transferable cases pending in federal court were coordinated in the Northern District of Illinois as part of MDL No. 2545. In addition to the federal cases filed against EPI that have been transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545, litigation has also been filed against EPI in the Court of Common Pleas Philadelphia County and in New York State Supreme Court. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545. However, we cannot predict the timing or outcome of any such litigation, or whether any such additional litigation will be brought against the Company or EPI, but EPI intends to contest the litigation vigorously and to explore all options as appropriate in the best interests of EPI and the Company. As of February 20, 2015, approximately 230 cases are currently pending against EPI and its new affiliate, Auxilium Pharmaceuticals, Inc., some of which were filed on behalf of multiple plaintiffs, and including a class action complaint filed in Canada.
In addition, on November 5, 2014, a civil class action complaint was filed in the Northern District of Illinois against EPI and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that had paid for certain testosterone products, alleging that the marketing efforts of EPI and other defendant manufacturers with respect to certain testosterone products constituted racketeering activity in violation of 18 U.S.C. §1962(c), and other civil RICO claims. Further, the complaint alleges that EPI and other defendant manufacturers violated various state consumer protection laws through their marketing of certain testosterone products. The Company and its subsidiaries are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.
Department of Health and Human Services Subpoena and Related Matters
As previously reported, in January 2007 and April 2011, the Company received subpoenas issued by the Office of the Inspector General of the Department of Health and Human Services (HHS-OIG) and the United States Department of Justice (DOJ), respectively. The subpoenas requested documents relating to Lidoderm® (lidocaine patch 5%), focused primarily on the sale, marketing and promotion of Lidoderm®. As previously reported, the Company resolved potential claims of the federal government and numerous states related to potential claims regarding the sale, marketing and promotion of Lidoderm®.
In September 2013, the State of Louisiana filed a Petition for Civil Penalties and Damages against the Company and its subsidiary, EPI in the Nineteenth Judicial District for the Parish of East Baton Rouge alleging that EPI and the Company engaged in unlawful marketing of Lidoderm® in the State of Louisiana. See State of Louisiana v. Endo Pharmaceuticals, Inc. et al., C624672 (19th Jud. Dist. La.). The State seeks civil fines, civil monetary penalties, damages, injunctive relief, attorneys’ fees and costs under various causes of action. Without admitting liability or wrongdoing, in February 2014, EPI and the State of Louisiana reached an agreement to resolve this case for a total of $1.4 million plus attorney’s fees. The case was dismissed on July 1, 2014.
As previously reported, EPI is in the process of responding to a Civil Investigative Demand issued by the State of Texas relating to Lidoderm® (lidocaine patch 5%), focused primarily on the sale, marketing and promotion of Lidoderm® in Texas. EPI and the Company are cooperating with the State’s investigation. The Company and its subsidiaries are unable to predict the outcome of this matter or the ultimate legal and financial liability and at this time cannot reasonably estimate the possible loss or range of loss for this matter but will explore all options as appropriate in the best interests of EPI and the Company.
Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against the Company or its subsidiaries.
Qualitest Pharmaceuticals Civil Investigative Demands
In April 2013, the Company’s subsidiaries, EPI and Qualitest, received Civil Investigative Demands (CIDs) from the U.S. Attorney’s Office for the Southern District of New York. The CIDs request documents and information regarding the manufacture and sale of chewable fluoride tablets and other products sold by Qualitest. EPI and Qualitest are cooperating with the government’s investigation. Preliminary discussions between EPI and Qualitest and the U.S. Attorney’s Office for the Southern District of New York have taken place, and the Company believes that a range of loss for this matter is reasonably estimable at this time. The estimated cost of this settlement has been incorporated into the increase in our legal loss contingency reserve. However, it is not possible at this time to determine with certainty the ultimate outcome of this matter. It is possible that the outcome of this matter could result in an additional loss that could have a material effect on our business, financial condition, results of operations and cash flows.
Unapproved Drug Litigation
In September 2013, the State of Louisiana filed a Petition for Damages against EPI, Qualitest and Boca and over 50 other pharmaceutical companies alleging the defendants or their subsidiaries marketed products that were not approved by the FDA. See State of Louisiana v. Abbott Laboratories, Inc., et al., C624522 (19th Jud. Dist. La.). The State of Louisiana seeks damages, fines, penalties, attorneys’ fees and costs under various causes of action.
EPI, Qualitest and Boca intend to contest the above case vigorously and to explore other options as appropriate in the best interests of the Company, EPI, Qualitest and Boca. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against the Company or its subsidiaries. The Company and its subsidiaries are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.
Opioid-Related Litigations, Subpoenas and Document Requests
In March 2013, the Company’s subsidiary, Endo Health Solutions Inc. received an Investigative Subpoena from the Corporation Counsel for the City of Chicago seeking documents and information regarding the sales and marketing of opioids, including Opana®. Following discussion with the Company, in May 2013, the Corporation Counsel for the city of Chicago served the Company with a revised Investigative Subpoena seeking the same documents and information. In June 2014, Corporation Counsel for the City of Chicago filed suit in Illinois state court against multiple defendants, including the Company, for alleged violations of city ordinances and other laws relating to defendants’ alleged opioid sales and marketing practices. On June 12, 2014, the case was removed to the United States District Court for the Northern District of Illinois. Plaintiffs initially moved to remand the case to state court but, on July 8, 2014, withdrew their motion to remand. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), an injunction, and attorneys’ fees and costs.
In May 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, against multiple defendants, including the Company. The complaint was amended on June 9, 2014, to include allegations against EPI, among other changes. The amended complaint asserts violations of California’s statutory Unfair Competition and False Advertising laws, as well as asserting a claim for public nuisance, based on alleged misrepresentations in connection with sales and marketing of opioids, including Opana®. On July 14, 2014, the case was removed to the United States District Court for the Central District of California. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), abatement, an injunction, and attorneys’ fees and costs.
In September 2013, the Company received a subpoena from the State of New York Office of Attorney General seeking documents and information regarding the sales and marketing of Opana® and in October 2014 received a Subpoena Ad Testificandum seeking testimony regarding the sales and marketing of Opana®. In January 2014, the Company received a set of informal document requests from the Office of the United States Attorney for the Eastern District of Pennsylvania seeking documents and information regarding the sales and marketing of Opana® ER. In September 2014, the Company received a Request for Information from the State of Tennessee Office of the Attorney General and Reporter seeking documents and information regarding the sales and marketing of opioids, including Opana® ER.
The Company is cooperating with the State of New York Office of Attorney General and the Office of the United States Attorney for the Eastern District of Pennsylvania and the State of Tennessee Office of the Attorney General and Reporter in their respective investigations. With respect to both the litigations brought on behalf of the City of Chicago and the People of the State of California, the Company intends to contest those matters vigorously and to explore all options as appropriate in the best interests of the Company. The Company and its subsidiaries are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in the best interests of EPI and the Company.
Antitrust Litigation and Investigations
Multiple direct and indirect purchasers of Lidoderm® have filed a number of cases against EPI and co-defendants Teikoku Seiyaku Co., Ltd., Teikoku Pharma USA, Inc. (collectively, Teikoku) and Actavis plc., f/k/a as Watson Pharmaceuticals, Inc., and a number of its subsidiaries (collectively, Actavis or Watson). The complaints in these cases generally allege that Endo, Teikoku and Actavis entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ’529 patent). Some of the complaints also allege that Teikoku wrongfully listed the ‘529 patent in the Orange Book as related to Lidoderm®, that Endo and Teikoku commenced sham patent litigation against Actavis and that Endo abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of Lidoderm®. The cases allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2) and various state antitrust and consumer protection statutes. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees.
The United States Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order on April 3, 2014, transferring these cases as In Re Lidoderm Antitrust Litigation, MDL No. 2521, to the U.S. District Court for the Northern District of California for coordinated or consolidated pretrial proceedings before Judge William H. Orrick.
Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of California as tag-along actions to In Re Lidoderm Antitrust Litigation.
On June 13, 2014, pursuant to a case management order entered by Judge Orrick, the direct and indirect purchasers each filed consolidated amended class complaints. In addition, one indirect purchaser, Government Employees Health Association (GEHA), filed a separate complaint. On November 17, 2014, the Court granted in part and denied in part motions to dismiss the complaints for failure to state a claim and for lack of standing, which were filed on behalf of all defendants. Plaintiffs filed amended complaints on December 19, 2014. Defendants jointly moved on January 30, 2015 to dismiss certain claims in the second amended indirect purchaser complaint and in GEHA’s second amended complaint. The Court has not reached a decision yet on defendants’ motion, and the cases are proceeding to the discovery phase of the litigation in accordance with the pre-trial schedule. Trial is currently scheduled to begin on April 10, 2017.
Multiple direct and indirect purchasers of Opana® ER have filed cases against EHSI, EPI, Penwest Pharmaceuticals Co., and Impax Laboratories Inc. in multiple federal courts. These cases generally allege that the agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to Opana® ER and EPI’s introduction of the re-formulation of Opana® ER violated antitrust laws. The complaints allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), various state antitrust and consumer protection statutes, as well as state common law. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees, and some allege that they will seek to represent classes of direct and indirect purchasers of Opana® ER. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against the Company or EPI. The United States Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order on December 12, 2014, transferring the federal cases as In Re Opana ER Antitrust Litigation, MDL No. 2580, to the U.S. District Court for the Northern District of California for coordinated or consolidated pretrial proceedings before Judge William H. Orrick.
The Company and its subsidiaries are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these matters, if any, but will explore all options as appropriate in the best interests of EPI and the Company.
On February 25, 2014, the Company’s subsidiary, EPI received a Civil Investigative Demand (the February 25 CID) from the U.S. Federal Trade Commission (the FTC). The FTC issued a second Civil Investigative Demand to EPI on March 25, 2014 (the March 25 CID). The February 25 CID requests documents and information concerning EPI’s settlement agreements with Actavis and Impax settling the Opana® ER patent litigation, EPI’s Development and Co-Promotion Agreement with Impax, and its settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Opana® ER and Lidoderm®. The March 25 CID requests documents and information concerning EPI’s acquisition of U.S. Patent No. 7,852,482 (the ‘482 patent), as well as additional information concerning certain litigation relating to, and the marketing and sales of Opana® ER. The FTC has also issued subpoenas for investigational hearings (similar to depositions) to Company employees and former Company employees. EPI intends to fully cooperate with the FTC’s investigation.
On November 3, 2014, EPI received a Civil Investigative Demand from the State of Florida Office of the Attorney General issued pursuant to the Florida Antitrust Act of 1980, Section 542.28 and seeking documents and other information concerning EPI’s settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Lidoderm®. EPI intends to fully cooperate with the FTC’s investigation. EPI intends to fully cooperate with the FTC’s investigation.
On February 9, 2015, EPI and EHSI received a Civil Investigative Demand for Production of Documents and Information from the State of Alaska Office of the Attorney General issued pursuant to Alaska’s Antitrust and Unfair Trade Practices and Consumer Protection law seeking documents and other information concerning settlement agreements with Actavis and Impax settling the Opana® ER patent litigation.
The Company and its subsidiaries are unable to predict the outcome of these investigations or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these investigations, if any, but will explore all options as appropriate in the best interests of EPI and the Company.
Paragraph IV Certifications on Lidoderm®
As previously reported, the Company’s subsidiary, EPI and the holders of the Lidoderm® New Drug Application and relevant patents, Teikoku, received a Paragraph IV Certification Notice under 21 U.S.C. 355(j) (a Paragraph IV Notice) from Watson advising of its filing of an ANDA for a generic version of Lidoderm® (lidocaine topical patch 5%), which resulted in litigation under the Hatch-Waxman Act.
On May 28, 2012, EPI entered into a Settlement and License Agreement (the Watson Settlement Agreement) among EPI and Teikoku, on the one hand, and Watson, on the other hand. The Watson Settlement Agreement settled all ongoing patent litigation among the parties relating to Watson’s generic version of Lidoderm®. Under the terms of the Watson Settlement Agreement, the parties dismissed their respective claims and counterclaims without prejudice. As part of the settlement, Watson agreed not to challenge the validity or enforceability of EPI’s and Teikoku’s patents relating to Lidoderm® with respect to Watson’s generic version of Lidoderm®. Watson received FDA approval of its generic version of Lidoderm® in August 2012 and began selling its generic version of Lidoderm® on September 16, 2013 (the Start Date) pursuant to a license granted by EPI and Teikoku under the Watson Settlement Agreement. The license to Watson was exclusive as to EPI’s launch of an authorized generic version of Lidoderm® until May 1, 2014. EPI received an at market royalty equal to 25% of the gross profit generated on Watson’s sales of its generic version of Lidoderm® during its period of exclusivity. During the years ended December 31, 2014 and 2013 we recorded Watson royalty income of $51.3 million and $58.7 million, respectively, which is included in Other revenues in our Consolidated Statements of Operations.
As of December 31, 2014, there is no remaining liability associated with our Patent litigation settlement and, during the year ended December 31, 2014, there was no related activity recorded in our Consolidated Statements of Operations. During the year ended December 31, 2013, the net impact of the Watson Settlement Agreement recorded in Other income, net consisted of the amounts shown below (in thousands):
	Year Ended December 31, 2013
Litigation settlement liability relieved during the year	$	85,123
Cost of product shipped to Watson’s wholesaler affiliate	(11,093		)
Estimated gross-to-net liabilities on product shipped to Watson’s wholesaler affiliate	(29,162		)
Rebate on product shipped to Watson’s wholesaler affiliate	5,532
Net gain included in Other income, net	$	50,400
As previously reported, in January 2011, EPI and Teikoku received a Paragraph IV Notice from Mylan Technologies Inc. (Mylan) advising of its filing of an ANDA for a generic version of Lidoderm®. The Paragraph IV Notice refers to U.S. Patent Nos. 5,827,529 and 5,741,510, which cover the formulation of Lidoderm® under the Hatch-Waxman Act. The patent expired on March 30, 2014. This suit is no longer pending. On October 4, 2013, the Company dismissed the suit against Mylan.
On May 16, 2012, EPI and Teikoku received a Paragraph IV Notice from Noven Pharmaceuticals, Inc. (Noven) advising of its filing of an ANDA for a generic version of Lidoderm®, which resulting in litigation under the Hatch-Waxman Act. On April 15, 2014, EPI entered into a Settlement and License Agreement (the Noven Settlement Agreement) among EPI and Teikoku, on the one hand, and Noven, on the other hand. The Noven Settlement Agreement settled all ongoing patent litigation among the parties relating to Noven’s generic version of Lidoderm®. Under the terms of the Noven Settlement Agreement, the parties dismissed their respective claims and counterclaims without prejudice. As part of the settlement, Noven agreed not to challenge the validity or enforceability of EPI’s and Teikoku’s patents relating to Lidoderm® with respect to Noven’s generic version of Lidoderm®. Under the terms of the Noven Settlement Agreement, should Noven receive FDA approval, Noven may begin selling its generic version of Lidoderm® on March 1, 2015.
On May 24, 2012, EPI and Teikoku received a Paragraph IV Notice from TWi Pharmaceuticals, Inc. (TWi) advising of its filing of an ANDA for a generic version of Lidoderm®, which resulted in litigation under the Hatch-Waxman Act. On April 18, 2014, EPI entered into a Settlement and License Agreement (the TWi Settlement Agreement) among EPI and Teikoku, on the one hand, and TWi, on the other hand. The TWi Settlement Agreement settled all ongoing patent litigation among the parties relating to TWi’s generic version of Lidoderm®. Under the terms of the TWi Settlement Agreement, the parties dismissed their respective claims and counterclaims without prejudice. As part of the settlement, TWi agreed not to challenge the validity or enforceability of EPI’s and Teikoku’s patents relating to Lidoderm® with respect to TWi’s generic version of Lidoderm®. Under the terms of the TWi Settlement Agreement, should TWi receive FDA approval, TWi may begin selling its generic version of Lidoderm® on March 1, 2015.
In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of Lidoderm®.
Paragraph IV Certifications on Opana® ER
As previously reported, starting in December 2007 through December 2011, EPI received Paragraph IV Notices from various generic drug manufacturers, including Impax Laboratories, Inc. (Impax), Actavis South Atlantic LLC (Actavis), Sandoz, Inc. (Sandoz), Barr Laboratories, Inc. (Teva), Watson Laboratories, Inc. (Watson), Roxane Laboratories, Inc. (Roxane) and most recently, Ranbaxy Inc. (Ranbaxy) advising of the filing by each such company of an ANDA for a generic version of the non-crush-resistant formulation of Opana® ER (oxymorphone hydrochloride extended-release tablets CII). To date, EPI settled all of the Paragraph IV litigation relating to the non-crush-resistant formulation of Opana® ER other than those cases discussed in the next paragraph. Under the terms of the settlements, each generic manufacturer agreed not to challenge the validity or enforceability of patents relating to the non-crush-resistant formulation of Opana® ER. As a result, Actavis launched its generic version of non-crush-resistant Opana® ER 7.5 and 15 mg tablets on July 15, 2011, and Impax launched its generic version of non-crush-resistant Opana® ER 5, 7.5, 10, 15, 20, 30 and 40 mg tablets on January 2, 2013. Pursuant to the terms of the respective settlement agreements, Sandoz, Teva, Watson, Roxane and Actavis were granted licenses to patents listed in the Orange Book at the time each generic filed its ANDA.
In late 2012, two patents (U.S. Patent Nos. 8,309,122 and 8,329,216) were issued to EPI covering Opana® ER. On December 11, 2012, EPI filed a Complaint against Actavis in U.S. District Court for the Southern District of New York for patent infringement based on its ANDA for a non-crush-resistant generic version of Opana® ER. Between May 22 and June 21, 2013, EPI filed similar suits in the U.S. District Court for the Southern District of New York against the following applicants for non-crush-resistant Opana® ER: Par Pharmaceuticals, Teva Pharmaceuticals, Mallinckrodt LLC, Sandoz, Roxane and Ranbaxy. Those suits allege infringement of U.S. Patent Nos. 7,851,482, 8,309,122, and 8,329,216. In July 2013, Actavis and Roxane were granted FDA approval to market all strengths of their respective non-crush-resistant formulations of Opana® ER. In June 2014, Mallinckrodt LLC was granted FDA approval to market all strengths of their respective non-crush-resistant formulations of Opana® ER. On August 1, 2013, EPI dismissed its suit against Teva Pharmaceuticals based on its demonstration to EPI that it does not, at this time, intend to pursue an ANDA for non-crush-resistant Opana® ER. On October 18, 2013, EPI dismissed its suit against Sandoz based on its demonstration to EPI that it does not, at this time, intend to pursue an ANDA for non-crush-resistant Opana® ER. On December 18, 2013, EPI dismissed its suit against Mallinckrodt LLC based on a settlement allowing Mallinckrodt LLC to launch its non-crush-resistant formulation of Opana ER in October 2017, under certain circumstances. On August 6, 2013, EPI filed motions for preliminary injunctions against Actavis and Roxane requesting the court enjoin Actavis and Roxane from launching additional Opana® ER generics pending the outcome of the patent case. On September 12, 2013, the court denied EPI’s motions for preliminary injunction. On that day, Actavis launched its generic version of non-crush-resistant Opana® ER 5, 10, 20, 30 and 40 mg tablets. EPI has appealed the denial of a preliminary injunction. A hearing on the appeal was heard January 9, 2014. On March 31, 2014, the Court of Appeals for the Federal Circuit vacated and remanded the district court ruling denying EPI’s motions. The case will return to the district court for further proceedings.
EPI intends to defend vigorously its intellectual property rights and to pursue all available legal and regulatory avenues in defense of the non-crush-resistant formulation Opana® ER, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that EPI will be successful. If EPI is unsuccessful, competitors that already have obtained, or are able to obtain, FDA approval of their products may be able to launch their generic versions of non-crush-resistant Opana® ER prior to the applicable patents’ expirations. Additionally, we cannot predict or determine the timing or outcome of related litigation but will explore all options as appropriate in the best interests of the Company and EPI. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of non-crush-resistant Opana® ER and challenge the applicable patents.
From September 21, 2012 through October 30, 2013, EPI and its partner Grünenthal received Paragraph IV Notices from each of Teva Pharmaceuticals USA, Inc. (Teva), Amneal Pharmaceuticals, LLC (Amneal), Sandoz Inc. (Sandoz), ThoRx Laboratories, Inc. (ThoRx), Par Pharmaceuticals (Par), Actavis South Atlantic LLC (Actavis), Impax Pharmaceuticals (Impax) and Ranbaxy Laboratories Limited (Ranbaxy), advising of the filing by each such company of an ANDA for a generic version of the formulation of Opana® ER designed to be crush-resistant. These Paragraph IV Notices refer to U.S. Patent Nos. 8,075,872, 8,114,383, 8,192,722, 7,851,482, 8,309,060, 8,309,122 and 8,329,216, which variously cover the formulation of Opana® ER, a highly pure version of the active pharmaceutical ingredient and the release profile of Opana® ER. EPI filed lawsuits against each of these filers in the U.S. District Court for the Southern District of New York. Each lawsuit was filed within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. On January 30, 2015, EPI informed all defendants that it no longer intends to assert U.S. Patent 7,851,482. EPI intends, and has been advised by Grünenthal that it too intends, to defend vigorously the intellectual property rights covering the formulation of Opana® ER designed to be crush-resistant and to pursue all available legal and regulatory avenues in defense of crush-resistant Opana® ER, including enforcement of the product’s intellectual property rights and approved labeling. A trial in this case has been set for March 23, 2015. However, there can be no assurance that EPI and Grünenthal will be successful. If we are unsuccessful and Teva, Amneal, Sandoz, ThoRx, Par, Actavis or Impax is able to obtain FDA approval of its product, generic versions of crush-resistant Opana® ER may be launched prior to the applicable patents’ expirations in 2023 through 2029. Additionally, we cannot predict or determine the timing or outcome of this defense but will explore all options as appropriate in the best interests of the Company and EPI. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of crush-resistant Opana® ER and challenge the applicable patents.
On August 19, 2014 and October 20, 2014, the United States Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using Opana ER and a highly pure version of the active pharmaceutical ingredient of Opana® ER. On November 7, 2014, EPI filed lawsuits against Teva, ThoRx, Par, Actavis, Impax, Ranbaxy, Roxane, Amneal, and Sandoz in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively.
Paragraph IV Certification on Fortesta® Gel
On January 18, 2013, EPI and its licensor Strakan Limited received a notice from Watson advising of the filing by Watson of an ANDA for a generic version of Fortesta® (testosterone) Gel. On February 28, 2013, EPI filed a lawsuit against Watson in the U.S. District Court for the Eastern District of Texas, Marshall division. Because the suit was filed within the 45-day period under the Hatch-Waxman Act for filing a patent infringement action, we believe that it triggered an automatic 30-month stay of approval under the Act. Trial has been set for February 26, 2015.
EPI intends, and has been advised by Strakan Limited that it too intends, to defend vigorously Fortesta® Gel and to pursue all available legal and regulatory avenues in defense of Fortesta® Gel, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that EPI and Strakan will be successful. If EPI and Strakan are unsuccessful and Watson is able to obtain FDA approval of its product, Watson may be able to launch its generic version of Fortesta® Gel prior to the applicable patents’ expirations in 2018. Additionally, we cannot predict or determine the timing or outcome of this litigation but will explore all options as appropriate in the best interests of the Company. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of Fortesta® Gel and challenge the applicable patents.
Paragraph IV Certification on Frova®
As previously reported, in July 2011, EPI and its licensor, Vernalis Development Limited received a notice from Mylan Technologies Inc. (Mylan) advising of the filing by Mylan of an ANDA for a generic version of Frova® (frovatriptan succinate) 2.5 mg tablets. Mylan’s notice included a Paragraph IV Notice with respect to U.S. Patent Nos. 5,464,864, 5,561,603, 5,637,611, 5,827,871 and 5,962,501, which cover Frova®. These patents are listed in the FDA’s Orange Book and either have expired or will expire by 2015. As a result of this Paragraph IV Notice, on August 16, 2011, EPI filed a lawsuit against Mylan in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 5,464,864, 5,637,611 and 5,827,871. Because the suit was filed within the 45-day period under the Hatch-Waxman Act for filing a patent infringement action, we believe that it triggered an automatic 30-month stay of approval under the Act. On September 22, 2011, Mylan filed an Answer and Counterclaims, claiming the asserted patents are invalid or not infringed. A trial in this case was held starting November 12, 2013. On January 28, 2014, the U.S. District Court for the District of Delaware issued a decision upholding the validity and infringement by Mylan of U.S. Patent No. 5,464,864. After the District court decision, Mylan moved to enforce a purported settlement entered into by the parties. A hearing was held in the U.S. District Court for the District of Delaware on March 18, 2014. As a result of that hearing, the court vacated the earlier decision, and held that Mylan and EPI settled the Frova litigation. The terms of that settlement allow Mylan to sell Mylan’s generic frovatriptan succinate 2.5 mg tablets not earlier than four weeks prior to the expiration of U.S. Patent 5,464,864. The Company has appealed this decision. A hearing on that appeal was held on December 1, 2014. On December 4, 2014 the Federal Circuit affirmed the decision of the Lower Court that the Company and Mylan reached a settlement consistent with the terms outlined above.
Other Legal Proceedings
In addition to the above proceedings, proceedings similar to those described above may also be brought in the future. Additionally, we and our subsidiaries are involved in, or have been involved in, arbitrations or various other legal proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these claims and other proceedings. Currently, neither we nor our subsidiaries are involved in any other legal proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.
Leases
We lease certain fixed assets under capital leases that expire through 2025. We lease automobiles, machinery and equipment and facilities under certain noncancelable operating leases that expire through 2024. These leases are renewable at our option.
On October 28, 2011, our subsidiary EPI entered into a lease agreement with RT/TC Atwater LP, a Delaware limited partnership, for a new Company headquarters to consist of approximately 300,000 square feet of office space located at 1400 Atwater Boulevard, Malvern, Pennsylvania (with a four-year option to lease up to approximately 150,000 additional square feet). The term of this triple net lease is 12 years and includes three renewal options, each for an additional 60-month period. The lease commenced on December 31, 2012 with a monthly lease rate for the initial year of $0.5 million, increasing by 2.25% each year thereafter. Additionally, beginning January 2015, approximately 60,000 square feet of this property was subleased.
This lease is accounted for as a direct financing arrangement whereby the Company recorded, over the construction period, the full cost of the asset in Property, plant and equipment, net. A corresponding liability was also recorded, net of leasehold improvements paid for by the Company, and is being amortized over the expected lease term through monthly rental payments using an effective interest method. At December 31, 2014, there was a liability of $49.9 million related to this arrangement, $3.9 million of which is included in Accounts payable and $46.0 million of which is included in Other liabilities in the accompanying Consolidated Balance Sheet.
A summary of minimum future rental payments required under capital and operating leases as of December 31, 2014 are as follows (in thousands):
	Capital Leases(1)			Operating Leases
2015	$	6,526		$	15,292
2016	6,640			9,320
2017	6,875			6,677
2018	7,072			4,310
2019	7,270			1,697
Thereafter	39,025			2,918
Total minimum lease payments	$	73,408		$	40,214
Less: Amount representing interest	8,041
Total present value of minimum payments	$	65,367
Less: Current portion of such obligations	6,526
Long-term capital lease obligations	$	58,841
__________
-1	The direct financing arrangement is included under Capital Leases. Minimum payments have not been reduced by minimum sublease rentals of $23.0 million due in the future under a noncancelable sublease.
Expense incurred under operating leases was $8.5 million, $18.7 million and $14.2 million for the years ended December 31, 2014, 2013 and 2012, respectively.

Other_Comprehensive_Loss_Incom

Other Comprehensive (Loss) Income	12 Months Ended
	Dec. 31, 2014
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive (Loss) Income	NOTE 15. OTHER COMPREHENSIVE (LOSS) INCOME
	The following table presents the tax effects allocated to each component of Other comprehensive (loss) income for the years ended December 31, (in thousands):
		2014									2013									2012
		Before-			Tax Benefit (Expense)			Net-of-Tax			Before-Tax			Tax (Expense) Benefit			Net-of-			Before-Tax			Tax (Expense) Benefit			Net-of-
		Tax						Amount			Amount						Tax			Amount						Tax
		Amount															Amount									Amount
	Net unrealized (loss) gain on securities:
	Unrealized (loss) gain arising during the period	$	(1,646	)	$	547		$	(1,099	)	$	1,233		$	(458	)	$	775		$	1,441		$	(38	)	$	1,403
	Less: reclassification adjustments for loss realized in net loss	17			—			17			—			—			—			—			—			—
	Net unrealized (losses) gains	(1,629		)	547			(1,082		)	1,233			(458		)	775			1,441			(38		)	1,403
	Foreign currency translation (loss) gain	(121,417		)	28			(121,389		)	682			32			714			2,104			60			2,164
	Fair value adjustment on derivatives designated as cash flow hedges:
	Fair value adjustment on derivatives designated as cash flow hedges arising during the period	—			—			—			853			(307		)	546			(1,892		)	680			(1,212		)
	Less: reclassification adjustments for cash flow hedges settled and included in net loss	—			—			—			(232		)	84			(148		)	436			(157		)	279
	Net unrealized fair value adjustment on derivatives designated as cash flow hedges	—			—			—			621			(223		)	398			(1,456		)	523			(933		)
	Other comprehensive (loss) income	$	(123,046	)	$	575		$	(122,471	)	$	2,536		$	(649	)	$	1,887		$	2,089		$	545		$	2,634
	Reclassifications adjustments out of Other comprehensive (loss) income are reflected in our Consolidated Statements of Operations as Other income, net.
	The following is a summary of the accumulated balances related to each component of Other comprehensive (loss) income, net of taxes, at December 31, 2014 and December 31, 2013 (in thousands):
		December 31,			December 31,
		2014			2013
	Net unrealized (losses) gains	$	(484	)	$	598
	Foreign currency translation loss	(123,604		)	(5,193		)
	Fair value adjustment on derivatives designated as cash flow hedges	—			(320		)
	Accumulated other comprehensive loss	$	(124,088	)	$	(4,915	)

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Shareholders' Equity	NOTE 16. SHAREHOLDERS' EQUITY
	In prior periods, our Consolidated Financial Statements presented the accounts of EHSI. On October 31, 2013, Endo International plc was incorporated in Ireland as a private limited company and re-registered effective February 18, 2014 as a public limited company. It was established for the purpose of facilitating the business combination between EHSI and Paladin. On February 28, 2014 we became the successor registrant of EHSI and Paladin in connection with the consummation of certain transactions. In addition, on February 28, 2014, the shares of Endo International plc began trading on the NASDAQ under the symbol “ENDP,” the same symbol under which Endo Health Solutions Inc.’s shares previously traded, as well as on the Toronto Stock Exchange under the symbol “ENL”. References throughout to “ordinary shares” refer to EHSI’s common shares, 350,000,000 authorized, par value $0.01 per share, prior to the consummation of the transactions and to Endo International plc’s ordinary shares, 1,000,000,000 authorized, par value $0.0001 per share, subsequent to the consummation of the transactions.
	In addition, on February 11, 2014 the Company issued 4,000,000 euro deferred shares of US$0.01 each at par. The euro deferred shares are held by nominees in order to satisfy an Irish legislative requirement to maintain a minimum level of issued share capital denominated in euro and to have at least seven registered shareholders. The euro deferred shares carry no voting rights and are not entitled to receive any dividend or distribution.
	Share Repurchase Program
	In August 2012, our Board of Directors approved a share repurchase program (the 2012 EHSI Share Repurchase Program). The 2012 EHSI Share Repurchase Program authorized the Company to repurchase in the aggregate up to $450.0 million of EHSI common stock and was due to expire on March 31, 2015. The Company’s ability to repurchase shares under this program ended on February 28, 2014, at the time of the Paladin acquisition. However, the Company does have broad shareholder authority to conduct share repurchases of its ordinary shares, as our shareholders granted to the Company a general authority (the 2014 Share Buyback Authority) to make overseas market purchases (as defined by section 212 of the Irish Companies Act 1990 (the 1990 Act)) of shares of the Company on such terms and conditions as our Board of Directors may approve, but subject to the provisions of the 1990 Act and certain other provisions. Our Board of Directors has not yet considered and approved the terms and conditions of any share repurchase program pursuant to the 2014 Share Buyback Authority.
	Pursuant to the 2012 EHSI Share Repurchase Program, we did not purchase any of our ordinary shares during the years ended December 31, 2014 and 2013.

Sharedbased_Compensation

Shared-based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shared-based Compensation	NOTE 17. SHARE-BASED COMPENSATION
	Stock Incentive Plans
	The Company’s approved stock incentive plans include the Endo International plc 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans (formerly known as the Endo Health Solutions Inc. Stock Incentive Plans). At December 31, 2014, approximately 13.0 million shares were reserved for future issuance upon exercise of options granted or to be granted under the various stock incentive plans. As of December 31, 2014, stock options, restricted stock awards, performance stock units and restricted stock units have been granted under these plans.
	All share-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense in the income statement over the requisite service period.
	The Company recognized share-based compensation expense of $32.7 million, $39.0 million and $59.4 million during the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards amounted to $57.8 million. This expected cost does not include the impact of any future share-based compensation awards.
	Presented below is the allocation of share-based compensation expense, as recorded in our Consolidated Statements of Operations for the years ended December 31 (in thousands).
		2014			2013				2012
	Selling, general and administrative expenses	$	21,690		$	24,982			$	35,482
	Research and development expenses	3,670			4,740				5,321
	Cost of revenues	1,479			—				—
	Discontinued operations (NOTE 3)	5,832			9,276				18,592
	Total share-based compensation expense	$	32,671		$	38,998			$	59,395
	Stock Options
	During the years ended December 31, 2014, 2013 and 2012, the Company granted stock options to employees of the Company as part of their annual share compensation award and, in certain circumstances, upon their commencement of service with the Company. For all of the Company’s share-based compensation plans, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s share price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. We estimate the expected term of options granted based on our historical experience with our employees’ exercise of stock options and other factors.
	A summary of the activity under our 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans for each of the three years-ended December 31, 2014 is presented below:
		Number of		Weighted				Weighted		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
	Outstanding as of January 1, 2012	8,115,467		$	25.79
	Granted	2,237,081		$	34.58
	Exercised	(853,794	)	$	22.66
	Forfeited	(613,613	)	$	31.31
	Expired	(60,436	)	$	27.61
	Outstanding as of December 31, 2012	8,824,705		$	27.93
	Granted	593,709		$	30.81
	Exercised	(3,836,560	)	$	25.32
	Forfeited	(1,291,043	)	$	32.73
	Expired	(45,022	)	$	30.06
	Outstanding as of December 31, 2013	4,245,789		$	29.3
	Granted	736,948		$	75.13
	Exercised	(1,528,295	)	$	27.09
	Forfeited	(371,410	)	$	39.76
	Expired	(19,680	)	$	24.56
	Outstanding as of December 31, 2014	3,063,352		$	40.15			5.32		$	103,208,779
	Vested and expected to vest as of December 31, 2014	2,929,508		$	39.23			5.25		$	101,160,091
	Exercisable as of December 31, 2014	1,477,631		$	28.3			4.56		$	65,901,298
	The range of exercise prices for the above stock options outstanding at December 31, 2014 is from $11.91 to $79.82.
	The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $41.4 million, $97.1 million and $19.3 million, respectively. The weighted average grant date fair value of the stock options granted in the years ended December 31, 2014, 2013 and 2012 was $20.28, $9.37 and $10.50 per option, respectively, determined using the following assumptions:
		2014		2013			2012
	Average expected term (years)	4		5			5
	Risk-free interest rate	1.3	%	0.8	%		0.9	%
	Dividend yield	—		—			—
	Expected volatility	32	%	33	%		33	%
	As of December 31, 2014, the weighted average remaining requisite service period of the non-vested stock options was 2.0 years. As of December 31, 2014, the total remaining unrecognized compensation cost related to non-vested stock options amounted to $14.3 million.
	Restricted Stock Units and Performance Stock Units
	During the years ended December 31, 2014, 2013 and 2012, the Company granted restricted stock units (RSUs) and performance stock units (PSUs) to employees and non-employee directors of the Company as part of their annual share compensation award and, in certain circumstances, upon their commencement of service with the Company. For grants prior to 2013, PSUs are tied to both the Company’s overall revenue and its total shareholder return (TSR) relative to the total shareholder return of a selected industry group. Starting in 2013, PSU grants are only tied to TSR relative to the TSR of a selected industry group. Each award covers a three-year performance cycle. The actual number of shares awarded is adjusted to between zero and 300% of the target award amount based upon achievement of pre-determined goals. TSR relative to peers is considered a market condition while cumulative revenue performance is considered a performance condition under applicable authoritative guidance. The PSUs linked to revenue performance are marked to market on a recurring basis based on management’s expectations of future revenues.
	A summary of our restricted and performance stock units for the three years ended December 31, 2014 is presented below:
		Number		Aggregate
		of Shares		Intrinsic
				Value
	Outstanding as of January 1, 2012	2,629,782
	Granted	1,087,171
	Forfeited	(362,682	)
	Vested	(930,659	)
	Outstanding as of December 31, 2012	2,423,612
	Granted	1,543,221
	Forfeited	(899,954	)
	Vested	(804,451	)
	Outstanding as of December 31, 2013	2,262,428
	Granted	609,357
	Forfeited	(374,463	)
	Vested	(842,569	)
Outstanding as of December 31, 2014	1,654,753		$	120,623,231
Vested and expected to vest as of December 31, 2014	1,444,957		$	99,516,485
As of December 31, 2014, the weighted average remaining requisite service period of these units was 1.9 years. The weighted average grant date fair value of the units granted during the years ended December 31, 2014, 2013 and 2012 was $73.70, $31.55 and $34.76 per unit, respectively. As of December 31, 2014, the total remaining unrecognized compensation cost related to non-vested RSUs and PSUs amounted to $27.1 million and $16.4 million, respectively.
Restricted Stock Awards
As of December 31, 2014, we had 8,046 unvested restricted stock awards outstanding with a weighted average remaining requisite service period of approximately 0.3 years.
Employee Stock Purchase Plan
The Endo International plc Employee Stock Purchase Plan (ESPP) is a Company-sponsored plan that enables employees to voluntarily elect, in advance of any of the four quarterly offering periods ending March 31, June 30, September 30 and December 31 of each year, to contribute up to 10% of their eligible compensation, subject to certain limitations, to purchase ordinary shares at 90% of the lower of the closing price of Endo ordinary shares on the first or last trading day of each offering period. The maximum number of shares that a participant may purchase in any calendar year is equal to $25,000 divided by the closing selling price per ordinary share on the first day of the offering period, subject to certain adjustments. Compensation expense is calculated in accordance with the applicable accounting guidance and is based on the share price at the beginning or end of each offering period and the purchase discount. Obligations under the ESPP may be satisfied by the reissuance of treasury stock, by the Company’s purchase of shares on the open market or by the authorization of new shares. The maximum number of shares available under the ESPP, pursuant to the terms of the ESPP plan document, is 1% of the common shares outstanding on April 15, 2011 or approximately 1.2 million shares. The ESPP shall continue in effect until the earlier of (i) the date when no shares are available for issuance under the ESPP, at which time the ESPP shall be suspended pursuant to the terms of the ESPP plan document, or (ii) December 31, 2022, unless earlier terminated. Compensation expense during the years ended December 31, 2014 and 2013 related to the Employee Stock Purchase Plan (ESPP) totaled $0.6 million and $2.5 million, respectively. The Company issued 75,450 shares from treasury with a cost totaling $4.6 million during the year ended December 31, 2014 pursuant to the ESPP and 188,374 shares with a cost totaling $5.3 million during the year ended December 31, 2013.

Other_Income_Net

Other Income, Net	12 Months Ended
	Dec. 31, 2014
Component of Operating Income [Abstract]
Other Income, Net	NOTE 18. OTHER INCOME, NET
	The components of Other income, net for the years ended December 31 are as follows (in thousands):
		2014			2013			2012
	Watson litigation settlement income, net	$	—		$	(50,400	)	$	—
	Net gain on sale of certain early-stage drug discovery and development assets	(5,200		)	—			—
	Foreign currency (gain) loss, net	(10,054		)	(21		)	—
	Equity earnings from unconsolidated subsidiaries, net	(8,325		)	(1,482		)	(386		)
	Other miscellaneous	(8,745		)	(1,156		)	(235		)
	Other income, net	$	(32,324	)	$	(53,059	)	$	(621	)
	See Note 14. Commitments and Contingencies for a discussion of the Watson litigation settlement income, net.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 19. INCOME TAXES
	The components of our (loss) income from continuing operations before income tax by geography the years ended December 31 were as follows (in thousands):
		2014			2013			2012
	Domestic	$	(33,459	)	$	385,366		$	(12,049	)
	International	133,334			—			—
	Total (loss) income from continuing operations before income tax	$	99,875		$	385,366		$	(12,049	)
	Income tax from continuing operations consists of the following for the years ended December 31 (in thousands):
		2014			2013			2012
	Current:
	Federal	$	30,385		$	93,212		$	102,695
	Foreign	(2,550		)	—			—
	State	16,270			10,980			14,098
	Total current income tax	44,105			104,192			116,793
	Deferred:
	Federal	(31,922		)	36,369			(79,313		)
	Foreign	(620		)	—			—
	State	(7,740		)	(1,336		)	(4,474		)
	Total deferred income tax	(40,282		)	35,033			(83,787		)
	Excess tax benefits of stock options exercised	33,501			4,315			2,530
	Valuation allowance	943			202			3,286
	Income tax	$	38,267		$	143,742		$	38,822
	A reconciliation of income tax from continuing operations at the federal statutory income tax rate to the income tax provision from continuing operations for the years ended December 31 (in thousands):
		2014			2013			2012
	Federal income tax at the statutory rate	$	34,956		$	134,878		$	(4,218	)
	State income tax, net of federal benefit	10,095			5,554			10,697
	Research and development credit	(2,535		)	(6,002		)	—
	Uncertain tax positions	2,494			2,779			13,741
	Tax effect of foreign operations	(52,246		)	—			—
	Change in valuation allowance	952			—			—
	Effect of permanent items:
	Branded prescription drug fee	16,336			12,060			6,108
	Domestic production activities deduction	5,468			(6,835		)	(2,859		)
	Transaction-related expenses	5,889			2,643			—
	Fines and penalties	—			17			11,176
	Excise tax	15,398			—			—
	Executive compensation limitation	3,590			417			1,286
	Extinguishment of convertible debt	(5,802		)	—			—
	Share based compensation	2,227			—			—
	Audit settlements	(1,875		)	—			—
	Other	3,320			(1,769		)	2,891
	Income tax	$	38,267		$	143,742		$	38,822
	The tax effects of temporary differences that comprise the current and non-current deferred income tax amounts, excluding assets and liabilities held for sale, shown on the balance sheets for the years ended December 31 are as follows (in thousands):
		2014			2013
	Deferred tax assets:
	Accrued expenses	$	644,858		$	410,750
	Compensation related to stock options	15,415			20,685
	Net operating loss carryforward	108,823			71,544
	Loss on capital assets	10,642			9,112
	Research and development credit carryforward	13,085			13,905
	Uncertain tax positions	6,574			8,659
	Prepaid royalties	5,190			—
	Tax credit carryforwards	12,249			110
	Other	23,299			40,943
	Total gross deferred income tax assets	840,135			575,708
	Deferred tax liabilities:
	Depreciation and amortization	(894,714		)	(556,086		)
	Non-cash interest expense	(6,012		)	(5,427		)
	Other	(9,492		)	—
	Total gross deferred income tax liabilities	(910,218		)	(561,513		)
	Valuation allowance	(40,646		)	(17,854		)
	Net deferred income tax liability	$	(110,729	)	$	(3,659	)
	At December 31, 2014, our NOLs and tax credit carryforwards related to multiple tax jurisdictions, including federal, foreign and various state jurisdictions, which expire at intervals between 2015 and 2034 or carry forward indefinitely. At December 31, 2014, we had gross federal and foreign net operating loss carry forwards of $431.6 million. As of December 31, 2014, we had pooled Scientific Research and Experimental Development (SR&ED) expenditures amounting to approximately $45.2 million available to offset future year’s taxable income from Canadian operations. The Company had approximately $25.3 million of Canadian investment tax credits, which expire at intervals between 2017 and 2031.
	The Company’s valuation allowance increased $22.8 million from $17.9 million in 2013 to $40.6 million in 2014. Of the $22.8 million increase, the amount charged to tax expense for 2014 was $0.9 million and the amount charged to other accounts was $21.9 million. The amount charged to other accounts related primarily to valuation allowances assumed as a part of our acquisition of Paladin.
	The Company is a multinational organization with operations in various foreign countries. As of December 31, 2014, deferred income taxes have not been provided on the undistributed earnings of our subsidiaries as these amounts are intended to be indefinitely reinvested in each subsidiary’s respective operations. In the unlikely event earnings from a foreign subsidiary are needed to fund the operations of another foreign subsidiary, the Company has a tax efficient structure in place that allows us to transfer funds within our structure in a tax efficient manner without incurring a tax cost.
In the event the Company repatriates earnings of its U.S. foreign subsidiaries, a provision of taxes would be required. However, it is the practice and intention of the Company to reinvest the earnings of its U.S. foreign subsidiaries in those operations. As of December 31, 2014, the Company has not made a provision for U.S income taxes or additional foreign withholding taxes on approximately $111.8 million of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. Generally, such amounts become subject to U.S. taxation upon the remittance of dividends and under certain other circumstances. It is not practicable at this time to calculate the amount of tax liability that would be incurred if the earnings were repatriated.
We evaluate our tax positions using the prescribed two-step process. Step 1 – Recognition, requires the Company to determine whether a tax position, based solely on its technical merits, has a likelihood of more than 50% (more-likely-than-not) that the tax position taken will be sustained upon examination. Step 2 – Measurement, which is only addressed if Step 1 has been satisfied, requires the Company to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis that is more-likely-than-not to be realized upon ultimate settlement.
The Company records accrued interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties resulted in income tax expense of $4.6 million for the year ended December 31, 2014, income tax benefit of $0.9 million for the year ended December 31, 2013 and income tax expense of $0.5 million for the year ended December 31, 2012.
A reconciliation of the change in the unrecognized tax benefits (UTB) balance from January 1, 2012 to December 31, 2014 is as follows (in thousands):
	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2012	$	40,628
Gross additions for current year positions	24,088
Gross additions for prior period positions	285
Gross reductions for prior period positions	(632		)
Decrease due to lapse of statute of limitations	(5,452		)
UTB Balance at December 31, 2012	$	58,917
Gross additions for current year positions	2,076
Gross additions for prior period positions	4,618
Gross reductions for prior period positions	(2,390		)
Decrease due to lapse of statute of limitations	(4,592		)
UTB Balance at December 31, 2013	$	58,629
Gross additions for current year	6,008
Gross additions for prior period positions	873
Gross reductions for prior period positions	(6,647		)
Decrease due to lapse of statute of limitations	(5,067		)
Decrease due to settlements	(597		)
Additions related to acquisitions	54,750
Currency translation adjustment	(2,619		)
UTB Balance at December 31, 2014	$	105,330
Accrued interest and penalties	10,474
Total UTB balance including accrued interest and penalties	$	115,804
Current portion (included in accrued expenses)	$	—
Non-current portion (included in other liabilities)	$	115,804
The Company and its subsidiaries are routinely examined by various taxing authorities, which have proposed adjustments to tax for issues such as certain tax credits and the deductibility of certain expenses. While it is possible that one or more of these examinations may be resolved within the next twelve months, it is not anticipated that the total amount of unrecognized tax benefits will significantly increase or decrease within the next twelve months. In addition, the expiration of statutes of limitations for various jurisdictions is expected to reduce the unrecognized tax benefits balance by an insignificant amount.
The Company files income tax returns in the U.S. Federal jurisdiction, and various state and foreign jurisdictions. The Company is subject to U.S. Federal, state and local, and non-U.S. income tax examinations by tax authorities. In general, the Company is no longer subject to U.S. Federal, state and local, and foreign income tax examinations by tax authorities for years before 2007. The Company believes that it has provided adequately for uncertain tax positions relating to all open tax years by tax jurisdiction.
The total amount of gross unrecognized tax benefits as of December 31, 2014 is $115.8 million, including interest and penalties, of which $109.2 million, if recognized, would affect the Company’s effective tax rate. This liability is included in Other liabilities in the Consolidated Balance Sheets. With the exception of $54.8 million in additions related to acquisitions, the change in the total amount of unrecognized tax benefits did not have a material impact on the Company’s results of operations or financial position as of December 31, 2014. Any future adjustments to our uncertain tax position liability will result in an impact to our income tax provision and effective tax rate.
It is expected that the amount of unrecognized tax benefits will change during the next twelve months; however, the Company does not anticipate any adjustments that would lead to a material impact on our results of operations or our financial position.

Net_Loss_Income_Per_Share

Net (Loss) Income Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Net (Loss) Income Per Share	NOTE 20. NET (LOSS) INCOME PER SHARE
	The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share as of December 31 (in thousands, except per share data):
		2014			2013			2012
	Numerator:
	Income (loss) from continuing operations	$	61,608		$	241,624		$	(50,871	)
	Less: Net (loss) income from continuing operations attributable to noncontrolling interests	(399		)	—			—
	Income (loss) from continuing operations attributable to Endo International plc ordinary shareholders	62,007			241,624			(50,871		)
	Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(783,326		)	(926,963		)	(689,466		)
	Net loss attributable to Endo International plc ordinary shareholders	$	(721,319	)	$	(685,339	)	$	(740,337	)
	Denominator:
	For basic per share data—weighted average shares	146,896			113,295			115,719
	Dilutive effect of ordinary share equivalents	2,600			2,453			—
	Dilutive effect of 1.75% Convertible Senior Subordinated Notes and warrants	7,234			4,081			—
	For diluted per share data—weighted average shares	156,730			119,829			115,719
	Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo International plc ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period. Ordinary share equivalents are measured under the treasury stock method.
	All stock options and stock awards were excluded from the diluted share calculation for the year ended December 31, 2012 because their effect would have been anti-dilutive, as the Company was in a loss position.
	The 1.75% Convertible Senior Subordinated Notes due April 15, 2015 are only included in the dilutive net loss per share calculations using the treasury stock method during periods in which the average market price of our ordinary shares was above the applicable conversion price of the Convertible Notes, or $29.20 per share and the impact would not be anti-dilutive. In these periods, under the treasury stock method, we calculated the number of shares issuable under the terms of these notes based on the average market price of the shares during the period, and included that number in the total diluted shares outstanding for the period.
	We have entered into convertible note hedge and warrant agreements that, in combination, have the economic effect of reducing the dilutive impact of the Convertible Notes. However, we separately analyze the impact of the convertible note hedge and the warrant agreements on diluted weighted average shares outstanding. As a result, the purchases of the convertible note hedges are excluded because their impact would be anti-dilutive. The treasury stock method is applied when the warrants are in-the-money with the proceeds from the exercise of the warrant used to repurchase shares based on the average share price in the calculation of diluted weighted average shares. Until the warrants are in-the-money, they have no impact to the diluted weighted average share calculation. The total number of shares that could potentially be included if the warrants were exercised is approximately 3.4 million at December 31, 2014.
	The maximum weighted average incremental potential dilution of shares that could have occurred if our Convertible Notes and warrants were converted to ordinary shares was 7.4 million, 21.9 million and 26.0 million shares for the years ended December 31, 2014, 2013 and 2012, respectively. These amounts were excluded from the diluted loss per share per share calculations for those respective periods.

Savings_And_Investment_Plan_An

Savings And Investment Plan And Deferred Compensation Plans	12 Months Ended
	Dec. 31, 2014
Savings And Investment Plan And Deferred Compensation Plans [Abstract]
Savings And Investment Plan And Deferred Compensation Plans	NOTE 21. SAVINGS AND INVESTMENT PLAN AND DEFERRED COMPENSATION PLANS
	Savings and Investment Plan
	Endo established a defined contribution Savings and Investment Plan (the Endo 401(k) Plan) covering all employees. Employee contributions can be made on a pre-tax basis under section 401(k) of the Internal Revenue Code (the Code). Effective January 1, 2014, the Endo 401(k) Plan was amended to modify the employer matching contributions such that the Company will match 100% of the first 3% of eligible cash compensation that a participant contributes to the Endo 401(k) Plan plus 50% of the next 2% for a total of up to 4% of the participants’ contributions subject to limitations under section 401(k) of the Code. This compares to 100% of the first 6% of eligible cash compensation that a participant contributes to the Endo 401(k) Plan, which was in effect until December 31, 2013. Participants are immediately vested with respect to their own contributions and the Company’s matching contributions.
	On July 2, 2010, the Company acquired HealthTronics, Inc., which sponsored the HealthTronics, Inc. and Subsidiaries 401(k) Plan (the HealthTronics Plan). The HealthTronics Plan was a defined contribution profit-sharing plan with a 401(k) option covering all employees of HealthTronics, Inc. In June 2011, former HealthTronics, Inc. employees began to participate in the Endo 401(k) Plan and the HealthTronics Plan assets were transferred into the Endo 401(k) Plan. On February 3, 2014, the Company sold its HealthTronics, Inc. subsidiary. In connection with this divestiture, all employee and employer contributions for HealthTronics employees in the Endo 401(k) Plan ended effective on the date of the transaction, February 3, 2014. HealthTronics employees were able to maintain their plan assets in the Plan after the transaction closed, and are able to withdraw or rollover their plan assets under the normal terms of the plan document.
	On June 17, 2011, the Company acquired AMS, which sponsors the AMS Savings and Investment Plan (the AMS Plan). The AMS Plan was a defined contribution profit-sharing plan with a 401(k) option covering all employees of AMS. In January 2013, former AMS employees began to participate in the Endo 401(k) Plan, and the AMS Plan assets were transferred into the Endo 401(k) Plan.
	Costs incurred for contributions made by us to the various 401(k) plans amounted to $7.5 million, $11.4 million and $12.0 million for the years ended December 31, 2014, 2013 and 2012, respectively, excluding amounts related to discontinued operations.
	Executive Deferred Compensation Plan
	In December 2007, Endo’s Board of Directors (the Board) adopted an executive deferred compensation plan (the Executive Deferred Compensation Plan) and a 401(k) restoration plan (the 401(k) Restoration Plan) both effective as of January 1, 2008. Both plans cover employees earning over the Internal Revenue Code plan compensation limit, which would include the chief executive officer, chief financial officer and other named executive officers. The Executive Deferred Compensation Plan allows for deferral of up to 50% of the bonus, with payout to occur as elected, either in a lump sum or in installments, and up to 100% of restricted stock units granted, with payout to occur either in a lump sum or in installments. Under the 401(k) Restoration Plan the participant may defer the amount of base salary and bonus that would have been deferrable under the Company’s Savings and Investment Plan (up to 50% of salary and bonus) if not for the qualified plan statutory limits on deferrals and contributions. Payment occurs as elected, either in lump sum or in installments.
	Directors Deferred Compensation Plan
	Also in December 2007, the Board adopted a directors deferred compensation plan (the Directors Deferred Compensation Plan), effective January 1, 2008. The purpose of this plan is to provide non-employee directors the opportunity to defer up to 100% of meeting fees, retainer fees, and restricted stock units, with payout to occur as elected either in lump sum or installments. Effective with the 2014 plan year, the Company discontinued the Endo Directors Deferred Compensation Plan.
	Directors Stock Election Plan
	In December 2007, Endo established a directors stock election plan (the Directors Stock Election Plan). The purpose of this plan is to provide non-employee directors the opportunity to have some, or all of their retainer fees delivered in the form of Endo ordinary shares. The amount of shares will be determined by dividing the portion of cash fees elected to be received as shares by the closing price of the shares on the day the payment would have otherwise been paid in cash.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 22. SUBSEQUENT EVENTS
	Acquisition of Auxilium Pharmaceuticals, Inc.
	On January 29, 2015, the Company acquired all of the outstanding shares of common stock of Auxilium Pharmaceuticals, Inc. (Auxilium) in a transaction valued at approximately $3.0 billion, including $790.8 million of cash paid to Auxilium shareholders. Pursuant to the terms of the Merger Agreement, of the 54.97 million outstanding Auxilium shares eligible to make an election, 94.9% elected to receive transaction consideration equal to 0.4880 Endo shares per Auxilium share (the Stock Election Consideration), 0.4% elected to receive 100% cash, which equated to $33.25 of cash per Auxilium share (the Cash Election Consideration) and 4.7% elected or defaulted to receive a mix of $16.625 in cash and 0.2440 Endo shares per Auxilium share (the Standard Election Consideration). The result of the elections led to an oversubscription of the Stock Election Consideration and, in accordance with the proration method described in the Merger Agreement and proxy statement/prospectus provided to Auxilium shareholders, each Auxilium share for which an election was made to receive the Stock Election Consideration was instead entitled to receive approximately 0.3448 Endo shares and $9.75 in cash.
	Also on January 29, 2015, in connection with the consummation of the merger, Endo and Auxilium entered into an agreement relating to Auxilium’s $350.0 million of 1.50% convertible senior notes due 2018 (the Auxilium Notes), pursuant to which the Auxilium Notes are no longer convertible into shares of Auxilium common stock and instead are convertible into cash and ordinary shares of Endo based on the weighted average of the cash and Endo ordinary shares received by Auxilium stockholders that affirmatively made an election in connection with the Merger. As a result of such elections, for each share of Auxilium common stock a holder of Auxilium Notes was previously entitled to receive upon conversion of Notes, such holder instead became entitled to receive $9.88 in cash and 0.3430 Endo ordinary shares. Pursuant to this agreement, Endo became a co-obligor of Auxilium’s obligations under the Auxilium Notes and expressly agreed to assume, jointly and severally with Auxilium, liability for (a) the due and punctual payment of the principal (and premium, if any) and interest, if any, on all of the Auxilium Notes issued under the corresponding indenture, (b) the due and punctual delivery of Endo ordinary shares and/or cash upon conversion of the Auxilium Notes by note holders and (c) the due and punctual performance and observance of all of the covenants and conditions of the corresponding indenture to be performed by Auxilium. From the closing of the acquisition on January 29, 2015 until February 20, 2015, holders of the Auxilium Notes converted the majority of the Auxilium Notes.
	The Auxilium 2004 Equity Compensation Plan was also terminated in connection with the consummation of the merger on January 29, 2015.
	In connection with Merger Agreement, Endo advanced to QLT, Inc. (QLT) the amount required to fund the payment of a termination fee of $28.4 million (QLT Termination Fee Loan) to terminate its agreement with Auxilium. QLT terminated its agreement with Auxilium effective October 8, 2014. The QLT Termination Fee Loan is to be repaid, together with interest thereon, within 12 months of the day after signing the Merger Agreement (by October 10, 2015), or sooner under certain circumstances.
	Auxilium is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specific patients’ needs. Auxilium, with a broad range of first- and second-line products across multiple indications, is an emerging leader in the men’s healthcare sector and has strategically focused its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. As a result, we believe its business is highly complementary to Endo’s branded pharmaceuticals business. The Company further believes this transaction is well aligned with our growth strategy and we see significant opportunities to leverage our leading presence in men’s health, as well as our R&D capabilities and financial resources to accelerate the growth of Auxilium’s Xiaflex® and its other products.
	6.00% Senior Notes Due 2025
	On January 27, 2015, Endo Limited, Endo Finance LLC and Endo Finco Inc. (collectively, the Issuers) issued $1.20 billion in aggregate principal amount of 6.00% senior notes due 2025 (the 2025 Notes). The 2025 Notes were issued in a private offering for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
	The 2025 Notes are senior unsecured obligations of the Issuers and are guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries. Interest on the 2025 Notes is payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2015. The 2025 Notes will mature on February 1, 2025, subject to earlier repurchase or redemption in accordance with the terms of the 2025 Notes indenture incorporated by reference herein.
	The 2025 Notes were issued to (i) finance its acquisition of Auxilium, (ii) refinance certain indebtedness of Auxilium and (iii) pay related transaction fees and expenses.
	On or after February 1, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2025 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on February 1 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From February 1, 2020 to and including January 31, 2021	103	%
	From February 1, 2021 to and including January 31, 2022	102	%
	From February 1, 2022 to and including January 31, 2023	101	%
	From February 1, 2023 and thereafter	100	%
	In addition, at any time prior to February 1, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2025 Notes at a specified redemption price set forth in the indenture, plus accrued and unpaid interest and additional interest, if any. In addition, prior to February 1, 2018, the Issuers may redeem up to 35% of the aggregate principal amount of the 2025 Notes with the net cash proceeds from specified equity offerings at a redemption price equal to 106.000% of the aggregate principal amount of the 2025 Notes redeemed, plus accrued and unpaid interest. If Endo Limited experiences certain change of control events, the Issuers must offer to repurchase the 2025 Notes at 101% of their principal amount, plus accrued and unpaid interest and additional interest, if any.
	The 2025 Notes indenture contains covenants that, among other things, restrict Endo Limited’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to payment restrictions on the ability of restricted subsidiaries to make payments to Endo Limited, create certain liens, merge, consolidate or sell substantially all of Endo Limited’s assets, or enter into certain transactions with affiliates. These covenants are subject to a number of important exceptions and qualifications, including the fall away or revision of certain of these covenants upon the 2025 Notes receiving investment grade credit ratings.
	Also on January 27, 2015, the Issuers and the guarantors of the 2025 Notes entered into a registration rights agreement under which they will be required to use their commercially reasonable efforts to (i) file with the SEC by March 31, 2016 an exchange offer registration statement pursuant to which they will offer, in exchange for the 2025 Notes, new notes having terms substantially identical in all material respects to those of the 2025 Notes (except the new notes will not contain terms with respect to transfer restrictions) (the A/B Exchange Offer), (ii) complete the A/B Exchange Offer by July 1, 2016 or, under specified circumstances, (iii) file a shelf registration statement with the SEC covering resales of the 2025 Notes. The Issuers may be required to pay additional interest if they fail to comply with the registration and exchange requirements set forth in the registration rights agreement.
	Acquisition of Remaining Shares of Litha
	On February 10, 2015, Paladin acquired substantially all of Litha’s remaining outstanding ordinary share capital which it did not own for consideration of approximately $0.24 per share in a cash transaction valued at approximately $40.1 million, based on the exchange rate in effect on December 31, 2014. At December 31, 2014, our Paladin subsidiary owned approximately 70.3% of the issued ordinary share capital of Litha. In connection with this transaction, Paladin had deposited cash into an escrow account, primarily for the purpose of guaranteeing amounts required to be paid to Litha’s security holders in connection with this acquisition. The balance in this account at December 31, 2014 of approximately $40.2 million is included in Restricted cash and cash equivalents in the Consolidated Balance Sheets.
	Disposition of AMS Business
	As further described in Note 3. Discontinued Operations, on February 24, 2015, the Board of Directors approved a plan to sell the Company’s AMS business, which comprised the entirety of our former Devices segment.  Subsequently, the Company entered into a definitive agreement to sell the Men’s Health and Prostate Health components of the AMS business to Boston Scientific Corporation (Boston Scientific) for up to $1.65 billion, with $1.6 billion in upfront cash. The Company is also eligible to receive a potential milestone payment of $50 million in cash conditioned on Boston Scientific achieving certain product revenue milestones in the Men’s Health and Prostate Health components in 2016. The transaction with Boston Scientific is expected to close in the third quarter of 2015, subject to customary conditions, including the expiration or termination of any applicable waiting periods under applicable competition laws. In addition, the Company is currently pursuing a sale of the Women’s Health component of the AMS business.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data [Abstract]
Quarterly Financial Data (Unaudited)	NOTE 23. QUARTERLY FINANCIAL DATA (UNAUDITED)
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		(in thousands, except share and per share data)
	2014 (1)(2)
	Total revenues	$	470,842		$	592,848		$	654,116		$	662,877
	Gross profit	$	258,163		$	289,403		$	312,923		$	288,697
	(Loss) income from continuing operations	$	(47,401	)	$	40,575		$	48,953		$	19,481
	Discontinued operations, net of tax	$	(385,877	)	$	(20,189	)	$	(301,002	)	$	(72,724	)
	Net (loss) income attributable to Endo International plc	$	(436,912	)	$	21,160		$	(252,084	)	$	(53,483	)
	Net (loss) income per share attributable to Endo International plc ordinary shareholders—Basic:
	Continuing operations	$	(0.37	)	$	0.27		$	0.32		$	0.13
	Discontinued operations	(3.04		)	(0.13		)	(1.96		)	(0.48		)
	Basic	$	(3.41	)	$	0.14		$	(1.64	)	$	(0.35	)
	Net (loss) income per share attributable to Endo International plc ordinary shareholders—Diluted:
	Continuing operations	$	(0.37	)	$	0.25		$	0.31		$	0.12
	Discontinued operations	(3.04		)	(0.12		)	(1.90		)	(0.46		)
	Diluted	$	(3.41	)	$	0.13		$	(1.59	)	$	(0.34	)
	Weighted average shares—Basic	128,135			152,368			153,309			153,772
	Weighted average shares—Diluted	128,135			163,369			158,975			159,213
	2013 (3)
	Total revenues	$	535,842		$	586,177		$	550,075		$	452,587
	Gross profit	$	318,497		$	351,547		$	328,174		$	239,860
	Income from continuing operations	$	58,660		$	80,688		$	91,680		$	10,596
	Discontinued operations, net of tax	$	(32,057	)	$	(32,577	)	$	(37,065	)	$	(772,339	)
	Net income (loss) attributable to Endo International plc	$	15,349		$	34,999		$	40,223		$	(775,910	)
	Net income (loss) per share attributable to Endo International plc ordinary shareholders—Basic:
	Continuing operations	$	0.53		$	0.72		$	0.8		$	0.09
	Discontinued operations	(0.39		)	(0.41		)	(0.45		)	(6.83		)
	Basic	$	0.14		$	0.31		$	0.35		$	(6.74	)
	Net income (loss) per share attributable to Endo International plc ordinary shareholders—Diluted:
	Continuing operations	$	0.52		$	0.69		$	0.76		$	0.08
	Discontinued operations	(0.38		)	(0.39		)	(0.43		)	(6.11		)
	Diluted	$	0.14		$	0.3		$	0.33		$	(6.03	)
	Weighted average shares—Basic	111,216			112,531			114,327			115,105
	Weighted average shares—Diluted	113,189			117,221			120,261			128,644
	__________
	-1	(Loss) income from continuing operations for the year ended December 31, 2014 was impacted by (1) milestone payments to collaborative partners of $11.2 million, $10.4 million, $13.4 million and $16.8 million in the first, second, third and fourth quarters, respectively (2) acquisition-related and integration items of $45.3 million, $19.6 million, $2.7 million and $9.8 million during the first, second, third and fourth quarters, respectively (3) asset impairment charges of $22.5 million during the fourth quarter (4) inventory step-up charges of $3.6 million, $19.1 million, $17.4 million and $25.5 million during the first, second, third and fourth quarters, respectively (5) amortization expense relating to intangible assets of $39.7 million, $52.8 million, $55.4 million and $70.9 million during the first, second, third and fourth quarters, respectively (6) adjustments to accruals for certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $(1.9) million, $11.4 million, $7.5 million and $8.7 million during the first, second, third and fourth quarters, respectively (7) other charges related to litigation-related and other contingent matters totaling $4.0 million, $3.1 million and $35.0 million during the second, third and fourth quarters, respectively (8) a charge for an additional year of the branded prescription drug fee in accordance with U.S. Internal Revenue Service (IRS) regulations issued in the third quarter of 2014 of $25.0 million and (9) amounts related to expense for the reimbursement of directors’ and certain employees’ excise tax liabilities pursuant to Section 4985 of the Internal Revenue Code of $60.0 million, $(4.7) million and $(1.0) million during the first, second and third quarters, respectively.
	-2	In the fourth quarter of 2014, the Company recorded certain measurement period adjustments reflecting changes in the preliminary estimated fair values of certain assets and liabilities acquired in connection with the Company’s various 2014 business combinations, including adjustments to intangible assets and inventory, among others. The Company considered the impact of these adjustments on the comparative financial information presented, which related primarily to intangible asset amortization expense and inventory step-up costs, and determined that the retrospective impact was not material to the Company’s Consolidated Financial Statements for any of the periods presented. Accordingly, in the fourth quarter of 2014, the Company recorded combined pre-tax charges for intangible asset amortization and inventory step-up of approximately $9.2 million, which included the cumulative effect of these measurement period adjustments, a portion of which related to each of the first, second and third quarters of 2014. This amount was recorded to Cost of revenues.
	-3	Income from continuing operations for the year ended December 31, 2013 was impacted by (1) milestone payments to collaborative partners of $2.6 million, $5.4 million, $3.1 million and $18.6 million in the first, second, third and fourth quarters, respectively (2) acquisition-related and integration items of $0.5 million, $1.6 million, $1.5 million and $4.1 million during the first, second, third and fourth quarters, respectively (3) asset impairment charges of $1.1 million, $2.8 million, $0.8 million and $27.3 million during the first, second, third and fourth quarters, respectively (4) amortization expense relating to intangible assets of $32.0 million, $35.6 million, $29.5 million and $26.5 million during the first, second, third and fourth quarters, respectively (5) certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $13.7 million, $41.6 million, $20.8 million and $15.3 million during the first, second, third and fourth quarters, respectively and (6) other litigation-related items and other contingent matters totaling $(18.8) million, $(16.5) million, $(14.6) million and $9.0 million during the first, second, third and fourth quarters, respectively.
	Quarterly and year to date computations of per share amounts are made independently, therefore the sum of the per share amounts for the quarters may not equal the per share amounts for the year.
	Through the date of its sale in February 2014, the assets and liabilities of the HealthTronics business are classified as held for sale in the Consolidated Balance Sheets for all periods presented. The majority of the assets and liabilities of the AMS business are classified as held for sale in the Consolidated Balance Sheets for all periods presented. Depreciation and amortization expense are not recorded on assets held for sale. The operating results of these businesses are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, see Note 3. Discontinued Operations.

SCHEDULE_IIValuation_and_Quali

SCHEDULE II--Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
SCHEDULE II--Valuation and Qualifying Accounts	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)
		Balance at Beginning of Period		Additions, Costs and Expenses		Deductions, Write-offs			Balance at End of Period
	Allowance For Doubtful Accounts:
	Year Ended December 31, 2012	$	5,255	$	2,817	$	(2,539	)	$	5,533
	Year Ended December 31, 2013	$	5,533	$	1,358	$	(1,297	)	$	5,594
	Year Ended December 31, 2014	$	5,594	$	165	$	(1,840	)	$	3,919

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation—The Consolidated Financial Statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. Certain prior period amounts have been reclassified to conform to the current period presentation.
	The Company owns majority controlling interests in certain entities. Additionally, prior to the sale of our HealthTronics business in February 2014, HealthTronics, Inc. owned interests in various partnerships and limited liability corporations where HealthTronics, Inc., as the general partner or managing member, exercised effective control. In accordance with the accounting consolidation principles, we consolidate various entities which neither we nor our subsidiaries own 100%.
Use of Estimates	Use of Estimates—The preparation of our Consolidated Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition and sales deductions for estimated chargebacks, rebates, sales incentives and allowances, certain royalties, distribution service fees, returns and allowances. Significant estimates and assumptions are also required when determining the fair value of certain financial instruments, the valuation of long-lived and indefinite-lived assets, income taxes, contingencies and share-based compensation. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Our estimates often are based on complex judgments, probabilities and assumptions that we believe to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by us, there may also be other estimates or assumptions that are reasonable.
	We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our Consolidated Financial Statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations.
Customer, Product And Supplier Concentration	Customer, Product and Supplier Concentration—We primarily sell our products directly to a limited number of large pharmacy chains and through a limited number of wholesale drug distributors who, in turn, supply products to pharmacies, hospitals, governmental agencies and physicians.
Revenue Recognition	Revenue Recognition—
	Pharmaceutical Products
	Our net pharmaceutical product sales consist of revenues from sales of our pharmaceutical products, less estimates for chargebacks, rebates, sales incentives and allowances, certain royalties, distribution service fees, returns and allowances as well as fees for services (collectively, revenue reserves which are classified as accrued expenses). Net pharmaceutical product sales also include sales of certain medical devices from our International Pharmaceuticals segment. We recognize revenue for product sales when title and risk of loss has passed to the customer, which is typically upon delivery to the customer, when estimated provisions for revenue reserves are reasonably determinable, and when collectability is reasonably assured. Revenue from the launch of a new or significantly unique product, for which we are unable to develop the requisite historical data on which to base estimates of returns and allowances due to the uniqueness of the therapeutic area or delivery technology as compared to other products in our portfolio and in the industry, may be deferred until such time that an estimate can be determined, all of the conditions above are met and when the product has achieved market acceptance, which is typically based on dispensed prescription data and other information obtained prior to and during the period following launch.
	Devices
	A portion of our revenue is generated from consigned inventory or from inventory with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to our customers providing there are no remaining performance obligations required from us or any matters requiring customer acceptance. In cases where we utilize distributors or ship product directly to the end user, we recognize revenue upon shipment provided all revenue recognition criteria have been met. We record estimated sales returns, discounts and rebates as a reduction of net sales in the period the related revenue is recognized.
	We provide incentives to customers, including volume based rebates. Customers are not required to provide documentation that would allow us to reasonably estimate the fair value of the benefit received and we do not receive an identifiable benefit in exchange for the consideration. Accordingly, the incentives are recorded as a reduction of revenue.
	Our AMS customers have rights of return for the occasional ordering or shipping error. We maintain an allowance for these returns and reduce reported revenue for expected returns from shipments during each reporting period. This allowance is based on historical and current trends in product returns.
	The operating results of this business segment are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
	Other
	Product royalties received from third party collaboration partners and licensees of our products and patents are recorded as other revenues. Royalties are recognized as earned in accordance with the contract terms when royalties from third parties can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.
	Services
	Until it was sold on February 3, 2014, our HealthTronics business’ fees for urology and pathology services were recorded when the procedure was performed and were based on contracted rates. Management fees from our HealthTronics, Inc. limited partnerships were recorded monthly when earned. The operating results of this business segment are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.
Sales Deductions	Sales Deductions—When we recognize net sales from the sale of our pharmaceutical products, we record an adjustment to revenue for estimated revenue reserves. These provisions are estimated based on historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our wholesale and indirect customers and other competitive factors. If the assumptions we used to calculate these adjustments do not appropriately reflect future activity, our financial position, results of operations and cash flows could be materially impacted.
Research and Development	Research and Development—Expenditures for research and development are expensed as incurred. In addition to upfront and milestone payments, total R&D expenses include the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, as well as clinical trials, medical support of marketed products, other payments under third-party collaborations and contracts and other costs. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for research and development activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Upfront and milestone payments made to third parties in connection with agreements with third parties are generally expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are generally capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.
Cash and Cash Equivalents	Cash and Cash Equivalents—The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2014, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances. The Company maintains its cash deposits and cash equivalents with well-known and stable financial institutions.
	Restricted Cash and Cash Equivalents—Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted cash and cash equivalents in the Consolidated Balance Sheets. At December 31, 2014, restricted cash and cash equivalents totaled $530.9 million, of which $485.2 million is held in Qualified Settlement Funds for mesh product liability settlement agreements and $40.2 million is held in an escrow account, primarily for the purpose of guaranteeing amounts required to be paid to Litha Healthcare Group Limited’s (Litha) security holders in connection with acquisition of Litha’s remaining outstanding issued share capital. The restricted cash related to Qualified Settlement Funds are for payments related to the Company’s vaginal mesh liability.
Marketable Securities	Marketable Securities—The Company has equity securities, which consist of investments in the stock of publicly traded companies.
Accounts Receivable	Accounts Receivable—Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information.
Concentrations Of Credit Risk	Concentrations of Credit Risk—Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, marketable debt securities and accounts receivable. We invest our excess cash in high-quality, liquid money market instruments maintained by major U.S. banks and financial institutions. We have not experienced any losses on our cash equivalents.
	We perform ongoing credit evaluations of our customers and generally do not require collateral. We have no history of significant losses from uncollectible accounts. Approximately 76% and 78% of our trade accounts receivable balance represent amounts due from three customers at December 31, 2014 and 2013, respectively.
	We do not expect our current or future credit risk exposures to have a significant impact on our operations. However, there can be no assurance that our business will not experience any adverse impact from credit risk in the future.
Inventories	Inventories—Inventories consist of finished goods held for distribution, raw materials and work-in-process. Our inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other Assets in the Consolidated Balance Sheets.
Property, Plant and Equipment	Property, plant and equipment—Property, plant and equipment is stated at cost less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction is in progress. Depreciation is computed over the estimated useful life of the related assets on a straight-line basis. Leasehold improvements and capital lease assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the terms of their respective leases. Depreciation is not recorded on assets held for sale. Gains and losses on disposals are included in Other income, net in the Consolidated Statements of Operations.
	Depreciation is based on the following estimated useful lives, as of December 31, 2014:
		Range of Useful Lives, from:
	Buildings	8 years	to	45 years
	Machinery and equipment	2 years	to	20 years
	Leasehold improvements	2 years	to	9 years
	Computer equipment and software	2 years	to	10 years
	Assets under capital lease	Shorter of useful life or lease term
	Furniture and fixtures	2 years	to	10 years
Computer Software	Computer Software—The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and amortized beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Lease Accounting	Lease Accounting—The Company accounts for operating lease transactions by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.
	Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated in a manner similar to other Property, plant and equipment.
	Certain construction projects may be accounted for as direct financing arrangements, whereby the Company records, over the construction period, the full cost of the asset in Property, plant and equipment, net in the Consolidated Balance Sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by the Company, and is amortized over the expected lease term through monthly rental payments using an effective interest method. Assets recorded under direct financing arrangements are depreciated over the lease term.
Long-Lived Asset Impairment Testing	Long-Lived Asset Impairment Testing—Long-lived assets, which include property, plant and equipment and definite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying amount of the asset exceeds the undiscounted future cash flows generated by that asset and the carrying amount is not considered recoverable, an impairment exists. An impairment loss is measured as the excess of the asset’s carrying amount over its fair value. An impairment loss is recognized in net income in the period that the impairment occurs.
In Process Research and Development (IPR&D)	In-Process Research and Development Assets (IPR&D)—The fair value of IPR&D acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Future cash flows are predominately based on the net income forecast of each project, consistent with historical pricing, margins and expense levels of similar products. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying patent. In determining the fair value of each research project, expected cash flows are adjusted for the technical and regulatory risk of completion.
	IPR&D is initially capitalized and considered indefinite-lived intangible assets subject to annual impairment reviews. The reviews, which occur annually or more frequently upon the occurrence of certain events, requires the determination of the fair value of the respective intangible assets. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are amortized over the expected useful lives.
Goodwill	Goodwill—Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis, as of October 1st of each year or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment model permits, and we utilize, a two-step method for determining goodwill impairment. In the first step, we determine the fair value of our reporting units using an appropriate valuation methodology. If the net book value of a reporting unit exceeds its fair value, we would then perform the second step of the impairment test which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations. Any residual fair value is allocated to goodwill. An impairment charge is recognized only when the implied fair value of our reporting unit’s goodwill is less than its carrying amount.
Contingencies	Contingencies—The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Contingent accruals are recorded with a corresponding charge to Litigation-related and other contingencies, net in the Consolidated Statements of Operations when the Company determines that a loss is both probable and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our assessments involve significant judgment regarding future events. The Company records a receivable from its product liability insurance carriers only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable.
Convertible Senior Subordinated Notes and Convertible Notes Hedge & Warrants	Convertible Senior Subordinated Notes—We accounted for the issuance of our 1.75% Convertible Senior Subordinated Notes due April 2015 (the Convertible Notes) in accordance with the guidance regarding the accounting for convertible debt instruments that may be settled in cash upon conversion, which among other items, specifies that contracts issued or held by an entity that are both (1) indexed to the entities own ordinary shares and (2) classified in shareholders’ equity in its statement of financial position are not considered to be derivative financial instruments if the appropriate provisions are met. Accordingly, we have recorded the Convertible Notes as debt in the Consolidated Balance Sheets.
	Convertible Notes Hedge & Warrants—Concurrent with the issuance of the Convertible Notes we entered into privately negotiated ordinary share call options with affiliates of the initial purchasers. In addition, we sold warrants to affiliates of certain of the initial purchasers. In addition to entering into the convertible note hedge transaction and the warrant transaction, we entered into a privately negotiated, accelerated share repurchase agreement with the same counterparty, as part of our broader share repurchase program described in Note 16. Shareholders' Equity. We accounted for the call options, warrants, and accelerated share repurchase agreement in accordance with the guidance regarding the accounting derivative financial instruments indexed to, and potentially settled in, a company’s own stock. The call options, warrants, and accelerated share repurchase agreement meet the requirements to be accounted for as equity instruments. The cost of the call options and the proceeds related to the sale of the warrants are included in Additional paid-in capital in the Consolidated Balance Sheets.
Treasury Stock	Treasury Stock—Treasury stock consists of shares of Endo International plc that have been issued but subsequently reacquired. We account for treasury stock purchases under the cost method. In accordance with the cost method, we account for the entire cost of acquiring our ordinary shares as treasury stock, which is a contra equity account. When these shares are reissued, we use an average cost method for determining cost. Proceeds in excess of cost are then credited to Additional paid-in capital in the Consolidated Balance Sheets.
Advertising Costs	Advertising Costs—Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations
Cost of Revenues	Cost of Revenues—Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. It includes purchasing and receiving costs, direct and indirect costs to manufacture products, including direct materials, direct labor, and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods. Cost of revenues also includes royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation, amortization of intangible assets, warehousing costs, freight charges, costs to operate our equipment, and other shipping and handling activity.
Share-Based Compensation	Share-Based Compensation—The Company accounts for its share-based compensation plans in accordance with FASB Codification Topic 718, Stock Compensation. Accordingly, share-based compensation for employees and non-employee directors is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs.
Foreign Currency Translation	Foreign Currency Translation—The financial statements for operations outside the U.S. are maintained primarily in their local currency. All assets and liabilities of our international subsidiaries are translated to U.S. dollars at year-end exchange rates, while elements of the Consolidated Statements of Operations are translated at average exchange rates in effect during the year. Translation adjustments arising from the use of differing exchange rates are included in Accumulated other comprehensive income (loss) in shareholders’ equity with the exception of inter-company balances not considered permanently invested which are included in Other income, net in the Consolidated Statements of Operations. Gains and losses on foreign currency transactions are also included in Other income, net.
Income Taxes	Income Taxes—Provisions for income taxes are calculated on reported pre-tax income based on current tax laws, statutory tax rates and available tax incentives and planning opportunities in various jurisdictions in which we operate. Such provisions differ from the amounts currently receivable or payable because certain items of income and expense are recognized in different time periods for financial reporting purposes than for income tax purposes. We recognize deferred taxes by the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for differences between the financial statement and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Significant judgment is required in determining income tax provisions and evaluating tax positions. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The factors used to assess the likelihood of realization are the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Comprehensive Income	Comprehensive Income—Comprehensive income includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.
Segment Information	Segment Information— The Company operates in three reportable segments. These segments are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals and (3) International Pharmaceuticals.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of an Entity” (ASU 2014-08). ASU 2014-08 changes the requirements for reporting discontinued operations by limiting discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The disclosure requirements for discontinued operations under ASU 2014-08 will be expanded in order to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. ASU 2014-08 is effective on a prospective basis for (1) all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years, and (2) all businesses that are classified as held for sale on acquisition that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years. We have applied the provisions of ASU 2014-08 to our AMS business. Refer to Note 3. Discontinued Operations.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim reporting periods within that reporting period. Early adoption is not permitted. Accordingly, the Company will adopt this ASU on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this ASU. The Company is currently evaluating the impact of ASU 2014-09 on the Company’s consolidated results of operations and financial position.
	In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (ASU 2014-15). This ASU states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company plans to adopt ASU 2014-15 in conjunction with the December 31, 2016 financial statements and will comply with the disclosure requirements of the standard in the Form 10-K for the period ended December 31, 2016.
License Rights
Summary Of Significant Accounting Policies [Line Items]
Intangible Assets	License Rights—The cost of licenses are either expensed immediately or, if capitalized, are stated at cost, less accumulated amortization and are amortized using the straight-line method over their estimated useful lives ranging from 3 years to 15 years, with a weighted average useful life of approximately 9 years. We determine amortization periods for licenses based on our assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the expected launch date of the product, the strength of the intellectual property protection of the product and various other competitive, developmental and regulatory issues, and contractual terms. Amortization expense is not recorded on assets held for sale.
Customer Relationships
Summary Of Significant Accounting Policies [Line Items]
Intangible Assets	Customer Relationships—Acquired customer relationships are recorded at fair value upon acquisition. All customer relationship assets relate to our AMS business and are classified as Assets held for sale in the Consolidated Balance Sheets. Amortization expense is not recorded on assets held for sale.
Tradenames
Summary Of Significant Accounting Policies [Line Items]
Intangible Assets	Trade names—Acquired trade names are recorded at fair value upon acquisition and, if deemed to have definite lives, are amortized using estimated useful lives ranging from 12 years to 15 years for our intangibles relating to continuing operations, with a weighted average useful life of approximately 15 years. We determine amortization periods for trade names based on our assessment of various factors impacting estimated useful lives and cash flows from the acquired assets. Such factors include the strength of the trade name and our plans regarding the future use of the trade name. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.
Developed Technology
Summary Of Significant Accounting Policies [Line Items]
Intangible Assets	Developed Technology—Acquired developed technology is recorded at fair value upon acquisition and amortized using estimated useful lives ranging from 3 years to 20 years for our intangibles relating to continuing operations, with a weighted average useful life of approximately 13 years. We determine amortization periods for developed technology based on our assessment of various factors impacting estimated useful lives and cash flows of the acquired assets. Such factors include the strength of the intellectual property protection of the product and various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale. The value of these assets is subject to continuing scientific, medical and marketplace uncertainty.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Concentration Risk [Line Items]
Estimated Useful Lives	Depreciation is based on the following estimated useful lives, as of December 31, 2014:
		Range of Useful Lives, from:
	Buildings	8 years		to	45 years
	Machinery and equipment	2 years		to	20 years
	Leasehold improvements	2 years		to	9 years
	Computer equipment and software	2 years		to	10 years
	Assets under capital lease	Shorter of useful life or lease term
	Furniture and fixtures	2 years		to	10 years
		Land and Buildings				Machinery and Equipment				Leasehold Improve-			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc-			Total
										ments												tion
		(In thousands)
	Cost:
	At January 1, 2014	$	191,141			$	83,431			$	22,323		$	73,057		$	5,012		$	4,743		$	69,497		$	449,204
	Additions	19,012				9,199				1,157			38,675			4,784			159			10,659			83,645
	Additions due to acquisitions	16,409				5,057				1,581			3,149			—			618			277			27,091
	Disposals/transfers/impairments/other	—				(5,175		)		(8,691		)	(25,789		)	(3,714		)	(2,208		)	(572		)	(46,149		)
	Effect of currency translation	(2,070		)		(613		)		(205		)	(108		)	—			(94		)	—			(3,090		)
	At December 31, 2014	$	224,492			$	91,899			$	16,165		$	88,984		$	6,082		$	3,218		$	79,861		$	510,701
	Accumulated Depreciation:
	At January 1, 2014	$	(17,388	)		$	(30,983	)		$	(15,625	)	$	(49,939	)	$	(3,357	)	$	(2,027	)	$	(3,011	)	$	(122,330	)
	Additions	(13,381		)		(11,599		)		(553		)	(14,360		)	(1,697		)	(1,075		)	—			(42,665		)
	Disposals/transfers/impairments/other	—				6,052				8,118			22,159			3,234			2,025			—			41,588
	Effect of currency translation	113				131				26			97			—			42			—			409
	At December 31, 2014	$	(30,656	)		$	(36,399	)		$	(8,034	)	$	(42,043	)	$	(1,820	)	$	(1,035	)	$	(3,011	)	$	(122,998	)
	Net Book Amount:
	At December 31, 2014	$	193,836			$	55,500			$	8,131		$	46,941		$	4,262		$	2,183		$	76,850		$	387,703
	At December 31, 2013	$	173,753			$	52,448			$	6,698		$	23,118		$	1,655		$	2,716		$	66,486		$	326,874
Customer Concentration Risk
Concentration Risk [Line Items]
Schedules of concentration of risk, by risk factor	Total revenues from customers who accounted for 10% or more of our total consolidated revenues during the years ended December 31 are as follows:
		2014			2013			2012
	Cardinal Health, Inc.	21	%		26	%		30	%
	McKesson Corporation	31	%		32	%		32	%
	AmerisourceBergen Corporation	16	%		19	%		15	%
Product Concentration Risk
Concentration Risk [Line Items]
Schedules of concentration of risk, by risk factor	The Company derives a majority of its total revenues from a limited number of products. Products that accounted for 10% or more of our total revenues during the years ended December 31 were as follows:
		2014			2013			2012
	Lidoderm®	7	%		28	%		41	%
	Opana® ER	8	%		11	%		13	%

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Operating Results of Discontinued Operations and Assets Held for Sale and Related Liabilities	The following table provides the operating results of Discontinued operations of HealthTronics, net of tax for the three years ended December 31(in thousands):
		2014			2013			2012
	Revenue	$	14,443		$	207,194		$	211,627
	Income (loss) from discontinued operations before income taxes	$	6,434		$	(119,690	)	$	(11,160	)
	Income taxes	757			(22,776		)	(17,147		)
	Discontinued operations, net of tax	$	5,677		$	(96,914	)	$	5,987
	There were no Assets and Liabilities held for sale relating to HealthTronics included in the Consolidated Balance Sheet as of December 31, 2014. The following table provides the components of Assets and Liabilities held for sale as of December 31, 2013 (in thousands):
		31-Dec-13
	Current assets	$	69,131
	Property, plant and equipment	23,461
	Goodwill and other intangibles, net	58,761
	Other assets	8,904
	Assets held for sale	$	160,257
	Current liabilities	$	27,656
	Long term debt, less current portion, net	3,354
	Other liabilities	561
	Liabilities held for sale	$	31,571
	The following table provides the operating results of the Discontinued operations of AMS, net of tax for the three years ended December 31 (in thousands):
		2014			2013			2012
	Revenue	$	496,505		$	492,226		$	504,487
	Litigation-related expense and other contingencies, net	1,273,358			474,792			92,000
	Loss from discontinued operations before income taxes	(1,225,576		)	(944,933		)	(718,374		)
	Income taxes	(440,107		)	(167,809		)	(75,237		)
	Discontinued operations, net of tax	$	(785,469	)	$	(777,124	)	$	(643,137	)
	The following table provides the components of Assets and Liabilities held for sale as of December 31, 2014 and 2013 (in thousands):
		December 31, 2014			December 31, 2013
	Current assets	$	165,075		$	168,760
	Property, plant and equipment	41,122			45,203
	Goodwill	862,960			806,838
	Other intangibles, net	861,174			925,460
	Other assets	7,533			6,616
	Assets held for sale	$	1,937,864		$	1,952,877
	Current liabilities	$	53,143		$	62,110
	Deferred income taxes	46,538			51,671
	Other liabilities	3,657			3,901
	Liabilities held for sale	$	103,338		$	117,682
	The following table provides the Depreciation and amortization and Purchases of property, plant and equipment of AMS for the three years ended December 31 (in thousands):
		2014			2013			2012
	Cash flows from discontinued operating activities:
	Net loss	$	(785,469	)	$	(777,124	)	$	(643,137	)
	Depreciation and amortization	70,275			72,003			84,089
	Cash flows from discontinued investing activities:
	Purchase of property, plant and equipment	$	(4,423	)	$	(3,517	)	$	(5,271	)

Restructuring_Tables

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost
		Employee Severance and Other Benefit-Related Costs			Other Restructuring Costs			Total
	Liability balance as of December 31, 2012	$	—		$	—		$	—
	Expenses	41,435			11,966			53,401
	Cash distributions	(34,056		)	(6,076		)	(40,132		)
	Other non-cash adjustments	—			(971		)	(971		)
	Liability balance as of December 31, 2013	$	7,379		$	4,919		$	12,298
	Expenses	$	1,224		$	880		$	2,104
	Cash distributions	(7,320		)	(4,453		)	(11,773		)
	Other non-cash adjustments	—			(1,191		)	(1,191		)
	Liability balance as of December 31, 2014	$	1,283		$	155		$	1,438
Restructuring and Related Costs	A summary of expenses related to the June 2013 restructuring initiatives is included below by reportable segment and for corporate unallocated for the year ended December 31, 2013 (in thousands):
		Employee Severance and Other Benefit-Related Costs			Asset Impairment Charges			Other Restructuring Costs			Total
	U.S. Branded Pharmaceuticals	$	22,847		$	2,849		$	8,780		$	34,476
	U.S. Generic Pharmaceuticals	262			—			1,142			1,404
	Discontinued operations (NOTE 3)	9,905			—			2,044			11,949
	Corporate unallocated	8,421			—			—			8,421
	Total	$	41,435		$	2,849		$	11,966		$	56,250

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Paladin Labs Inc.
Business Acquisition [Line Items]
Schedule of business acquisitions by acquisition, equity interest issued or issuable	The acquisition consideration was as follows (in thousands of U.S. dollars, except for per share amounts):
	Number of Paladin shares paid through the delivery of Endo International ordinary shares	20,765
	Exchange ratio	1.6331
	Number of ordinary shares of Endo International—as exchanged*	33,912
	Endo International ordinary share price on February 28, 2014	$	80
	Fair value of ordinary shares of Endo International issued to Paladin Shareholders*				$	2,712,956
	Number of Paladin shares paid in cash	20,765
	Per share cash consideration for Paladin shares (1)	$	1.09
	Cash distribution to Paladin shareholders*				22,647
	Fair value of the vested portion of Paladin stock options outstanding—1.3 million at February 28, 2014 (2)				131,323
	Total acquisition consideration				$	2,866,926
	__________
	*	Amounts do not recalculate due to rounding.
	-1	Represents the cash consideration per the arrangement agreement of C$1.16 per Paladin share translated into U.S. dollars utilizing an exchange rate of $0.9402.
	-2	Represents the fair value of vested Paladin stock option awards attributed to pre-combination services that were outstanding on the Paladin Acquisition Date and settled on a cash-less exercise basis for Endo International plc shares.
Schedule of fair values of the assets acquired and liabilities assumed at the acquisition date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the Paladin Acquisition Date (in thousands):
		February 28, 2014 (As initially reported)			Measurement period adjustments			February 28, 2014 (As adjusted)
	Cash and cash equivalents	$	113,571		$	—		$	113,571
	Marketable securities	89,420			—			89,420
	Accounts receivable	93,832			3,262			97,094
	Inventories	62,095			1,498			63,593
	Prepaid expenses and other current assets	32,605			9			32,614
	Deferred income tax assets, current	11,719			1,423			13,142
	Property, plant and equipment	7,299			4			7,303
	Intangible assets	676,000			(1,752		)	674,248
	Other assets	56,289			1,255			57,544
	Total identifiable assets	$	1,142,830		$	5,699		$	1,148,529
	Accounts payable and accrued expenses	$	124,321		$	7,099		$	131,420
	Income taxes payable	22,524			934			23,458
	Deferred income taxes	160,620			(22,967		)	137,653
	Debt	23,826			—			23,826
	Other liabilities	9,578			30,890			40,468
	Total liabilities assumed	$	340,869		$	15,956		$	356,825
	Net identifiable assets acquired	$	801,961		$	(10,257	)	$	791,704
	Noncontrolling interests	$	(69,600	)	$	30,800		$	(38,800	)
	Goodwill	2,134,565			(20,543		)	2,114,022
	Net assets acquired	$	2,866,926		$	—		$	2,866,926
Schedule of valuation of the intangible assets acquired and related amortization periods	The valuation of the intangible assets acquired and related amortization periods are as follows:
		Valuation			Amortization
		(in millions)			Period
					(in years)
	Developed Technology:
	Canada Base Prescription	$	410		12
	Canada OTC	50			11
	Canada Other	74.2			11
	Litha	70			12
	Licenses not renewed	4.5			3
	Total	$	608.7
	In Process Research & Development (IPR&D):
	Serelaxin	$	55		n/a
	Other	10.5			n/a
	Total	$	65.5
	Total other intangible assets	$	674.2
Schedule of revenue and net loss of acquired included in condensed consolidated statements of operations	The amounts of Paladin Revenue and Net income attributable to Endo International plc included in the Company’s Consolidated Statements of Operations from February 28, 2014 to December 31, 2014 are as follows (in thousands, except per share data):
	Revenue	$	224,806
	Net income attributable to Endo International plc	$	26,966
	Basic net income per share	$	0.18
	Diluted net income per share	$	0.17
Schedule of pro forma consolidated results	This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2013, nor are they indicative of any future results.
		Year Ended December 31, 2014			Year Ended December 31, 2013
	Unaudited pro forma consolidated results (in thousands, except per share data):
	Revenue	$	2,423,683		$	2,392,687
	Net loss attributable to Endo International plc	$	(727,961	)	$	(574,407	)
	Basic net loss per share	$	(4.96	)	$	(5.07	)
	Diluted net loss per share	$	(4.64	)	$	(4.79	)
DAVA Pharmaceuticals, Inc
Business Acquisition [Line Items]
Schedule of fair values of the assets acquired and liabilities assumed at the acquisition date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the DAVA Acquisition Date (in thousands):
		August 6, 2014 (As initially reported)			Measurement period adjustments			August 6, 2014 (As adjusted)
	Cash and cash equivalents	$	533		$	—		$	533
	Accounts receivable	15,842			2,246			18,088
	Inventories	120,626			(47,400		)	73,226
	Prepaid expenses and other current assets	2,672			—			2,672
	Property, plant and equipment	2,659			—			2,659
	Intangible assets	439,623			75,277			514,900
	Other assets	21,029			—			21,029
	Total identifiable assets	$	602,984		$	30,123		$	633,107
	Accounts payable and accrued expenses	$	17,585		$	6,892		$	24,477
	Deferred income taxes	195,915			10,357			206,272
	Other liabilities	21,139			—			21,139
	Total liabilities assumed	$	234,639		$	17,249		$	251,888
	Net identifiable assets acquired	$	368,345		$	12,874		$	381,219
	Goodwill	226,683			(12,574		)	214,109
	Net assets acquired	$	595,028		$	300		$	595,328

Segment_Results_Tables

Segment Results (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of reportable segments information	The following represents selected information for the Company’s reportable segments for the years ended December 31 (in thousands):
		2014			2013			2012
	Net revenues to external customers:
	U.S. Branded Pharmaceuticals	$	969,437		$	1,394,015		$	1,677,984
	U.S. Generic Pharmaceuticals	1,140,821			730,666			633,265
	International Pharmaceuticals (1)	270,425			—			—
	Total net revenues to external customers	$	2,380,683		$	2,124,681		$	2,311,249
	Adjusted income (loss) from continuing operations before income tax:
	U.S. Branded Pharmaceuticals	$	529,507		$	783,927		$	906,839
	U.S. Generic Pharmaceuticals	464,029			193,643			171,418
	International Pharmaceuticals	80,683			—			—
	__________
	-1	Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
Schedule of reconciliations of consolidated adjusted income before income tax	The table below provides reconciliations of our segment adjusted income from continuing operations before income tax to our consolidated income (loss) from continuing operations before income tax, which is determined in accordance with U.S. GAAP, for the years ended December 31 (in thousands):
		2014			2013			2012
	Total segment adjusted income from continuing operations before income tax:	$	1,074,219		$	977,570		$	1,078,257
	Corporate unallocated costs	(355,417		)	(315,743		)	(328,633		)
	Upfront and milestone payments to partners	(51,774		)	(29,703		)	(60,778		)
	Asset impairment charges	(22,542		)	(32,011		)	(72,551		)
	Acquisition-related and integration items (1)	(77,384		)	(7,614		)	(18,432		)
	Separation benefits and other cost reduction initiatives (2)	(25,760		)	(91,530		)	(23,489		)
	Excise tax (3)	(54,300		)	—			—
	Amortization of intangible assets	(218,712		)	(123,547		)	(146,898		)
	Inventory step-up	(65,582		)	—			—
	Non-cash interest expense related to the 1.75% Convertible Senior Subordinated Notes	(12,192		)	(22,742		)	(20,762		)
	Loss on extinguishment of debt	(31,817		)	(11,312		)	(7,215		)
	Watson litigation settlement income, net	—			50,400			—
	Accrual for payment to Impax Laboratories Inc. related to sales of Opana® ER	—			—			(102,000		)
	Patent litigation settlement items, net	—			—			(85,123		)
	Certain litigation-related charges, net (4)	(42,084		)	(9,450		)	(224,425		)
	Charge related to the non-recoverability of certain non-trade receivables	(10,000		)	—			—
	Net gain on sale of certain early-stage drug discovery and development assets	5,200			—			—
	Foreign currency impact related to the remeasurement of intercompany debt instruments	13,153			—			—
	Charge for an additional year of the branded prescription drug fee in accordance with IRS regulations issued in the third quarter of 2014	(24,972		)	—			—
	Other, net	(161		)	1,048			—
	Total consolidated income (loss) from continuing operations before income tax	$	99,875		$	385,366		$	(12,049	)
	__________
	-1	Acquisition-related and integration-items include costs directly associated with the closing of certain acquisitions, changes in the fair value of contingent consideration and the costs of integration activities related to both current and prior period acquisitions.
	-2	Separation benefits and other cost reduction initiatives include employee separation costs of $14.4 million, $35.2 million and $20.0 million in 2014, 2013 and 2012, respectively. Contract termination fees of $5.8 million in 2013 are also included in this amount. The amount of separation benefits and other cost reduction initiatives in 2013 includes an expense recorded upon the cease use date of our Chadds Ford, Pennsylvania and Westbury, New York properties in the first quarter of 2013, representing the liability for our remaining obligations under the respective lease agreements of $7.2 million. These expenses were primarily recorded as Selling, general and administrative and Research and development expense in our Consolidated Statements of Operations. The amounts in this table exclude amounts related to discontinued operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.
	-3	This amount represents charges related to the expense for the reimbursement of directors’ and certain employees’ excise tax liabilities pursuant to Section 4985 of the Internal Revenue Code.
	-4	These amounts include charges for Litigation-related and other contingencies, net
Additional selected financial information for reportable segments	The following represents additional selected financial information for our reportable segments for the years ended December 31 (in thousands):
		2014			2013			2012
	Depreciation expense:
	U.S. Branded Pharmaceuticals	$	16,209		$	19,828		$	15,540
	U.S. Generic Pharmaceuticals	16,751			13,354			12,343
	International Pharmaceuticals	1,856			—			—
	Corporate unallocated	7,849			8,354			5,033
	Total depreciation expense	$	42,665		$	41,536		$	32,916
		2014			2013			2012
	Amortization expense:
	U.S. Branded Pharmaceuticals	$	78,890		$	80,223		$	105,974
	U.S. Generic Pharmaceuticals	95,042			43,924			41,524
	International Pharmaceuticals	44,780			—			$	—
	Total amortization expense	$	218,712		$	124,147		$	147,498

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Financial assets and liabilities measured at fair value on recurring basis	The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013 were as follows (in thousands):
		Fair Value Measurements at Reporting Date using:
	December 31, 2014	Quoted Prices in		Significant Other			Significant			Total
		Active Markets		Observable			Unobservable
		for Identical		Inputs (Level 2)			Inputs (Level 3)
		Assets (Level 1)
	Assets:
	Money market funds	$	279,327	$	—		$	—		$	279,327
	Equity securities	2,321		$	—		—			2,321
	Total	$	281,648	$	—		$	—		$	281,648
	Liabilities:
	Acquisition-related contingent consideration—short-term	$	—	$	—		$	4,282		$	4,282
	Acquisition-related contingent consideration—long-term	—		—			41,723			41,723
	Total	$	—	$	—		$	46,005		$	46,005
	At December 31, 2014, money market funds include $124.4 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 14. Commitments and Contingencies for further discussion of our product liability cases.
		Fair Value Measurements at Reporting Date using:
	December 31, 2013	Quoted Prices in		Significant Other			Significant			Total
		Active Markets		Observable			Unobservable
		for Identical		Inputs (Level 2)			Inputs (Level 3)
		Assets (Level 1)
	Assets:
	Money market funds	$	843,390	$	—		$	—		$	843,390
	Equity securities	2,979		—			—			2,979
	Total	$	846,369	$	—		$	—		$	846,369
	Liabilities:
	Acquisition-related contingent consideration—short-term	$	—	$	—		$	3,878		$	3,878
	Acquisition-related contingent consideration—long-term	—		—			869			869
	Total	$	—	$	—		$	4,747		$	4,747
Changes to liability for acquisition-related contingent consideration	The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2014 and 2013 (in thousands):
		2014		2013
	Beginning of period	$	4,747	$	8,924
	Amounts acquired	40,224		—
	Amounts settled	—		(5,000		)
	Transfers (in) and/or out of Level 3	—		—
	Changes in fair value recorded in earnings	1,034		823
	End of period	$	46,005	$	4,747
Summary of available-for-sale securities	The following is a summary of available-for-sale securities held by the Company at December 31, 2014 and December 31, 2013 (in thousands):
		Available-for-sale
		Amortized		Gross			Gross			Fair Value
		Cost		Unrealized			Unrealized
				Gains			(Losses)
	December 31, 2014
	Money market funds	$	279,327	$	—		$	—		$	279,327
	Total included in cash and cash equivalents	$	154,959	$	—		$	—		$	154,959
	Total included in restricted cash and cash equivalents	$	124,368	$	—		$	—		$	124,368
	Equity securities	$	805	$	10		$	—		$	815
	Total other short-term available-for-sale securities	$	805	$	10		$	—		$	815
	Equity securities	$	1,766	$	—		$	(260	)	$	1,506
	Long-term available-for-sale securities	$	1,766	$	—		$	(260	)	$	1,506
		Available-for-sale
		Amortized		Gross			Gross			Fair Value
		Cost		Unrealized			Unrealized
				Gains			(Losses)
	December 31, 2013
	Money market funds	$	843,390	$	—		$	—		$	843,390
	Total included in cash and cash equivalents	$	73,390	$	—		$	—		$	73,390
	Total included in restricted cash and cash equivalents	$	770,000	$	—		$	—		$	770,000
	Equity securities	$	1,766	$	1,213		$	—		$	2,979
	Long-term available-for-sale securities	$	1,766	$	1,213		$	—		$	2,979
Financial assets measured at fair value on a nonrecurring basis	The Company’s financial assets measured at fair value on a nonrecurring basis during the year ended December 31, 2014 were as follows (in thousands):
		Fair Value Measurements at Reporting Date using:								Total Income (Expense) for the Year Ended December 31, 2014
		Quoted Prices in		Significant Other			Significant
		Active Markets		Observable Inputs			Unobservable Inputs
		for Identical Assets		(Level 2)			(Level 3)
		(Level 1)
	Assets:
	Certain other intangible assets	$	—	$	—		$	3,300		$	(18,200	)
	Property, plant and equipment (See Note 9)	—		—			—			(4,342		)
		$	—	$	—		$	3,300		$	(22,542	)
	Liabilities:
	Minimum Voltaren® Gel royalties due to Novartis	$	—	$	—		$	37,500		$	—
	Total	$	—	$	—		$	37,500		$	—
	The Company’s financial assets, excluding assets held for sale, measured at fair value on a nonrecurring basis during the year ended December 31, 2013 were as follows (in thousands):
		Fair Value Measurements at Measurement Date using:								Total Expense for the Year Ended December 31, 2013
		Quoted Prices in		Significant Other			Significant
		Active Markets		Observable Inputs			Unobservable Inputs
		for Identical Assets		(Level 2)			(Level 3)
		(Level 1)
	Assets:
	AMS IPR&D intangible asset	$	—	$	—		$	8,000		$	(6,000	)
	Qualitest IPR&D intangible assets	—		—			—			(17,000		)
	Epicept intangible asset	—		—			—			(1,500		)
	Property, plant and equipment (See Note 9)	—		—			—			(7,511		)
	Total	$	—	$	—		$	8,000		$	(32,011	)
	Liabilities:
	Minimum Voltaren® Gel royalties due to Novartis	$	—	$	—		$	21,451		$	—
	Total	$	—	$	—		$	21,451		$	—

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following at December 31, 2014 and December 31, 2013 (in thousands):
		December 31, 2014		December 31, 2013
	Raw materials	$	118,431	$	89,640
	Work-in-process	43,290		45,713
	Finished goods	261,600		188,974
	Total	$	423,321	$	324,327

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule Of Property, Plant And Equipment	Depreciation is based on the following estimated useful lives, as of December 31, 2014:
		Range of Useful Lives, from:
	Buildings	8 years		to	45 years
	Machinery and equipment	2 years		to	20 years
	Leasehold improvements	2 years		to	9 years
	Computer equipment and software	2 years		to	10 years
	Assets under capital lease	Shorter of useful life or lease term
	Furniture and fixtures	2 years		to	10 years
		Land and Buildings				Machinery and Equipment			Leasehold Improve-			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construc-			Total
									ments												tion
		(In thousands)
	Cost:
	At January 1, 2014	$	191,141			$	83,431		$	22,323		$	73,057		$	5,012		$	4,743		$	69,497		$	449,204
	Additions	19,012				9,199			1,157			38,675			4,784			159			10,659			83,645
	Additions due to acquisitions	16,409				5,057			1,581			3,149			—			618			277			27,091
	Disposals/transfers/impairments/other	—				(5,175		)	(8,691		)	(25,789		)	(3,714		)	(2,208		)	(572		)	(46,149		)
	Effect of currency translation	(2,070		)		(613		)	(205		)	(108		)	—			(94		)	—			(3,090		)
	At December 31, 2014	$	224,492			$	91,899		$	16,165		$	88,984		$	6,082		$	3,218		$	79,861		$	510,701
	Accumulated Depreciation:
	At January 1, 2014	$	(17,388	)		$	(30,983	)	$	(15,625	)	$	(49,939	)	$	(3,357	)	$	(2,027	)	$	(3,011	)	$	(122,330	)
	Additions	(13,381		)		(11,599		)	(553		)	(14,360		)	(1,697		)	(1,075		)	—			(42,665		)
	Disposals/transfers/impairments/other	—				6,052			8,118			22,159			3,234			2,025			—			41,588
	Effect of currency translation	113				131			26			97			—			42			—			409
	At December 31, 2014	$	(30,656	)		$	(36,399	)	$	(8,034	)	$	(42,043	)	$	(1,820	)	$	(1,035	)	$	(3,011	)	$	(122,998	)
	Net Book Amount:
	At December 31, 2014	$	193,836			$	55,500		$	8,131		$	46,941		$	4,262		$	2,183		$	76,850		$	387,703
	At December 31, 2013	$	173,753			$	52,448		$	6,698		$	23,118		$	1,655		$	2,716		$	66,486		$	326,874

Goodwill_And_Other_Intangibles1

Goodwill And Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	Changes in the carrying amount of our goodwill for the year ended December 31, 2014 were as follows (in thousands):
		U.S. Branded Pharmaceuticals			U.S. Generic Pharmaceuticals			International Pharmaceuticals			Total Consolidated
	Balance as of December 31, 2013:
	Goodwill	$	290,793		$	275,201		$	—		$	565,994
	Accumulated impairment losses	—			—			—			—
		$	290,793		$	275,201		$	—		$	565,994
	Goodwill acquired during the period	841,139			796,436			738,862			2,376,437
	Effect of currency translation	—			—			(42,844		)	(42,844		)
	Balance as of December 31, 2014:
	Goodwill	1,131,932			1,071,637			696,018			2,899,587
	Accumulated impairment losses	—			—			—			—
		$	1,131,932		$	1,071,637		$	696,018		$	2,899,587
Schedule of other intangible assets	The following is a summary of other intangibles held by the Company at December 31, 2014 and December 31, 2013 (in thousands):
	Cost basis:	Balance as of December 31, 2013			Acquisitions			Impairments			Other			Effect of Currency Translation			Balance as of December 31, 2014
					-1			-2			-3
	Indefinite-lived intangibles:
	In-process research and development	$	67,400		$	173,700		$	(5,900	)	$	(45,000	)	$	(5,602	)	$	184,598
	Total indefinite-lived intangibles	$	67,400		$	173,700		$	(5,900	)	$	(45,000	)	$	(5,602	)	$	184,598
	Definite-lived intangibles:
	Licenses (weighted average life of 9 years)	$	587,127		$	—		$	—		$	77,240		$	—		$	664,367
	Tradenames (weighted average life of 15 years)	20,000			1,500			—			—			(185		)	21,315
	Developed technology (weighted average life of 13 years)	838,901			1,470,172			(23,500		)	5,812			(48,169		)	2,243,216
	Total definite-lived intangibles (weighted average life of 12 years)	$	1,446,028		$	1,471,672		$	(23,500	)	$	83,052		$	(48,354	)	$	2,928,898
	Total other intangibles	$	1,513,428		$	1,645,372		$	(29,400	)	$	38,052		$	(53,956	)	$	3,113,496
	Accumulated amortization:	Balance as of December 31, 2013			Amortization			Impairments			Other			Effect of Currency Translation			Balance as of December 31, 2014
								-2			-3
	Indefinite-lived intangibles:
	In-process research and development	$	—		$	—		$	—		$	—		$	—		$	—
	Total indefinite-lived intangibles	$	—		$	—		$	—		$	—		$	—		$	—
	Definite-lived intangibles:
	Licenses	$	(357,439	)	$	(68,974	)	$	—		$	—		$	—		$	(426,413	)
	Tradenames	(4,088		)	(1,378		)	—			—			4			(5,462		)
	Developed technology	(204,435		)	(148,360		)	3,190			—			1,177			(348,428		)
	Total definite-lived intangibles	$	(565,962	)	$	(218,712	)	$	3,190		$	—		$	1,181		$	(780,303	)
	Total other intangibles	$	(565,962	)	$	(218,712	)	$	3,190		$	—		$	1,181		$	(780,303	)
	Net other intangibles	$	947,466														$	2,333,193
	__________
	-1	Includes intangible assets acquired in connection with the acquisitions of Boca, Paladin, Sumavel® DosePro®, Somar, DAVA and Natesto™. See Note 5. Acquisitions for further information.
	-2	We assessed the value of certain other in-process research and development assets and determined that approximately $5.9 million was impaired. The $23.5 million impairment relates to the write-off of a definite-lived license intangible asset related to Opana® ER. See further information below under the caption “Impairments.”
	-3	On March 6, 2014, we announced that the FDA approved Aveed® for the treatment of hypogonadism in adult men. Upon approval, the Company reclassified the intangible asset, with a balance of $35.0 million, from IPR&D to Licenses. At this time, the Company also capitalized an additional milestone payment of $5.0 million related to the approval of Aveed®. See Note 11. License and Collaboration Agreements for further information. Pursuant to the Company’s Voltaren® Gel Agreement with Novartis, we renewed the agreement for an additional one-year period during 2014, and as a result, we capitalized an intangible asset valued at $37.5 million. See Note 11. License and Collaboration Agreements for further information. During the third quarter of 2014, certain IPR&D assets totaling $10.0 million were put into service. During the third quarter of 2014, the Company divested its Canadian rights to Oralair, an intangible asset acquired during the Paladin acquisition, for total proceeds of approximately $4.2 million.
	Amortization expense for the years ended December 31, 2014, 2013 and 2012 totaled $218.7 million, $124.1 million and $147.5 million, respectively. Estimated amortization of intangibles for the five years subsequent to December 31, 2014 is as follows (in thousands):
	2015	$	253,391
	2016	$	203,218
	2017	$	194,225
	2018	$	193,959
	2019	$	178,670
Schedule of changes in gross carrying amount of other intangible assets	Changes in the gross carrying amount of our other intangibles for the year ended December 31, 2014 were as follows (in thousands):
		Gross
		Carrying
		Amount
	December 31, 2013	$	1,513,428
	Aveed® approval milestone	5,000
	Paladin acquisition	674,248
	Boca acquisition	140,900
	Sumavel acquisition	90,024
	Somar acquisition	169,300
	DAVA acquisition	514,900
	Natesto™ acquisition	56,000
	Intangible assets sold	(4,448		)
	Voltaren® Gel license extension	37,500
	Opana® ER license write-off	(23,500		)
	Other in-process research and development asset impairment	(5,900		)
	Effect of currency translation	(53,956		)
	December 31, 2014	$	3,113,496

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Schedule of Accrued Expenses	Accrued expenses are comprised of the following for each of the years ended December 31, (in thousands):
		2014		2013
	Chargebacks	$	217,402	$	118,014
	Returns and allowances	174,940		104,699
	Rebates	497,362		336,084
	Other sales deductions	25,380		12,897
	Other	234,461		146,999
	Total	$	1,149,545	$	718,693

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Instruments [Abstract]
Schedule of Long-term Debt Instruments	The following table presents the carrying amounts and estimated fair values of the Company’s total indebtedness at December 31, 2014 and December 31, 2013 (in thousands):
		December 31, 2014					December 31, 2013
		Carrying			Fair Value		Carrying			Fair Value
		Amount					Amount
	1.75% Convertible Senior Subordinated Notes due 2015	$	98,818				$	379,500
	Unamortized discount on 1.75% Convertible Senior Subordinated Notes due 2015	(1,759		)			(34,079		)
	1.75% Convertible Senior Subordinated Notes due 2015, net	$	97,059		$	98,317	$	345,421		$	372,481
	7.00% Senior Notes due 2019	499,875			522,813		500,000			536,563
	7.00% Senior Notes due 2020	$	400,000				$	400,000
	Unamortized initial purchaser’s discount	(2,338		)			(2,800		)
	7.00% Senior Notes due 2020, net	$	397,662		422,250		$	397,200		430,500
	7.25% Senior Notes due 2022	400,000			429,278		400,000			431,750
	5.75% Senior Notes due 2022	700,000			707,000		700,000			703,500
	5.375% Senior Notes due 2023	750,000			735,469		—			—
	Term Loan A Facility Due 2019	1,069,063			1,062,889		—			—
	Term Loan B Facility Due 2021	421,812			409,685		—			—
	Term Loan A Facility Due 2018	—			—		1,335,469			1,335,345
	Term Loan B Facility Due 2018	—			—		60,550			60,686
	Other debt	22,822			22,886		133			133
	Total long-term debt, net	$	4,358,293		$	4,410,587	$	3,738,773		$	3,870,958
	Less current portion, net	155,937			154,226		414,929			441,989
	Total long-term debt, less current portion, net	$	4,202,356		$	4,256,361	$	3,323,844		$	3,428,969
Debt Instrument [Line Items]
Schedule of Maturities of Long-term Debt	Maturities on long-term debt for each of the next 5 years as of December 31, 2014 are as follows (in thousands):
		December 31,
		2014
	2015	$	157,695
	2016	$	82,229
	2017	$	109,946
	2018	$	155,500
	2019	$	1,191,625
7.00% Senior Notes due 2019
Debt Instrument [Line Items]
Outstanding Principal Balance Of Non Recourse Notes Percentage	On or after July 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2019 Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From July 15, 2015 to and including July 14, 2016	103.5	%
	From July 15, 2016 to and including July 14, 2017	101.75	%
	From July 15, 2017 and thereafter	100	%
7.00% Senior Notes due 2020
Debt Instrument [Line Items]
Outstanding Principal Balance Of Non Recourse Notes Percentage	On or after December 15, 2015, the issuers may on any one or more occasions redeem all or a part of the 2020 Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on December 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From December 15, 2015 to and including December 14, 2016	103.5	%
	From December 15, 2016 to and including December 14, 2017	102.333	%
	From December 15, 2017 to and including December 14, 2018	101.167	%
	From December 15, 2018 and thereafter	100	%
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Outstanding Principal Balance Of Non Recourse Notes Percentage	On or after July 15, 2016, the issuers may on any one or more occasions redeem all or a part of the 2022 Notes—7.25% at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From July 15, 2016 to and including July 14, 2017	103.625	%
	From July 15, 2017 to and including July 14, 2018	102.417	%
	From July 15, 2018 to and including July 14, 2019	101.208	%
	From July 15, 2019 and thereafter	100	%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Outstanding Principal Balance Of Non Recourse Notes Percentage	On or after January 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2022 Notes—5.75%, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on January 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From January 15, 2017 to and including January 14, 2018	104.313	%
	From January 15, 2018 to and including January 14, 2019	102.875	%
	From January 15, 2019 to and including January 14, 2020	101.438	%
	From January 15, 2020 and thereafter	100	%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Outstanding Principal Balance Of Non Recourse Notes Percentage	On or after July 15, 2017, the Endo Finance Issuers may on any one or more occasions redeem all or a part of the 2023 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From July 15, 2017 to and including July 14, 2018	104.031	%
	From July 15, 2018 to and including July 14, 2019	102.688	%
	From July 15, 2019 to and including July 14, 2020	101.344	%
	From July 15, 2020 and thereafter	100	%

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Changes in Qualified Settlement Funds accounts and product liability balance	The following table presents the changes in the vaginal mesh Qualified Settlement Funds and product liability balance during the year ended December 31, 2014 (in thousands):
		Qualified Settlement Funds			Product Liability
	Balance as of December 31, 2013	$	11,518		$	520,000
	Additional charges	—			1,273,358
	Cash distributions to Qualified Settlement Funds	585,165			—
	Cash distributions to settle disputes from Qualified Settlement Funds	(111,454		)	(111,454		)
	Cash distributions to settle disputes	—			(26,709		)
	Balance as of December 31, 2014	$	485,229		$	1,655,195
Schedule of Net Impact of Settlement Agreement	During the year ended December 31, 2013, the net impact of the Watson Settlement Agreement recorded in Other income, net consisted of the amounts shown below (in thousands):
		Year Ended December 31, 2013
	Litigation settlement liability relieved during the year	$	85,123
	Cost of product shipped to Watson’s wholesaler affiliate	(11,093		)
	Estimated gross-to-net liabilities on product shipped to Watson’s wholesaler affiliate	(29,162		)
	Rebate on product shipped to Watson’s wholesaler affiliate	5,532
	Net gain included in Other income, net	$	50,400
Schedule of Future Minimum Rental Payments for Operating Leases	A summary of minimum future rental payments required under capital and operating leases as of December 31, 2014 are as follows (in thousands):
		Capital Leases(1)			Operating Leases
	2015	$	6,526		$	15,292
	2016	6,640			9,320
	2017	6,875			6,677
	2018	7,072			4,310
	2019	7,270			1,697
	Thereafter	39,025			2,918
	Total minimum lease payments	$	73,408		$	40,214
	Less: Amount representing interest	8,041
	Total present value of minimum payments	$	65,367
	Less: Current portion of such obligations	6,526
	Long-term capital lease obligations	$	58,841
	__________
	-1	The direct financing arrangement is included under Capital Leases. Minimum payments have not been reduced by minimum sublease rentals of $23.0 million due in the future under a noncancelable sublease.

Other_Comprehensive_Loss_Incom1

Other Comprehensive (Loss) Income (Tables)	12 Months Ended
	Dec. 31, 2014
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of tax effects allocated to each component of other comprehensive income	The following table presents the tax effects allocated to each component of Other comprehensive (loss) income for the years ended December 31, (in thousands):
		2014									2013									2012
		Before-			Tax Benefit (Expense)			Net-of-Tax			Before-Tax			Tax (Expense) Benefit			Net-of-			Before-Tax			Tax (Expense) Benefit			Net-of-
		Tax						Amount			Amount						Tax			Amount						Tax
		Amount															Amount									Amount
	Net unrealized (loss) gain on securities:
	Unrealized (loss) gain arising during the period	$	(1,646	)	$	547		$	(1,099	)	$	1,233		$	(458	)	$	775		$	1,441		$	(38	)	$	1,403
	Less: reclassification adjustments for loss realized in net loss	17			—			17			—			—			—			—			—			—
	Net unrealized (losses) gains	(1,629		)	547			(1,082		)	1,233			(458		)	775			1,441			(38		)	1,403
	Foreign currency translation (loss) gain	(121,417		)	28			(121,389		)	682			32			714			2,104			60			2,164
	Fair value adjustment on derivatives designated as cash flow hedges:
	Fair value adjustment on derivatives designated as cash flow hedges arising during the period	—			—			—			853			(307		)	546			(1,892		)	680			(1,212		)
	Less: reclassification adjustments for cash flow hedges settled and included in net loss	—			—			—			(232		)	84			(148		)	436			(157		)	279
	Net unrealized fair value adjustment on derivatives designated as cash flow hedges	—			—			—			621			(223		)	398			(1,456		)	523			(933		)
	Other comprehensive (loss) income	$	(123,046	)	$	575		$	(122,471	)	$	2,536		$	(649	)	$	1,887		$	2,089		$	545		$	2,634
Schedule of accumulated other comprehensive income (loss)	The following is a summary of the accumulated balances related to each component of Other comprehensive (loss) income, net of taxes, at December 31, 2014 and December 31, 2013 (in thousands):
		December 31,			December 31,
		2014			2013
	Net unrealized (losses) gains	$	(484	)	$	598
	Foreign currency translation loss	(123,604		)	(5,193		)
	Fair value adjustment on derivatives designated as cash flow hedges	—			(320		)
	Accumulated other comprehensive loss	$	(124,088	)	$	(4,915	)

Sharedbased_Compensation_Table

Shared-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of allocation of stock-based compensation	Presented below is the allocation of share-based compensation expense, as recorded in our Consolidated Statements of Operations for the years ended December 31 (in thousands).
		2014			2013				2012
	Selling, general and administrative expenses	$	21,690		$	24,982			$	35,482
	Research and development expenses	3,670			4,740				5,321
	Cost of revenues	1,479			—				—
	Discontinued operations (NOTE 3)	5,832			9,276				18,592
	Total share-based compensation expense	$	32,671		$	38,998			$	59,395
Summary of activity under stock incentive plans	A summary of the activity under our 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans for each of the three years-ended December 31, 2014 is presented below:
		Number of		Weighted				Weighted		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
	Outstanding as of January 1, 2012	8,115,467		$	25.79
	Granted	2,237,081		$	34.58
	Exercised	(853,794	)	$	22.66
	Forfeited	(613,613	)	$	31.31
	Expired	(60,436	)	$	27.61
	Outstanding as of December 31, 2012	8,824,705		$	27.93
	Granted	593,709		$	30.81
	Exercised	(3,836,560	)	$	25.32
	Forfeited	(1,291,043	)	$	32.73
	Expired	(45,022	)	$	30.06
	Outstanding as of December 31, 2013	4,245,789		$	29.3
	Granted	736,948		$	75.13
	Exercised	(1,528,295	)	$	27.09
	Forfeited	(371,410	)	$	39.76
	Expired	(19,680	)	$	24.56
	Outstanding as of December 31, 2014	3,063,352		$	40.15			5.32		$	103,208,779
	Vested and expected to vest as of December 31, 2014	2,929,508		$	39.23			5.25		$	101,160,091
	Exercisable as of December 31, 2014	1,477,631		$	28.3			4.56		$	65,901,298
Stock option assumption	The weighted average grant date fair value of the stock options granted in the years ended December 31, 2014, 2013 and 2012 was $20.28, $9.37 and $10.50 per option, respectively, determined using the following assumptions:
		2014		2013			2012
	Average expected term (years)	4		5			5
	Risk-free interest rate	1.3	%	0.8	%		0.9	%
	Dividend yield	—		—			—
	Expected volatility	32	%	33	%		33	%
Summary of restricted and performance stock units activity	A summary of our restricted and performance stock units for the three years ended December 31, 2014 is presented below:
		Number		Aggregate
		of Shares		Intrinsic
				Value
	Outstanding as of January 1, 2012	2,629,782
	Granted	1,087,171
	Forfeited	(362,682	)
	Vested	(930,659	)
	Outstanding as of December 31, 2012	2,423,612
	Granted	1,543,221
	Forfeited	(899,954	)
	Vested	(804,451	)
	Outstanding as of December 31, 2013	2,262,428
	Granted	609,357
	Forfeited	(374,463	)
	Vested	(842,569	)
	Outstanding as of December 31, 2014	1,654,753		$	120,623,231
	Vested and expected to vest as of December 31, 2014	1,444,957		$	99,516,485

Other_Income_Net_Tables

Other Income, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Component of Operating Income [Abstract]
Schedule Of Components Of Other Income, Net	The components of Other income, net for the years ended December 31 are as follows (in thousands):
		2014			2013			2012
	Watson litigation settlement income, net	$	—		$	(50,400	)	$	—
	Net gain on sale of certain early-stage drug discovery and development assets	(5,200		)	—			—
	Foreign currency (gain) loss, net	(10,054		)	(21		)	—
	Equity earnings from unconsolidated subsidiaries, net	(8,325		)	(1,482		)	(386		)
	Other miscellaneous	(8,745		)	(1,156		)	(235		)
	Other income, net	$	(32,324	)	$	(53,059	)	$	(621	)

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components Of Income Before Income Tax By Geography	The components of our (loss) income from continuing operations before income tax by geography the years ended December 31 were as follows (in thousands):
		2014			2013			2012
	Domestic	$	(33,459	)	$	385,366		$	(12,049	)
	International	133,334			—			—
	Total (loss) income from continuing operations before income tax	$	99,875		$	385,366		$	(12,049	)
Schedule of Income Tax	Income tax from continuing operations consists of the following for the years ended December 31 (in thousands):
		2014			2013			2012
	Current:
	Federal	$	30,385		$	93,212		$	102,695
	Foreign	(2,550		)	—			—
	State	16,270			10,980			14,098
	Total current income tax	44,105			104,192			116,793
	Deferred:
	Federal	(31,922		)	36,369			(79,313		)
	Foreign	(620		)	—			—
	State	(7,740		)	(1,336		)	(4,474		)
	Total deferred income tax	(40,282		)	35,033			(83,787		)
	Excess tax benefits of stock options exercised	33,501			4,315			2,530
	Valuation allowance	943			202			3,286
	Income tax	$	38,267		$	143,742		$	38,822
Schedule Of Reconciliation Of Income Tax At Federal Statutory Income Tax Rate To Total Income Tax Provision	A reconciliation of income tax from continuing operations at the federal statutory income tax rate to the income tax provision from continuing operations for the years ended December 31 (in thousands):
		2014			2013			2012
	Federal income tax at the statutory rate	$	34,956		$	134,878		$	(4,218	)
	State income tax, net of federal benefit	10,095			5,554			10,697
	Research and development credit	(2,535		)	(6,002		)	—
	Uncertain tax positions	2,494			2,779			13,741
	Tax effect of foreign operations	(52,246		)	—			—
	Change in valuation allowance	952			—			—
	Effect of permanent items:
	Branded prescription drug fee	16,336			12,060			6,108
	Domestic production activities deduction	5,468			(6,835		)	(2,859		)
	Transaction-related expenses	5,889			2,643			—
	Fines and penalties	—			17			11,176
	Excise tax	15,398			—			—
	Executive compensation limitation	3,590			417			1,286
	Extinguishment of convertible debt	(5,802		)	—			—
	Share based compensation	2,227			—			—
	Audit settlements	(1,875		)	—			—
	Other	3,320			(1,769		)	2,891
	Income tax	$	38,267		$	143,742		$	38,822
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that comprise the current and non-current deferred income tax amounts, excluding assets and liabilities held for sale, shown on the balance sheets for the years ended December 31 are as follows (in thousands):
		2014			2013
	Deferred tax assets:
	Accrued expenses	$	644,858		$	410,750
	Compensation related to stock options	15,415			20,685
	Net operating loss carryforward	108,823			71,544
	Loss on capital assets	10,642			9,112
	Research and development credit carryforward	13,085			13,905
	Uncertain tax positions	6,574			8,659
	Prepaid royalties	5,190			—
	Tax credit carryforwards	12,249			110
	Other	23,299			40,943
	Total gross deferred income tax assets	840,135			575,708
	Deferred tax liabilities:
	Depreciation and amortization	(894,714		)	(556,086		)
	Non-cash interest expense	(6,012		)	(5,427		)
	Other	(9,492		)	—
	Total gross deferred income tax liabilities	(910,218		)	(561,513		)
	Valuation allowance	(40,646		)	(17,854		)
	Net deferred income tax liability	$	(110,729	)	$	(3,659	)
Schedule Of Reconciliation Of Change In Uncertain Tax Benefits	A reconciliation of the change in the unrecognized tax benefits (UTB) balance from January 1, 2012 to December 31, 2014 is as follows (in thousands):
		Unrecognized Tax Benefit Federal, State, and Foreign Tax
	UTB Balance at January 1, 2012	$	40,628
	Gross additions for current year positions	24,088
	Gross additions for prior period positions	285
	Gross reductions for prior period positions	(632		)
	Decrease due to lapse of statute of limitations	(5,452		)
	UTB Balance at December 31, 2012	$	58,917
	Gross additions for current year positions	2,076
	Gross additions for prior period positions	4,618
	Gross reductions for prior period positions	(2,390		)
	Decrease due to lapse of statute of limitations	(4,592		)
	UTB Balance at December 31, 2013	$	58,629
	Gross additions for current year	6,008
	Gross additions for prior period positions	873
	Gross reductions for prior period positions	(6,647		)
	Decrease due to lapse of statute of limitations	(5,067		)
	Decrease due to settlements	(597		)
	Additions related to acquisitions	54,750
	Currency translation adjustment	(2,619		)
	UTB Balance at December 31, 2014	$	105,330
	Accrued interest and penalties	10,474
	Total UTB balance including accrued interest and penalties	$	115,804
	Current portion (included in accrued expenses)	$	—
	Non-current portion (included in other liabilities)	$	115,804

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net (Loss) Income Per Share	The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share as of December 31 (in thousands, except per share data):
		2014			2013			2012
	Numerator:
	Income (loss) from continuing operations	$	61,608		$	241,624		$	(50,871	)
	Less: Net (loss) income from continuing operations attributable to noncontrolling interests	(399		)	—			—
	Income (loss) from continuing operations attributable to Endo International plc ordinary shareholders	62,007			241,624			(50,871		)
	Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(783,326		)	(926,963		)	(689,466		)
	Net loss attributable to Endo International plc ordinary shareholders	$	(721,319	)	$	(685,339	)	$	(740,337	)
	Denominator:
	For basic per share data—weighted average shares	146,896			113,295			115,719
	Dilutive effect of ordinary share equivalents	2,600			2,453			—
	Dilutive effect of 1.75% Convertible Senior Subordinated Notes and warrants	7,234			4,081			—
	For diluted per share data—weighted average shares	156,730			119,829			115,719

Subsequent_Events_Tables

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Debt Instrument Redemption	On or after February 1, 2020, the Issuers may on any one or more occasions redeem all or a part of the 2025 Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest and additional interest, if any, if redeemed during the twelve-month period beginning on February 1 of the years indicated below:
	Payment Dates (between indicated dates)	Redemption
		Percentage
	From February 1, 2020 to and including January 31, 2021	103	%
	From February 1, 2021 to and including January 31, 2022	102	%
	From February 1, 2022 to and including January 31, 2023	101	%
	From February 1, 2023 and thereafter	100	%

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Information
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		(in thousands, except share and per share data)
	2014 (1)(2)
	Total revenues	$	470,842		$	592,848		$	654,116		$	662,877
	Gross profit	$	258,163		$	289,403		$	312,923		$	288,697
	(Loss) income from continuing operations	$	(47,401	)	$	40,575		$	48,953		$	19,481
	Discontinued operations, net of tax	$	(385,877	)	$	(20,189	)	$	(301,002	)	$	(72,724	)
	Net (loss) income attributable to Endo International plc	$	(436,912	)	$	21,160		$	(252,084	)	$	(53,483	)
	Net (loss) income per share attributable to Endo International plc ordinary shareholders—Basic:
	Continuing operations	$	(0.37	)	$	0.27		$	0.32		$	0.13
	Discontinued operations	(3.04		)	(0.13		)	(1.96		)	(0.48		)
	Basic	$	(3.41	)	$	0.14		$	(1.64	)	$	(0.35	)
	Net (loss) income per share attributable to Endo International plc ordinary shareholders—Diluted:
	Continuing operations	$	(0.37	)	$	0.25		$	0.31		$	0.12
	Discontinued operations	(3.04		)	(0.12		)	(1.90		)	(0.46		)
	Diluted	$	(3.41	)	$	0.13		$	(1.59	)	$	(0.34	)
	Weighted average shares—Basic	128,135			152,368			153,309			153,772
	Weighted average shares—Diluted	128,135			163,369			158,975			159,213
	2013 (3)
	Total revenues	$	535,842		$	586,177		$	550,075		$	452,587
	Gross profit	$	318,497		$	351,547		$	328,174		$	239,860
	Income from continuing operations	$	58,660		$	80,688		$	91,680		$	10,596
	Discontinued operations, net of tax	$	(32,057	)	$	(32,577	)	$	(37,065	)	$	(772,339	)
	Net income (loss) attributable to Endo International plc	$	15,349		$	34,999		$	40,223		$	(775,910	)
	Net income (loss) per share attributable to Endo International plc ordinary shareholders—Basic:
	Continuing operations	$	0.53		$	0.72		$	0.8		$	0.09
	Discontinued operations	(0.39		)	(0.41		)	(0.45		)	(6.83		)
	Basic	$	0.14		$	0.31		$	0.35		$	(6.74	)
	Net income (loss) per share attributable to Endo International plc ordinary shareholders—Diluted:
	Continuing operations	$	0.52		$	0.69		$	0.76		$	0.08
	Discontinued operations	(0.38		)	(0.39		)	(0.43		)	(6.11		)
	Diluted	$	0.14		$	0.3		$	0.33		$	(6.03	)
	Weighted average shares—Basic	111,216			112,531			114,327			115,105
	Weighted average shares—Diluted	113,189			117,221			120,261			128,644
	__________
	-1	(Loss) income from continuing operations for the year ended December 31, 2014 was impacted by (1) milestone payments to collaborative partners of $11.2 million, $10.4 million, $13.4 million and $16.8 million in the first, second, third and fourth quarters, respectively (2) acquisition-related and integration items of $45.3 million, $19.6 million, $2.7 million and $9.8 million during the first, second, third and fourth quarters, respectively (3) asset impairment charges of $22.5 million during the fourth quarter (4) inventory step-up charges of $3.6 million, $19.1 million, $17.4 million and $25.5 million during the first, second, third and fourth quarters, respectively (5) amortization expense relating to intangible assets of $39.7 million, $52.8 million, $55.4 million and $70.9 million during the first, second, third and fourth quarters, respectively (6) adjustments to accruals for certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $(1.9) million, $11.4 million, $7.5 million and $8.7 million during the first, second, third and fourth quarters, respectively (7) other charges related to litigation-related and other contingent matters totaling $4.0 million, $3.1 million and $35.0 million during the second, third and fourth quarters, respectively (8) a charge for an additional year of the branded prescription drug fee in accordance with U.S. Internal Revenue Service (IRS) regulations issued in the third quarter of 2014 of $25.0 million and (9) amounts related to expense for the reimbursement of directors’ and certain employees’ excise tax liabilities pursuant to Section 4985 of the Internal Revenue Code of $60.0 million, $(4.7) million and $(1.0) million during the first, second and third quarters, respectively.
	-2	In the fourth quarter of 2014, the Company recorded certain measurement period adjustments reflecting changes in the preliminary estimated fair values of certain assets and liabilities acquired in connection with the Company’s various 2014 business combinations, including adjustments to intangible assets and inventory, among others. The Company considered the impact of these adjustments on the comparative financial information presented, which related primarily to intangible asset amortization expense and inventory step-up costs, and determined that the retrospective impact was not material to the Company’s Consolidated Financial Statements for any of the periods presented. Accordingly, in the fourth quarter of 2014, the Company recorded combined pre-tax charges for intangible asset amortization and inventory step-up of approximately $9.2 million, which included the cumulative effect of these measurement period adjustments, a portion of which related to each of the first, second and third quarters of 2014. This amount was recorded to Cost of revenues.
	-3	Income from continuing operations for the year ended December 31, 2013 was impacted by (1) milestone payments to collaborative partners of $2.6 million, $5.4 million, $3.1 million and $18.6 million in the first, second, third and fourth quarters, respectively (2) acquisition-related and integration items of $0.5 million, $1.6 million, $1.5 million and $4.1 million during the first, second, third and fourth quarters, respectively (3) asset impairment charges of $1.1 million, $2.8 million, $0.8 million and $27.3 million during the first, second, third and fourth quarters, respectively (4) amortization expense relating to intangible assets of $32.0 million, $35.6 million, $29.5 million and $26.5 million during the first, second, third and fourth quarters, respectively (5) certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $13.7 million, $41.6 million, $20.8 million and $15.3 million during the first, second, third and fourth quarters, respectively and (6) other litigation-related items and other contingent matters totaling $(18.8) million, $(16.5) million, $(14.6) million and $9.0 million during the first, second, third and fourth quarters, respectively

Description_of_Business_Detail

Description of Business (Details) (USD $)	Dec. 31, 2014	Feb. 11, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common stock, shares authorized	350,000,000		350,000,000
Common stock, par value (in dollars per share)	$0.01		$0.01
Ordinary shares, shares authorized	1,000,000,000
Ordinary shares, par value (in dollars per share)	$0.00
Euro deferred shares, shares issued	4,000,000	4,000,000
Euro deferred shares, par value (in dollars per share)	$0.01	$0.01

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Schedule of Concentration Risk, By Risk Factor, Customer) (Details) (Customer Concentration Risk)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cardinal Health, Inc.
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	21.00%	26.00%	30.00%
McKesson Corporation
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	31.00%	32.00%	32.00%
AmerisourceBergen Corporation
Concentration Risk [Line Items]
Percentage of trade accounts receivable from major customers	16.00%	19.00%	15.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of Concentration Risk, By Risk Factor, Product) (Details) (Sales Revenue, Goods, Net [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Lidoderm®
Concentration Risk [Line Items]
Percentage of revenue from products accounted for more than 10% of total revenue	7.00%	28.00%	41.00%
Opana® ER
Concentration Risk [Line Items]
Percentage of revenue from products accounted for more than 10% of total revenue	8.00%	11.00%	13.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 19, 2013
	Reportable_Business_Segments	customer
	customer
Summary Of Significant Accounting Policies [Line Items]
Restricted cash and cash equivalents	$530,930,000	$770,000,000
Restricted cash transferred from unrestricted cash		70,000,000
Number of customers	3	3
Advertising costs	28,100,000	31,600,000	36,000,000
Number of reportable segments	3
Minimum | License Rights
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Minimum | Tradenames
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Minimum | Developed technology
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum | License Rights
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum | Tradenames
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum | Developed technology
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Weighted Average
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Weighted Average | License Rights
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years
Weighted Average | Tradenames
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Weighted Average | Developed technology
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	13 years
Buildings | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	8 years
Buildings | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	45 years
Machinery and equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	2 years
Machinery and equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	20 years
Leasehold improvements | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	2 years
Leasehold improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	9 years
Computer equipment and software | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	2 years
Computer equipment and software | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	10 years
Furniture and fixtures | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	2 years
Furniture and fixtures | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	10 years
Trade Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Percentage of trade accounts receivable from major customers	76.00%	78.00%
5.75% Senior Notes due 2022
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of notes		700,000,000
Debt Instrument, Interest Rate, Stated Percentage	5.75%			5.75%
1.75% Convertible Senior Subordinated Notes due 2015
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.75%
Vaginal mesh cases
Summary Of Significant Accounting Policies [Line Items]
Settlement Funds	485,229,000	11,518,000
Paladin Labs Inc. | Litha Healthcare Group Limited
Summary Of Significant Accounting Policies [Line Items]
Escrow deposit	$40,200,000

Discontinued_Operations_Narrat

Discontinued Operations (Narrative) (Details) (USD $)	3 Months Ended					12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 24, 2015	Dec. 28, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges	$22,500,000	$27,300,000	$800,000	$2,800,000	$1,100,000	$22,542,000	$32,011,000	$72,551,000
Noncontrolling interests	33,456,000	59,198,000				33,456,000	59,198,000
Healthtronics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges		118,900,000
Upfront cash payment subject to cash and other working capital adjustments										85,000,000
Future cash payments based on operating performance	4,700,000					4,700,000
Approved plan consideration amount	119,700,000					119,700,000
Goodwill impairment charges			38,000,000
Pre-tax gain (loss)						3,600,000
Noncontrolling interests		59,200,000					59,200,000
Healthtronics | Subsidiaries
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Future cash payments based on operating performance	30,000,000					30,000,000
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges							481,000,000	507,500,000
Anatomical Pathology Services and HITS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges								49,900,000
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges							12,000,000	128,500,000
AMS | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Expected Sale Price									1,650,000,000
Expected Proceeds from Divestiture of Businesses									1,600,000,000
AMS | Subsequent Event | Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Expected Milestone Payment									50,000,000
Series B Preferred Stock [Member] | AMS | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Expected proceeds from issuance of preferred stock and preference stock									$60,000,000
Expected stock to be issued (in shares)									60,000
Preferred stock, dividend rate, annual increase									0.25%
Series B Preferred Stock [Member] | AMS | Subsequent Event | Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Preferred stock, dividend rate									11.50%
Series B Preferred Stock [Member] | AMS | Subsequent Event | Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Preferred stock, dividend rate									7.25%

Discontinued_Operations_Operat

Discontinued Operations (Operating Results of Discontinued Operations) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation-related and other contingencies, net	$42,084	$9,450	$224,425
Discontinued operations, net of tax	-779,792	-874,038	-637,150
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	496,505	492,226	504,487
Litigation-related and other contingencies, net	1,273,358	474,792	92,000
Income (loss) from discontinued operations before income taxes	-1,225,576	-944,933	-718,374
Income taxes	-440,107	-167,809	-75,237
Discontinued operations, net of tax	-785,469	-777,124	-643,137
Healthtronics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	14,443	207,194	211,627
Income (loss) from discontinued operations before income taxes	6,434	-119,690	-11,160
Income taxes	757	-22,776	-17,147
Discontinued operations, net of tax	$5,677	($96,914)	$5,987

Discontinued_Operations_Assets

Discontinued Operations (Assets Held for Sale and Related Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liabilities of Disposal Group, Including Discontinued Operation
Liabilities held for sale	$103,338	$149,253
AMS
Assets of Disposal Group, Including Discontinued Operation
Current assets	165,075	168,760
Property, plant and equipment	41,122	45,203
Goodwill	862,960	806,838
Other intangibles, net	861,174	925,460
Other assets	7,533	6,616
Assets held for sale	1,937,864	1,952,877
Liabilities of Disposal Group, Including Discontinued Operation
Current liabilities	53,143	62,110
Deferred income taxes	46,538	51,671
Other liabilities	3,657	3,901
Liabilities held for sale	103,338	117,682
Healthtronics
Assets of Disposal Group, Including Discontinued Operation
Current assets		69,131
Property, plant and equipment		23,461
Goodwill		58,761
Other assets		8,904
Assets held for sale		160,257
Liabilities of Disposal Group, Including Discontinued Operation
Current liabilities		27,656
Long term debt, less current portion, net		3,354
Other liabilities		561
Liabilities held for sale		$31,571

Discontinued_Operations_Cash_F

Discontinued Operations (Cash Flow Activities) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchases of property, plant and equipment	($80,425)	($96,483)	($99,818)
AMS
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss	-785,469	-777,124	-643,137
Depreciation and amortization	70,275	72,003	84,089
Purchases of property, plant and equipment	($4,423)	($3,517)	($5,271)

Restructuring_Narrative_Detail

Restructuring (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	Jun. 04, 2013
June 2013 Restructuring
Restructuring Cost and Reserve [Line Items]
Expected positions eliminated (percent)					15.00%
Restructuring expenses	$2,104	$56,250
Restructuring reserve	1,438	12,298	0
June 2013 Restructuring | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,224	41,435
Restructuring reserve	1,283	7,379	0
June 2013 Restructuring | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	880	11,966
Restructuring reserve	155	4,919	0
June 2013 Restructuring | Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		2,849
Other Restructuring Initiatives
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	15,600	16,100
Other Restructuring Initiatives | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	21,200	10,300	43,600
Other Restructuring Initiatives | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				$7,800

Restructuring_Summary_of_Restr

Restructuring (Summary of Restructuring Actions) (Details) (June 2013 Restructuring, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$2,104	$56,250
Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,224	41,435
Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		2,849
Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	880	11,966
U.S. Branded Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		34,476
U.S. Branded Pharmaceuticals | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		22,847
U.S. Branded Pharmaceuticals | Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		2,849
U.S. Branded Pharmaceuticals | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		8,780
U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		1,404
U.S. Generic Pharmaceuticals | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		262
U.S. Generic Pharmaceuticals | Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0
U.S. Generic Pharmaceuticals | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		1,142
Discontinued operations
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		11,949
Discontinued operations | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		9,905
Discontinued operations | Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0
Discontinued operations | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		2,044
Corporate unallocated
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		8,421
Corporate unallocated | Employee Severance and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		8,421
Corporate unallocated | Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0
Corporate unallocated | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		$0

Restructuring_Changes_to_Restr

Restructuring (Changes to Restructuring Accrual) (Details) (June 2013 Restructuring, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Restructuring Reserve [Roll Forward]
Beginning balance	$12,298	$0
Expenses		53,401
Expenses	2,104	56,250
Cash distributions	-11,773	-40,132
Other non-cash adjustments	-1,191	-971
Ending balance	1,438	12,298
Employee Severance and Other Benefit-Related Costs
Restructuring Reserve [Roll Forward]
Beginning balance	7,379	0
Expenses		41,435
Expenses	1,224	41,435
Cash distributions	-7,320	-34,056
Other non-cash adjustments	0	0
Ending balance	1,283	7,379
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning balance	4,919	0
Expenses		11,966
Expenses	880	11,966
Cash distributions	-4,453	-6,076
Other non-cash adjustments	-1,191	-971
Ending balance	$155	$4,919

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Feb. 03, 2014

Feb. 03, 2014

Feb. 03, 2014

Feb. 03, 2014

Feb. 03, 2014

19-May-14

Dec. 31, 2014

19-May-14

Jun. 30, 2014

Jun. 30, 2014

19-May-14

Jul. 24, 2014

Jul. 24, 2014

Aug. 06, 2014

Dec. 31, 2014

Aug. 06, 2014

Aug. 06, 2014

Aug. 06, 2014

Aug. 06, 2014

Aug. 06, 2014

Dec. 09, 2014

Dec. 31, 2014

Dec. 09, 2014

Dec. 09, 2014

Dec. 09, 2014

Dec. 09, 2014

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Developed technology

Endo Health Solutions Inc.

Paladin Labs Inc.

Paladin Labs Inc.

Paladin Labs Inc.

Paladin Labs Inc.

Paladin Labs Inc.

Paladin Labs Inc.

Boca Pharmacal, LLC

Boca Pharmacal, LLC

Boca Pharmacal, LLC

Boca Pharmacal, LLC

Boca Pharmacal, LLC

Sumavel DosePro

Sumavel DosePro

Sumavel DosePro

Sumavel DosePro

Sumavel DosePro

Sumavel DosePro

Grupo Farmacéutico Somar

Grupo Farmacéutico Somar

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

DAVA Pharmaceuticals, Inc

Natesto

Natesto

Natesto

Natesto

Natesto

Natesto

USD ($)

USD ($)

CAD

USD ($)

USD ($)

Minimum

Maximum

USD ($)

USD ($)

Developed technology

Developed technology

In process research & development

USD ($)

USD ($)

USD ($)

Minimum

Maximum

Zogenix, Inc

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Developed technology

Developed technology

In process research & development

Maximum

USD ($)

USD ($)

USD ($)

Developed technology

Developed technology

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Business Acquisition [Line Items]

Number of New Endo shares Issued per share of Paladin Labs (shares)

1.6331

1.6331

Number of New Endo shares issued of Paladin Labs (shares)

35,500,000

35,500,000

Cash payment issued per share of acquired entity (cd per share)

$1.09

1.16

Aggregate consideration transferred

$2,866,926,000

$595,300,000

$61,000,000

Number of New Endo shares issued per share of Endo (shares)

1

Equity interest in combined entity (percent)

79.00%

21.00%

21.00%

Proceeds from sale of intangible assets

4,200,000

Discount rate range (percent)

9.50%

15.50%

Transaction costs

27,500,000

Increase (decrease) to interest expense

-4,100,000

8,200,000

Amortization of intangible assets

70,900,000

55,400,000

52,800,000

39,700,000

26,500,000

29,500,000

35,600,000

32,000,000

218,712,000

123,547,000

146,898,000

148,360,000

2,800,000

14,600,000

Accrued excise taxes

54,300,000

54,300,000

Payments to acquire business

236,600,000

89,700,000

270,100,000

590,200,000

25,000,000

Net identifiable assets acquired

791,704,000

212,300,000

93,800,000

184,400,000

381,219,000

61,000,000

Goodwill

2,899,587,000

565,994,000

2,899,587,000

565,994,000

2,114,022,000

24,300,000

85,700,000

214,109,000

Identifiable intangible assets

140,900,000

112,300,000

28,600,000

90,000,000

149,300,000

Estimated useful life

11 years

13 years

12 years

12 years

10 years

Estimated fair value

93,800,000

Contingent consideration

4,700,000

4,100,000

0

20,000,000

5,100,000

5,100,000

25,000,000

31,000,000

31,000,000

165,000,000

Loan for working capital needs

7,000,000

Revenue reported by acquired entity for last annual period

100,000,000

Intangible assets

674,248,000

169,300,000

514,900,000

455,300,000

59,600,000

56,000,000

Indefinite intangible assets

20,000,000

Prepaid inventory

$5,000,000

Acquisitions_Schedule_of_Acqui

Acquisitions (Schedule of Acquisition Consideration) (Details)	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2014
In Thousands, except Share data, unless otherwise specified	CAD	Paladin Labs Inc.	Paladin Labs Inc.
		USD ($)	CAD
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Number of Paladin shares paid in cash		20,765,000	20,765,000
Exchange ratio (in shares)		1.6331	1.6331
Number of ordinary shares of Endo International—as exchanged		33,912,000	33,912,000
Endo common stock price (in dollars per share)		$80
Fair value of ordinary shares of Endo International issued to Paladin Shareholders		$2,712,956
Per share cash consideration for Paladin shares (usd per share)		$1.09	1.16
Cash distribution to Paladin shareholders		22,647
Fair value of the vested portion of Paladin stock options outstanding		131,323
Total acquisition consideration		$2,866,926
Exchange rate (cad per usd)	0.9402
Number of vested Paladin stock options outstanding		1,300,000	1,300,000

Acquisitions_Schedule_Of_Fair_

Acquisitions (Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2014	Aug. 06, 2014
In Thousands, unless otherwise specified
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Goodwill	$2,899,587	$565,994
Paladin Labs Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents			113,571
Marketable securities			89,420
Accounts receivable			97,094
Inventories			63,593
Prepaid expenses and other current assets			32,614
Deferred income tax assets, current			13,142
Property, plant and equipment			7,303
Intangible assets			674,248
Other assets			57,544
Total identifiable assets			1,148,529
Accounts payable and accrued expenses			131,420
Income taxes payable			23,458
Deferred income taxes			137,653
Debt			23,826
Other liabilities			40,468
Total liabilities assumed			356,825
Net identifiable assets acquired			791,704
Noncontrolling interests			-38,800
Goodwill			2,114,022
Net assets acquired			2,866,926
DAVA Pharmaceuticals, Inc
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents				533
Accounts receivable				18,088
Inventories				73,226
Prepaid expenses and other current assets				2,672
Property, plant and equipment				2,659
Intangible assets				514,900
Other assets				21,029
Total identifiable assets				633,107
Accounts payable and accrued expenses				24,477
Deferred income taxes				206,272
Other liabilities				21,139
Total liabilities assumed				251,888
Net identifiable assets acquired				381,219
Goodwill				214,109
Net assets acquired				595,328
As initially reported | Paladin Labs Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents			113,571
Marketable securities			89,420
Accounts receivable			93,832
Inventories			62,095
Prepaid expenses and other current assets			32,605
Deferred income tax assets, current			11,719
Property, plant and equipment			7,299
Intangible assets			676,000
Other assets			56,289
Total identifiable assets			1,142,830
Accounts payable and accrued expenses			124,321
Income taxes payable			22,524
Deferred income taxes			160,620
Debt			23,826
Other liabilities			9,578
Total liabilities assumed			340,869
Net identifiable assets acquired			801,961
Noncontrolling interests			-69,600
Goodwill			2,134,565
Net assets acquired			2,866,926
As initially reported | DAVA Pharmaceuticals, Inc
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents				533
Accounts receivable				15,842
Inventories				120,626
Prepaid expenses and other current assets				2,672
Property, plant and equipment				2,659
Intangible assets				439,623
Other assets				21,029
Total identifiable assets				602,984
Accounts payable and accrued expenses				17,585
Deferred income taxes				195,915
Other liabilities				21,139
Total liabilities assumed				234,639
Net identifiable assets acquired				368,345
Goodwill				226,683
Net assets acquired				595,028
Measurement period adjustments | Paladin Labs Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents			0
Marketable securities			0
Accounts receivable			3,262
Inventories			1,498
Prepaid expenses and other current assets			9
Deferred income tax assets, current			1,423
Property, plant and equipment			4
Intangible assets			-1,752
Other assets			1,255
Total identifiable assets			5,699
Accounts payable and accrued expenses			7,099
Income taxes payable			934
Deferred income taxes			-22,967
Debt			0
Other liabilities			30,890
Total liabilities assumed			15,956
Net identifiable assets acquired			-10,257
Noncontrolling interests			30,800
Goodwill			-20,543
Net assets acquired			0
Measurement period adjustments | DAVA Pharmaceuticals, Inc
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents				0
Accounts receivable				2,246
Inventories				-47,400
Prepaid expenses and other current assets				0
Property, plant and equipment				0
Intangible assets				75,277
Other assets				0
Total identifiable assets				30,123
Accounts payable and accrued expenses				6,892
Deferred income taxes				10,357
Other liabilities				0
Total liabilities assumed				17,249
Net identifiable assets acquired				12,874
Goodwill				-12,574
Net assets acquired				$300

Acquisitions_Schedule_Of_Valua

Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	$1,471,672
Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	674,248
Paladin Labs Inc. | In process research & development
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	65,500
Paladin Labs Inc. | Total other intangible assets
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	674,200
Paladin Labs Inc. | Serelaxin | In process research & development
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	55,000
Paladin Labs Inc. | Other | In process research & development
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	10,500
Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	1,470,172
Developed Technology | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	608,700
Developed Technology | Canada Base Prescription | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	410,000
Amortization Period (in years)	12 years
Developed Technology | Canada OTC | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	50,000
Amortization Period (in years)	11 years
Developed Technology | Canada Other | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	74,200
Amortization Period (in years)	11 years
Developed Technology | Litha | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	70,000
Amortization Period (in years)	12 years
Developed Technology | Licenses not renewed | Paladin Labs Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation (in millions)	$4,500
Amortization Period (in years)	3 years

Acquisitions_Schedule_Of_Reven

Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Net loss attributable to Endo International plc ordinary shareholders	($53,483)	($252,084)	$21,160	($436,912)	($775,910)	$40,223	$34,999	$15,349	($721,319)	($685,339)	($740,337)
Basic net income per share (usd per share)	($0.35)	($1.64)	$0.14	($3.41)	($6.74)	$0.35	$0.31	$0.14	($4.91)	($6.05)	($6.40)
Diluted net income per share (usd per share)	($0.34)	($1.59)	$0.13	($3.41)	($6.03)	$0.33	$0.30	$0.14	($4.60)	($5.72)	($6.40)
Paladin Labs Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue									224,806
Net loss attributable to Endo International plc ordinary shareholders									$26,966
Basic net income per share (usd per share)									$0.18
Diluted net income per share (usd per share)									$0.17

Acquisitions_Schedule_Of_Pro_F

Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) (Paladin Labs Inc., USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Paladin Labs Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue	$2,423,683	$2,392,687
Net loss attributable to Endo International plc	($727,961)	($574,407)
Basic and diluted net (loss) income per share (in dollars per share)	($4.96)	($5.07)
Business Acquisition, Pro Forma Earnings Per Share, Diluted	($4.64)	($4.79)

Segment_Results_Schedule_Of_Re

Segment Results (Schedule Of Reportable Segments Information) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	segment
Segment Reporting [Abstract]
Number of reportable segments (segments)	3
Segment Reporting Information [Line Items]
Net revenues to external customers	2,380,683	$2,124,681	$2,311,249
Adjusted income (loss) from continuing operations before income tax	1,074,219	977,570	1,078,257
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues to external customers	2,380,683	2,124,681	2,311,249
U.S. Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Net revenues to external customers	969,437	1,394,015	1,677,984
Adjusted income (loss) from continuing operations before income tax	529,507	783,927	906,839
U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Net revenues to external customers	1,140,821	730,666	633,265
Adjusted income (loss) from continuing operations before income tax	464,029	193,643	171,418
International Pharmaceuticals
Segment Reporting Information [Line Items]
Net revenues to external customers	270,425	0	0
Adjusted income (loss) from continuing operations before income tax	80,683	$0	$0

Segment_Results_Schedule_Of_Re1

Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Total segment adjusted income from continuing operations before income tax:									$1,074,219,000	$977,570,000	$1,078,257,000
Corporate unallocated costs									-355,417,000	-315,743,000	-328,633,000
Upfront and milestone payments to partners									-51,774,000	-29,703,000	-60,778,000
Asset impairment charges	-22,500,000				-27,300,000	-800,000	-2,800,000	-1,100,000	-22,542,000	-32,011,000	-72,551,000
Acquisition-related and integration items	-9,800,000	-2,700,000	-19,600,000	-45,300,000	-4,100,000	-1,500,000	-1,600,000	-500,000	-77,384,000	-7,614,000	-18,432,000
Separation benefits and other cost reduction initiatives									-25,760,000	-91,530,000	-23,489,000
Excise tax									-54,300,000	0	0
Amortization of intangible assets	-70,900,000	-55,400,000	-52,800,000	-39,700,000	-26,500,000	-29,500,000	-35,600,000	-32,000,000	-218,712,000	-123,547,000	-146,898,000
Inventory step-up									-65,582,000	0	0
Non-cash interest expense related to the 1.75% Convertible Senior Subordinated Notes									-12,192,000	-22,742,000	-20,762,000
Loss on extinguishment of debt									-31,817,000	-11,312,000	-7,215,000
Watson litigation settlement income, net									0	50,400,000	0
Accrual for payment to Impax Laboratories Inc. related to sales of Opana® ER									0	0	-102,000,000
Patent litigation settlement items, net									0	0	-85,123,000
Certain litigation-related charges, net									-42,084,000	-9,450,000	-224,425,000
Charge related to the non-recoverability of certain non-trade receivables									-10,000,000	0	0
Net gain on sale of certain early-stage drug discovery and development assets									5,200,000	0	0
Foreign currency impact related to the remeasurement of intercompany debt instruments									13,153,000	0	0
Charge for an additional year of the branded prescription drug fee in accordance with IRS regulations issued in the third quarter of 2014									-24,972,000	0	0
Other, net									-161,000	1,048,000	0
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAX									99,875,000	385,366,000	-12,049,000
Severance costs	8,700,000	7,500,000	11,400,000	-1,900,000	15,300,000	20,800,000	41,600,000	13,700,000	14,400,000	35,200,000	20,000,000
Business Exit Costs										5,800,000
Chadds Ford, Pennsylvania Properties
Segment Reporting Information [Line Items]
Operating leases, future minimum payments due								$7,200,000

Segment_Results_Additional_Sel

Segment Results (Additional Selected Financial Information For Reportable Segments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Depreciation expense	$42,665	$41,536	$32,916
Amortization expense	218,712	124,147	147,498
U.S. Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	16,209	19,828	15,540
Amortization expense	78,890	80,223	105,974
U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	16,751	13,354	12,343
Amortization expense	95,042	43,924	41,524
International Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	1,856	0	0
Amortization expense	44,780	0	0
Corporate unallocated
Segment Reporting Information [Line Items]
Depreciation expense	$7,849	$8,354	$5,033

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

19-May-14

Aug. 06, 2014

Dec. 09, 2014

Jun. 30, 2014

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Net asset value required to be maintained by money market funds (Per Unit)

1

1

Restricted Cash Transferred From Unrestricted Cash

$70,000,000

$70,000,000

Asset impairment charges

22,500,000

27,300,000

800,000

2,800,000

1,100,000

22,542,000

32,011,000

72,551,000

Sumavel DosePro

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

4,700,000

4,700,000

4,100,000

DAVA Pharmaceuticals, Inc

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

5,100,000

5,100,000

5,100,000

Natesto

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

31,000,000

31,000,000

31,000,000

Minimum | Sumavel DosePro

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

0

Maximum | Sumavel DosePro

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

20,000,000

Maximum | DAVA Pharmaceuticals, Inc

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

25,000,000

Maximum | Natesto

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

165,000,000

Qualitest

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair value of contractual obligation

5,200,000

4,700,000

5,200,000

4,700,000

Qualitest | Prime Rate

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair Value Inputs, Discount Rate, Basis Spread On Variable Rate

3.00%

Qualitest | Minimum

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low

0

0

Qualitest | Maximum

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

7,500,000

7,500,000

5.75% Senior Notes due 2022

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Proceeds from issuance of notes

700,000,000

Restricted cash and cash equivalents

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Available-for-sale Securities, Amortized Cost Basis

124,368,000

770,000,000

124,368,000

770,000,000

Paladin Labs Inc.

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Equity Method Investments

31,400,000

31,400,000

Loans Receivable

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Loans receivable from joint venture

16,300,000

16,300,000

Fair value, measurements, nonrecurring

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Asset impairment charges

22,542,000

32,011,000

Fair value, measurements, nonrecurring | AMS and HealthTronics

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Asset impairment charges

$648,200,000

Fair_Value_Measurements_Financ

Fair Value Measurements (Financial Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:
Fair value of financial assets measured on recurring basis	$281,648	$846,369
Liabilities:
Fair value of financial liabilities measured on recurring basis	46,005	4,747
Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	4,282	3,878
Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	41,723	869
Money market funds
Assets:
Fair value of financial assets measured on recurring basis	279,327	843,390
Equity securities
Assets:
Fair value of financial assets measured on recurring basis	2,321	2,979
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Fair value of financial assets measured on recurring basis	281,648	846,369
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Assets:
Fair value of financial assets measured on recurring basis	279,327	843,390
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity securities
Assets:
Fair value of financial assets measured on recurring basis	2,321	2,979
Significant Other Observable Inputs (Level 2)
Assets:
Fair value of financial assets measured on recurring basis	0	0
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Equity securities
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3)
Assets:
Fair value of financial assets measured on recurring basis	0	0
Liabilities:
Fair value of financial liabilities measured on recurring basis	46,005	4,747
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	4,282	3,878
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	41,723	869
Significant Unobservable Inputs (Level 3) | Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Equity securities
Assets:
Fair value of financial assets measured on recurring basis	$0	$0

Fair_Value_Measurements_Financ1

Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) (Acquisition-related contingent consideration, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Acquisition-related contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$4,747	$8,924
Amounts acquired	40,224	0
Amounts settled	0	-5,000
Transfers (in) and/or out of Level 3	0	0
Changes in fair value recorded in earnings	1,034	823
Ending Balance	$46,005	$4,747

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Available-For-Sale Securities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash and cash equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$154,959	$73,390
Gross Unrealized Gains	0	0
Gross Unrealized (Losses)	0	0
Fair Value	154,959	73,390
Restricted cash and cash equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	124,368	770,000
Gross Unrealized Gains	0	0
Gross Unrealized (Losses)	0	0
Fair Value	124,368	770,000
Long-term available-for-sale securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,766	1,766
Gross Unrealized Gains	0	1,213
Gross Unrealized (Losses)	-260	0
Fair Value	1,506	2,979
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	279,327	843,390
Gross Unrealized Gains	0	0
Gross Unrealized (Losses)	0	0
Fair Value	279,327	843,390
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,766	1,766
Gross Unrealized Gains	0	1,213
Gross Unrealized (Losses)	-260	0
Fair Value	1,506	2,979
Equity securities | Short-term available for sale securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	805
Gross Unrealized Gains	10
Gross Unrealized (Losses)	0
Fair Value	$815

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) (USD $)	3 Months Ended					12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense	($22,500)	($27,300)	($800)	($2,800)	($1,100)	($22,542)	($32,011)	($72,551)
Qualitest
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense		-17,000
Fair value, measurements, nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense						-22,542	-32,011
Fair value, measurements, nonrecurring | Property, plant and equipment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense						-4,342	-7,511
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0				0	0
Property, plant, and equipment	0	0				0	0
Minimum Voltaren Gel royalties due to Novartis	0	0				0	0
Liabilities	0	0				0	0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0				0	0
Property, plant, and equipment	0	0				0	0
Minimum Voltaren Gel royalties due to Novartis	0	0				0	0
Liabilities	0	0				0	0
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	3,300	8,000				3,300	8,000
Property, plant, and equipment	0	0				0	0
Minimum Voltaren Gel royalties due to Novartis	37,500	21,451				37,500	21,451
Liabilities	37,500	21,451				37,500	21,451
Fair value, measurements, nonrecurring | Opana
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense						-18,200
Fair value, measurements, nonrecurring | Opana | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0					0
Fair value, measurements, nonrecurring | Opana | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0					0
Fair value, measurements, nonrecurring | Opana | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	3,300					3,300
Fair value, measurements, nonrecurring | AMS IPR&D
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense							-6,000
Fair value, measurements, nonrecurring | AMS IPR&D | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | AMS IPR&D | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | AMS IPR&D | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		8,000					8,000
Fair value, measurements, nonrecurring | Qualitest
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense							-17,000
Fair value, measurements, nonrecurring | Qualitest | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | Qualitest | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | Qualitest | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | Epicept
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Expense							-1,500
Fair value, measurements, nonrecurring | Epicept | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | Epicept | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		0					0
Fair value, measurements, nonrecurring | Epicept | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		$0					$0

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$118,431	$89,640
Work-in-process	43,290	45,713
Finished goods	261,600	188,974
Total	$423,321	$324,327

Property_Plant_And_Equipment_S

Property, Plant And Equipment (Schedule Of Property, Plant And Equipment) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cost:
Beginning Balance	$449,204
Additions	83,645
Disposals/transfers/impairments/other	-46,149
Effect of currency translation	-3,090
Ending Balance	510,701
Accumulated Depreciation:
Beginning Balance	-122,330
Additions	-42,665
Disposals/transfers/impairments/other	41,588
Effect of currency translation	409
Ending Balance	-122,998
Net Book Amount:	387,703	326,874
All Acquirees
Cost:
Additions	27,091
Land and Buildings
Cost:
Beginning Balance	191,141
Additions	19,012
Disposals/transfers/impairments/other	0
Effect of currency translation	-2,070
Ending Balance	224,492
Accumulated Depreciation:
Beginning Balance	-17,388
Additions	-13,381
Disposals/transfers/impairments/other	0
Effect of currency translation	113
Ending Balance	-30,656
Net Book Amount:	193,836	173,753
Land and Buildings | All Acquirees
Cost:
Additions	16,409
Machinery and Equipment
Cost:
Beginning Balance	83,431
Additions	9,199
Disposals/transfers/impairments/other	-5,175
Effect of currency translation	-613
Ending Balance	91,899
Accumulated Depreciation:
Beginning Balance	-30,983
Additions	-11,599
Disposals/transfers/impairments/other	6,052
Effect of currency translation	131
Ending Balance	-36,399
Net Book Amount:	55,500	52,448
Machinery and Equipment | All Acquirees
Cost:
Additions	5,057
Leasehold Improve- ments
Cost:
Beginning Balance	22,323
Additions	1,157
Disposals/transfers/impairments/other	-8,691
Effect of currency translation	-205
Ending Balance	16,165
Accumulated Depreciation:
Beginning Balance	-15,625
Additions	-553
Disposals/transfers/impairments/other	8,118
Effect of currency translation	26
Ending Balance	-8,034
Net Book Amount:	8,131	6,698
Leasehold Improve- ments | All Acquirees
Cost:
Additions	1,581
Computer Equipment and Software
Cost:
Beginning Balance	73,057
Additions	38,675
Disposals/transfers/impairments/other	-25,789
Effect of currency translation	-108
Ending Balance	88,984
Accumulated Depreciation:
Beginning Balance	-49,939
Additions	-14,360
Disposals/transfers/impairments/other	22,159
Effect of currency translation	97
Ending Balance	-42,043
Net Book Amount:	46,941	23,118
Computer Equipment and Software | All Acquirees
Cost:
Additions	3,149
Assets under Capital Lease
Cost:
Beginning Balance	5,012
Additions	4,784
Disposals/transfers/impairments/other	-3,714
Effect of currency translation	0
Ending Balance	6,082
Accumulated Depreciation:
Beginning Balance	-3,357
Additions	-1,697
Disposals/transfers/impairments/other	3,234
Effect of currency translation	0
Ending Balance	-1,820
Net Book Amount:	4,262	1,655
Assets under Capital Lease | All Acquirees
Cost:
Additions	0
Furniture and Fixtures
Cost:
Beginning Balance	4,743
Additions	159
Disposals/transfers/impairments/other	-2,208
Effect of currency translation	-94
Ending Balance	3,218
Accumulated Depreciation:
Beginning Balance	-2,027
Additions	-1,075
Disposals/transfers/impairments/other	2,025
Effect of currency translation	42
Ending Balance	-1,035
Net Book Amount:	2,183	2,716
Furniture and Fixtures | All Acquirees
Cost:
Additions	618
Assets under Construc- tion
Cost:
Beginning Balance	69,497
Additions	10,659
Disposals/transfers/impairments/other	-572
Effect of currency translation	0
Ending Balance	79,861
Accumulated Depreciation:
Beginning Balance	-3,011
Additions	0
Disposals/transfers/impairments/other	0
Effect of currency translation	0
Ending Balance	-3,011
Net Book Amount:	76,850	66,486
Assets under Construc- tion | All Acquirees
Cost:
Additions	$277

Property_Plant_And_Equipment_N

Property, Plant And Equipment (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation expense	$42,665,000	$41,536,000	$32,916,000
Asset impairment charges	$4,300,000	$7,500,000	$5,700,000

Goodwill_And_Other_Intangibles2

Goodwill And Other Intangibles (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill, gross beginning balance	$565,994
Accumulated impairment losses, beginning balance	0
Goodwill, net, beginning balance	565,994
Goodwill acquired during the period	2,376,437
Effect of currency translation	-42,844
Goodwill, gross ending balance	2,899,587
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	2,899,587
U.S. Branded Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, gross beginning balance	290,793
Accumulated impairment losses, beginning balance	0
Goodwill, net, beginning balance	290,793
Goodwill acquired during the period	841,139
Effect of currency translation	0
Goodwill, gross ending balance	1,131,932
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	1,131,932
U.S. Generic Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, gross beginning balance	275,201
Accumulated impairment losses, beginning balance	0
Goodwill, net, beginning balance	275,201
Goodwill acquired during the period	796,436
Effect of currency translation	0
Goodwill, gross ending balance	1,071,637
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	1,071,637
International Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, gross beginning balance	0
Accumulated impairment losses, beginning balance	0
Goodwill, net, beginning balance	0
Goodwill acquired during the period	738,862
Effect of currency translation	-42,844
Goodwill, gross ending balance	696,018
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	$696,018

Goodwill_And_Other_Intangibles3

Goodwill And Other Intangibles (Schedule Of Other Intangible Assets) (Details) (USD $)	3 Months Ended								12 Months Ended			0 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 06, 2014
Indefinite-lived intangibles:
Balance				$67,400,000					$67,400,000
Acquisitions									173,700,000
Impairments									-5,900,000
Other									-45,000,000
Effect of Currency Translation									-5,602,000
Balance	184,598,000				67,400,000				184,598,000	67,400,000
Definite-lived intangibles:
Balance				1,446,028,000					1,446,028,000
Acquisitions									1,471,672,000
Impairments									-23,500,000
Other									83,052,000
Effect of Currency Translation									-48,354,000
Balance	2,928,898,000				1,446,028,000				2,928,898,000	1,446,028,000
Total other intangibles
Balance				1,513,428,000					1,513,428,000
Acquisitions									1,645,372,000
Impairments									-29,400,000
Other									38,052,000
Effect of Currency Translation									-53,956,000
Balance	3,113,496,000				1,513,428,000				3,113,496,000	1,513,428,000
Accumulated amortization:
Balance				-565,962,000					-565,962,000
Amortization	-70,900,000	-55,400,000	-52,800,000	-39,700,000	-26,500,000	-29,500,000	-35,600,000	-32,000,000	-218,712,000	-123,547,000	-146,898,000
Impairments									3,190,000
Effect of Currency Translation									1,181,000
Balance	-780,303,000				-565,962,000				-780,303,000	-565,962,000
Net other intangibles	2,333,193,000				947,466,000				2,333,193,000	947,466,000
Voltaren Gel
Accumulated amortization:
Increase (Decrease) in Royalty Liability									37,500,000	21,500,000
Weighted Average
Accumulated amortization:
Estimated life of license agreement (years)									12 years
Licenses
Definite-lived intangibles:
Balance				587,127,000					587,127,000
Acquisitions									0
Impairments									0
Other									77,240,000	-47,100,000
Effect of Currency Translation									0
Balance	664,367,000				587,127,000				664,367,000	587,127,000
Accumulated amortization:
Balance				-357,439,000					-357,439,000
Amortization									-68,974,000
Balance	-426,413,000				-357,439,000				-426,413,000	-357,439,000
Licenses | Weighted Average
Accumulated amortization:
Estimated life of license agreement (years)									9 years
Tradenames
Definite-lived intangibles:
Balance				20,000,000					20,000,000
Acquisitions									1,500,000
Impairments									0
Other									0
Effect of Currency Translation									-185,000
Balance	21,315,000								21,315,000
Accumulated amortization:
Balance				-4,088,000					-4,088,000
Amortization									-1,378,000
Effect of Currency Translation									4,000
Balance	-5,462,000								-5,462,000
Tradenames | Weighted Average
Accumulated amortization:
Estimated life of license agreement (years)									15 years
Developed technology
Definite-lived intangibles:
Balance				838,901,000					838,901,000
Acquisitions									1,470,172,000
Impairments									-23,500,000
Other		-4,200,000							5,812,000
Effect of Currency Translation									-48,169,000
Balance	2,243,216,000								2,243,216,000
Accumulated amortization:
Balance				-204,435,000					-204,435,000
Amortization									-148,360,000
Impairments									3,190,000
Effect of Currency Translation									1,177,000
Balance	-348,428,000								-348,428,000
Developed technology | Weighted Average
Accumulated amortization:
Estimated life of license agreement (years)									13 years
In process research & development
Indefinite-lived intangibles:
Balance				67,400,000					67,400,000
Acquisitions									173,700,000
Impairments									-5,900,000
Other	-10,000,000								-45,000,000			35,000,000
Effect of Currency Translation									-5,602,000
Balance	184,598,000								184,598,000
Bayerschering Agreement | Aveed
Accumulated amortization:
Additional milestone payment												$5,000,000

Goodwill_And_Other_Intangibles4

Goodwill And Other Intangibles (Narrative) (Details) (USD $)	3 Months Ended					12 Months Ended			1 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Mar. 30, 2012	Oct. 01, 2014	Oct. 01, 2013	Oct. 01, 2012	Mar. 31, 2012	Oct. 02, 2013
Goodwill	$2,899,587,000	$565,994,000				$2,899,587,000	$565,994,000
Goodwill acquired during the period						2,376,437,000
Goodwill effects of currency translation						-42,844,000
Amortization						218,712,000	124,147,000	147,498,000
Finite-Lived Intangible Assets, Other						83,052,000
Asset impairment charges	22,500,000	27,300,000	800,000	2,800,000	1,100,000	22,542,000	32,011,000	72,551,000
Impairment of Intangible Assets, Finite-lived						23,500,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	184,598,000	67,400,000				184,598,000	67,400,000
Asset impairment charges						5,900,000
AMS
Asset impairment charges							12,000,000	128,500,000
Devices
Goodwill	863,000,000	806,800,000				863,000,000	806,800,000
Goodwill acquired during the period						62,000,000
Goodwill effects of currency translation						5,800,000
U.S. Branded Pharmaceuticals
Goodwill	1,131,932,000	290,793,000				1,131,932,000	290,793,000
Goodwill acquired during the period						841,139,000
Goodwill effects of currency translation						0
Amortization						78,890,000	80,223,000	105,974,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)									5,000,000					21,600,000
Asset impairment charges									11,200,000	40,000,000
Qualitest
Asset impairment charges		17,000,000
UEO
Excess Fair Value Over Carrying Amount, Amount												904,700,000
Excess Fair Value Over Carrying Amount, Percent												100.00%
Generics
Excess Fair Value Over Carrying Amount, Amount												1,600,000,000
Excess Fair Value Over Carrying Amount, Percent															100.00%
Urology Services
Goodwill													139,900,000
Excess Fair Value Over Carrying Amount, Amount													16,400,000
Excess Fair Value Over Carrying Amount, Percent													8.00%
Assets Held-for-sale | AMS
Asset impairment charges							6,000,000
Minimum
Excess Fair Value Over Carrying Amount, Amount													355,800,000
Excess Fair Value Over Carrying Amount, Percent													70.00%
Maximum
Excess Fair Value Over Carrying Amount, Amount													1,500,000,000
Excess Fair Value Over Carrying Amount, Percent													100.00%
Significant Unobservable Inputs (Level 3) | Minimum | Goodwill and Indefinite-lived Intangible Assets
Discount rate range (percent)											8.50%	9.50%	9.50%
Significant Unobservable Inputs (Level 3) | Maximum | Goodwill and Indefinite-lived Intangible Assets
Discount rate range (percent)											15.50%	14.50%	10.00%
Licenses
Finite-Lived Intangible Assets, Other						77,240,000	-47,100,000
Impairment of Intangible Assets, Finite-lived						0
Licenses | U.S. Branded Pharmaceuticals
Impairment of Intangible Assets, Finite-lived						$12,300,000

Goodwill_And_Other_Intangibles5

Goodwill And Other Intangibles (Schedule Of Estimated Amortization Of Intangibles) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$253,391
2016	203,218
2017	194,225
2018	193,959
2019	$178,670

Goodwill_And_Other_Intangibles6

Goodwill And Other Intangibles (Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Definite-lived intangibles:
Beginning balance	$1,513,428
Approval milestone	5,000
Acquisition	1,471,672
Intangible assets sold	-4,448
Voltaren® Gel license extension	37,500
Opana® ER license write-off	-23,500
Other in-process research and development asset impairment	-5,900
Effect of currency translation	-53,956
Ending balance	3,113,496
In process research & development
Definite-lived intangibles:
Other in-process research and development asset impairment	-5,900
Developed technology
Definite-lived intangibles:
Acquisition	1,470,172
Opana® ER license write-off	-23,500
Paladin Labs Inc.
Definite-lived intangibles:
Acquisition	674,248
Paladin Labs Inc. | In process research & development
Definite-lived intangibles:
Acquisition	65,500
Paladin Labs Inc. | Developed technology
Definite-lived intangibles:
Acquisition	608,700
Boca Pharmacal, LLC
Definite-lived intangibles:
Acquisition	140,900
Sumavel DosePro
Definite-lived intangibles:
Acquisition	90,024
Grupo Farmacéutico Somar
Definite-lived intangibles:
Acquisition	169,300
DAVA Pharmaceuticals, Inc
Definite-lived intangibles:
Acquisition	514,900
Natesto
Definite-lived intangibles:
Acquisition	$56,000

License_And_Collaboration_Agre1

License And Collaboration Agreements (Commercial Products) (Narrative 1) (Details)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Jun. 30, 2014

Dec. 31, 2014

Oct. 31, 1997

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Mar. 04, 2008

Mar. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Mar. 04, 2008

Jul. 31, 2004

Dec. 31, 2006

Dec. 31, 2005

Jul. 31, 2004

Jul. 31, 2004

Dec. 31, 2014

Dec. 31, 2014

Feb. 28, 2008

Dec. 31, 2010

Aug. 31, 2009

Jun. 30, 2011

Dec. 31, 2010

Aug. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Jul. 31, 2005

Mar. 06, 2014

Jul. 31, 2005

Dec. 31, 2014

USD ($)

USD ($)

USD ($)

Novartis Consumer Health Inc

Novartis Consumer Health Inc

Novartis Consumer Health Inc

Population Council

Voltaren Gel

Voltaren Gel

Voltaren Gel

Vantas

Vantas

Vantas

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Voltaren Gel Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Vernalis License Agreement

Pro Strakan Agreement

Pro Strakan Agreement

Pro Strakan Agreement

Pro Strakan Agreement, Commercial And Regulatory Milestone

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement

Grunenthal Agreement, Completion Of Clinical Milestone

Bayerschering Agreement

Bayerschering Agreement

Bayerschering Agreement

Bayerschering Agreement

Voltaren Gel Agreement Extending Through June 2012

Voltaren Gel Agreement Extending Through June 2014

Voltaren Gel Agreement Extending Through June 2015

USD ($)

USD ($)

Voltaren Gel Agreement Extending Through June 2013

Population Council

Population Council

Population Council

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Voltaren Gel Agreement Extending Through June 2013

Voltaren Gel Agreement Extending Through June 2013

Voltaren Gel Agreement Extending Through June 2014

Voltaren Gel Agreement Extending Through June 2014

Voltaren Gel

USD ($)

USD ($)

USD ($)

Minimum

Maximum

Maximum

Frova

Frova

USD ($)

USD ($)

USD ($)

Fortesta

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

Aveed

Aveed

Aveed

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Minimum

Maximum

Term

USD ($)

payment

USD ($)

USD ($)

USD ($)

USD ($)

Minimum

USD ($)

USD ($)

USD ($)

USD ($)

License And Collaboration Agreements [Line Items]

License Agreement Term

5 years

Upfront cash payment

$85,000,000

$30,000,000

$10,000,000

$30,000,000

Guaranteed minimum annual royalty payments in the fourth year

30,000,000

Conditional milestone payment

25,000,000

10,000,000

75,000,000

255,000,000

4,900,000

17,500,000

Net Sales Threshold

300,000,000

200,000,000

1,200,000,000

85,000,000

Finite-lived Intangible Assets, Fair Value Disclosure

129,000,000

Finite-Lived Intangible Asset, Useful Life

5 years

Guaranteed Minimum Royalty Payment

7,500,000

Payments for royalties

30,000,000

30,000,000

21,600,000

0

Long Term Purchase Commitment Percentage

13.00%

Long-term Purchase Commitment, Amount

16,000,000

5,900,000

8,400,000

Marketing and Advertising Expense

5,500,000

8,100,000

9,400,000

Agreement expiration date

June 30, 2013

Number Of Successive Terms

2

License Agreement Term Extension, Duration

1 year

1 year

1 year

Increase (Decrease) in Royalty Liability

37,500,000

21,500,000

21,300,000

Renewal Term Cancellation Period Number Of Months

6 months

Termination Of Agreement Notice Period

90 days

6 months

Annual Payment under the Agreement

15,000,000

Upfront Cash Payment Capitalized

30,000,000

Number of Anniversary Payments

2

Annual Payment Capitalized

15,000,000

Maximum Number Of Years For Royalty Payments

20 years

Expiration of agreement

25 years

Payment Required For Termination Of Agreement

40,000,000

Payments made under product utilization agreement to date

14,800,000

Rate Of Net Sales Of Specified Products Required To Be Paid

3.00%

Royalty rate on net sales

0.50%

4.00%

25.00%

Rate Of Profits And Payments Received From Licensing Of Specified Products Required To Be Paid

30.00%

Rate Of Specified Products Required To Be Paid

5.00%

Conditional Milestone Payment Capitalized

12,500,000

Additional milestone payment recognized

7,500,000

32,900,000

35,300,000

35,700,000

Additional milestone payment

160,000,000

4,900,000

65,100,000

53,900,000

4,900,000

5,000,000

Commercial Milestone Charge

$10,400,000

License_And_Collaboration_Agre2

License And Collaboration Agreements (Products In Development) (Narrative 2) (Details) (USD $)	12 Months Ended				1 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Jan. 31, 2012	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2012	Mar. 31, 2012
License And Collaboration Agreements [Line Items]
Research and development	$112,708,000	$97,465,000	$161,365,000
Impax Agreement
License And Collaboration Agreements [Line Items]
Upfront cash payment				10,000,000
Impax Agreement, Clinical Regulatory And Commercial Milestones
License And Collaboration Agreements [Line Items]
Additional milestone payment	30,000,000
Hydron Agreement
License And Collaboration Agreements [Line Items]
Royalties Owed Maximum	5.00%
BioDelivery
License And Collaboration Agreements [Line Items]
Upfront cash payment										30,000,000
Additional milestone payment	50,000,000					10,000,000	10,000,000	10,000,000	15,000,000
Research and development	30,000,000
Period To Terminate					10 years
Bio Delivery, Buprenorphine And Commercial And Regulatory Milestone
License And Collaboration Agreements [Line Items]
Additional milestone payment	$55,000,000

Accrued_Expenses_Schedule_Of_A

Accrued Expenses (Schedule Of Accrued Expenses) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]
Chargebacks	$217,402	$118,014
Returns and allowances	174,940	104,699
Rebates	497,362	336,084
Other sales deductions	25,380	12,897
Other	234,461	146,999
Accrued expenses, Total	$1,149,545	$718,693

Debt_Components_Of_Total_Indeb

Debt (Components Of Total Indebtedness) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jun. 08, 2011	Nov. 30, 2010	Dec. 19, 2013	Jun. 30, 2014
Debt Instrument [Line Items]
Other debt	$22,822,000	$133,000
Total long-term debt, net	4,358,293,000	3,738,773,000
Less current portion, net	155,937,000	414,929,000
Total long-term debt, less current portion, net	4,202,356,000	3,323,844,000
Other debt, Fair Value	22,886,000	133,000
Total long-term debt, net, Fair Value	4,410,587,000	3,870,958,000
Less current portion, net, Fair Value	154,226,000	441,989,000
Total long-term debt, less current portion, net, Fair Value	4,256,361,000	3,428,969,000
1.75% Convertible Senior Subordinated Notes due 2015
Debt Instrument [Line Items]
Convertible Senior Subordinated Notes	98,818,000	379,500,000
Unamortized discount on 1.75% Convertible Senior Subordinated Notes due 2015	-1,759,000	-34,079,000
Net carrying amount of the debt component	97,059,000	345,421,000
Convertible Notes, Fair Value	98,317,000	372,481,000
Interest Rate (percent)	1.75%
7.00% Senior Notes due 2019
Debt Instrument [Line Items]
Senior notes, carrying amount	499,875,000	500,000,000	500,000,000
Senior Notes, Fair Value	522,813,000	536,563,000
Interest Rate (percent)	7.00%		7.00%
7.00% Senior Notes due 2020
Debt Instrument [Line Items]
Senior notes, carrying amount	400,000,000	400,000,000		400,000,000
Unamortized initial purchaser's discount	-2,338,000	-2,800,000
Senior notes	397,662,000	397,200,000
Senior Notes, Fair Value	422,250,000	430,500,000
Interest Rate (percent)	7.00%			7.00%
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Senior notes, carrying amount	400,000,000	400,000,000	400,000,000
Senior Notes, Fair Value	429,278,000	431,750,000
Interest Rate (percent)	7.25%		7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Senior notes, carrying amount	700,000,000	700,000,000			700,000,000
Senior Notes, Fair Value	707,000,000	703,500,000
Interest Rate (percent)	5.75%				5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Senior notes, carrying amount	750,000,000	0				750,000,000
Senior Notes, Fair Value	735,469,000	0
Interest Rate (percent)	5.38%					5.38%
Term Loan A Facility Due 2019
Debt Instrument [Line Items]
Total long-term debt, net	1,069,063,000	0
Term Loan Facility Due, Fair Value	1,062,889,000	0
Term Loan B Facility Due 2021
Debt Instrument [Line Items]
Total long-term debt, net	421,812,000	0
Term Loan Facility Due, Fair Value	409,685,000	0
Term Loan A Facility Due 2018
Debt Instrument [Line Items]
Total long-term debt, net	0	1,335,469,000
Term Loan Facility Due, Fair Value	0	1,335,345,000
Term Loan B Facility Due 2018
Debt Instrument [Line Items]
Total long-term debt, net	0	60,550,000
Term Loan Facility Due, Fair Value	$0	$60,686,000

Debt_Credit_Facility_Narrative

Debt (Credit Facility) (Narrative) (Details) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 26, 2013	Sep. 30, 2012	Jul. 31, 2012	Feb. 29, 2012
Line of Credit Facility [Line Items]
Amount outstanding	$1,400,000,000
Maximum leverage ratio	2.75
Maximum borrowing capacity of line of credit facility	75,000,000
Payments of financing costs		62,715,000	10,475,000	0
Loss on extinguishment of debt		-31,817,000	-11,312,000	-7,215,000
Paladin Labs Inc.
Line of Credit Facility [Line Items]
Previously existing debt assumed	23,826,000
Paladin Labs Inc. | As initially reported
Line of Credit Facility [Line Items]
Previously existing debt assumed	23,826,000
2013 Credit Facility
Line of Credit Facility [Line Items]
Payments and accruals of deferred financing costs	27,800,000				8,100,000
Payments of financing costs	26,700,000				7,600,000
Loss on extinguishment of debt	1,100,000				500,000
2011 Credit Facility
Line of Credit Facility [Line Items]
Loss on extinguishment of debt	8,600,000				8,600,000
Revolving Credit Facility And Together With Term Loan Facilities 2011 Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity of line of credit facility					500,000,000
License Agreement Term Extension, Duration					2 years
Swing Line Loan
Line of Credit Facility [Line Items]
Current borrowing capacity of line of credit facility	50,000,000
Letter of Credit
Line of Credit Facility [Line Items]
Current borrowing capacity of line of credit facility	50,000,000
Minimum | 2013 Credit Facility | London Inter-Bank Offer Rate (LIBOR)
Line of Credit Facility [Line Items]
Margin rate over base rate	1.50%
Minimum | 2013 Credit Facility | Alternative Base Rate
Line of Credit Facility [Line Items]
Margin rate over base rate	0.50%
Minimum | 2011 Credit Facility
Line of Credit Facility [Line Items]
Commitment fee basis points	0.30%
Maximum | 2013 Credit Facility | London Inter-Bank Offer Rate (LIBOR)
Line of Credit Facility [Line Items]
Margin rate over base rate	2.25%
Maximum | 2013 Credit Facility | Alternative Base Rate
Line of Credit Facility [Line Items]
Margin rate over base rate	1.25%
Maximum | 2011 Credit Facility
Line of Credit Facility [Line Items]
Commitment fee basis points	0.50%
Five Year Senior Secured Term A Facility
Line of Credit Facility [Line Items]
Debt instrument, term	5 years
Term Loan A Facility Due 2019
Line of Credit Facility [Line Items]
Face value of debt instrument	1,100,000,000
Five Year Senior Secured Term B Facility
Line of Credit Facility [Line Items]
Debt instrument, term	7 years
Term Loan B Facility Due 2021
Line of Credit Facility [Line Items]
Face value of debt instrument	425,000,000
Five Year Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt instrument, term	5 years
Current borrowing capacity of line of credit facility	750,000,000
Five Year Revolving Credit Facility | Maximum
Line of Credit Facility [Line Items]
Uncommitted expansion provision amount	1,000,000,000
Term Loan B Facility Due 2018
Line of Credit Facility [Line Items]
Amount outstanding					60,600,000
Loss on extinguishment of debt					2,200,000
Repayments of Long-term Debt					100,000,000
Prepayment Of Term Loan Facility						39,700,000	33,000,000	205,000,000
Unamortized Finance Cost Written Off						7,200,000
Term Loan B Facility Due 2018 | London Inter-Bank Offer Rate (LIBOR)
Line of Credit Facility [Line Items]
Minimum effective interest rate	0.75%
Maximum effective interest rate	2.50%
Term Loan B Facility Due 2018 | 2011 Credit Facility | Alternative Base Rate
Line of Credit Facility [Line Items]
Margin rate over base rate	1.50%
Term Loan A Facility Due 2018
Line of Credit Facility [Line Items]
Amount outstanding					$1,400,000,000

Debt_Senior_Notes_Narrative_De

Debt (Senior Notes) (Narrative) (Details) (USD $)	0 Months Ended		1 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	6-May-14	Jun. 08, 2011	Nov. 30, 2010	Dec. 19, 2013	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
7.00% Senior Notes due 2019
Debt Instrument [Line Items]
Long-term Debt, Gross		$500,000,000			$499,875,000		$500,000,000
Interest Rate (percent)		7.00%			7.00%
Debt Instrument Maturity Year		2019
Debt repurchase amount	481,900,000
Percentage Of Principal Amount	101.00%
EHSI 2019 Notes
Debt Instrument [Line Items]
Long-term Debt, Gross	481,900,000				18,000,000
Interest Rate (percent)	7.00%
Debt repurchase amount	481,900,000
7.00% Senior Notes due 2020
Debt Instrument [Line Items]
Long-term Debt, Gross			400,000,000		400,000,000		400,000,000
Interest Rate (percent)			7.00%		7.00%
Debt Instrument Maturity Year			2020
Debt repurchase amount	393,000,000
Percentage Of Principal Amount	101.00%
Issue Price Percentage			99.11%
EHSI 2020 Notes
Debt Instrument [Line Items]
Long-term Debt, Gross	393,000,000				7,000,000
Interest Rate (percent)	7.00%
Debt repurchase amount	393,000,000
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Long-term Debt, Gross		400,000,000			400,000,000		400,000,000
Interest Rate (percent)		7.25%			7.25%
Debt Instrument Maturity Year		2022
Debt repurchase amount	396,300,000
Percentage Of Principal Amount	101.00%
Debt Issuance Cost	11,700,000
Debt Extinguishment Costs	5,300,000
EHSI 2022 Notes
Debt Instrument [Line Items]
Long-term Debt, Gross	396,300,000				3,700,000
Interest Rate (percent)	7.25%
Debt repurchase amount	396,300,000
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Long-term Debt, Gross				700,000,000	700,000,000		700,000,000
Interest Rate (percent)				5.75%	5.75%
Debt Instrument Maturity Year				2022
Percentage Of Principal Amount					105.75%
Redemption Percentage					35.00%
Debt Instrument, Redemption Price, Percentage					101.00%
5.75% Senior Notes due 2022 | Prepaid Expenses and Other Current Assets
Debt Instrument [Line Items]
Amount Of Cost Paid To Investment Bankers				12,800,000
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Long-term Debt, Gross					750,000,000	750,000,000	0
Interest Rate (percent)					5.38%	5.38%
Percentage Of Principal Amount					105.38%
Debt Issuance Cost						$12,600,000
Redemption Percentage					35.00%
Debt Instrument, Redemption Price, Percentage					101.00%

Debt_Percentage_Of_Outstanding

Debt (Percentage Of Outstanding Principal Balance Of Non-Recourse Notes) (Details)	0 Months Ended	12 Months Ended	0 Months Ended
	6-May-14	Dec. 31, 2014	Dec. 19, 2013	Jun. 30, 2014
7.00% Senior Notes due 2019 | From July 15, 2015 to and including July 14, 2016
Debt Instrument [Line Items]
Redemption Percentage	103.50%
7.00% Senior Notes due 2019 | From July 15, 2016 to and including July 14, 2017
Debt Instrument [Line Items]
Redemption Percentage	101.75%
7.00% Senior Notes due 2019 | From July 15, 2017 and thereafter
Debt Instrument [Line Items]
Redemption Percentage	100.00%
7.00% Senior Notes due 2020 | From December 15, 2015 to and including December 14, 2016
Debt Instrument [Line Items]
Redemption Percentage	103.50%
7.00% Senior Notes due 2020 | From December 15, 2016 to and including December 14, 2017
Debt Instrument [Line Items]
Redemption Percentage	102.33%
7.00% Senior Notes due 2020 | From December 15, 2017 to and including December 14, 2018
Debt Instrument [Line Items]
Redemption Percentage	101.17%
7.00% Senior Notes due 2020 | From December 15, 2018 and thereafter
Debt Instrument [Line Items]
Redemption Percentage	100.00%
7.25% Senior Notes due 2022 | From July 15, 2016 to and including July 14, 2017
Debt Instrument [Line Items]
Redemption Percentage	103.63%
7.25% Senior Notes due 2022 | From July 15, 2017 to and including July 14, 2018
Debt Instrument [Line Items]
Redemption Percentage	102.42%
7.25% Senior Notes due 2022 | From July 15, 2018 to and including July 14, 2019
Debt Instrument [Line Items]
Redemption Percentage	101.21%
7.25% Senior Notes due 2022 | From July 15, 2019 and thereafter
Debt Instrument [Line Items]
Redemption Percentage	100.00%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Redemption Percentage		35.00%
5.75% Senior Notes due 2022 | From January 15, 2017 to and including January 14, 2018
Debt Instrument [Line Items]
Redemption Percentage			104.31%
5.75% Senior Notes due 2022 | From January 15, 2018 to and including January 14, 2019
Debt Instrument [Line Items]
Redemption Percentage			102.88%
5.75% Senior Notes due 2022 | From January 15, 2019 to and including January 14, 2020
Debt Instrument [Line Items]
Redemption Percentage			101.44%
5.75% Senior Notes due 2022 | From January 15, 2020 and thereafter
Debt Instrument [Line Items]
Redemption Percentage			100.00%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Redemption Percentage		35.00%
5.375% Senior Notes due 2023 | From July 15, 2017 to and including July 14, 2018
Debt Instrument [Line Items]
Redemption Percentage				104.03%
5.375% Senior Notes due 2023 | From July 15, 2018 to and including July 14, 2019
Debt Instrument [Line Items]
Redemption Percentage				102.69%
5.375% Senior Notes due 2023 | From July 15, 2019 to and including July 14, 2020
Debt Instrument [Line Items]
Redemption Percentage				101.34%
5.375% Senior Notes due 2023 | From July 15, 2020 and thereafter
Debt Instrument [Line Items]
Redemption Percentage				100.00%

Debt_Convertible_Senior_Subord

Debt (Convertible Senior Subordinated Notes Due) (Narrative) (Details) (USD $)	12 Months Ended	1 Months Ended		0 Months Ended
	Dec. 31, 2014	Jul. 31, 2014	30-May-14	Apr. 09, 2008	Dec. 31, 2013	Sep. 17, 2013
Subsidiary, Sale of Stock [Line Items]
Settlement of the hedge on convertible senior subordinated notes due 2015	$356,265,000
1.75% Convertible Senior Subordinated Notes due 2015
Subsidiary, Sale of Stock [Line Items]
Interest Rate (percent)	1.75%
Convertible notes, maturity date	15-Apr-15
Debt repurchase amount		40,000,000	240,700,000
Early repayment of subordinated debt		95,200,000	548,200,000
Stock issued during period, conversion of convertible securities (shares)		798,367
Settlement of the hedge on convertible senior subordinated notes due 2015		55,200,000
Convertible Note Gross	98,818,000				379,500,000
Loss on extinguishment of debt		2,000,000	14,800,000
Adjustments to additional paid in capital, equity component of convertible debt		365,000,000
Share price (usd per share)						$37.96
Percent of initial conversion price (percent)						130.00%
Initial conversion price (in dollars per share)	$29.20					$29.20
Convertible notes, conversion premium over the closing price				61.10%
1.75% Convertible Senior Subordinated Notes due 2015 | Warrants
Subsidiary, Sale of Stock [Line Items]
Share issued for repurchase of senior note (shares)	3,400,000	1,400,000	8,200,000	13,000,000
Call option strike price per share (in dollars per share)	40			40
Proceeds from Issuance of Warrants				50,400,000
Cash paid on settlement		42,300,000	242,200,000
1.75% Convertible Senior Subordinated Notes due 2015 | Call Options Purchased
Subsidiary, Sale of Stock [Line Items]
Convertible notes, maturity date	15-Apr-15
Share issued for repurchase of senior note (shares)	3,400,000	1,400,000	8,200,000	13,000,000
Convertible notes, convertible amount per share (in dollars per share)				$24.85		$40
Call option strike price per share (in dollars per share)	29.2			29.2
Investment Owned, at Cost				107,600,000
Cash paid on settlement		$54,200,000	$302,100,000

Debt_Maturities_On_LongTerm_De

Debt (Maturities On Long-Term Debt For Each Of The Next Five Years) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$157,695
2016	82,229
2017	109,946
2018	155,500
2019	$1,191,625

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details) (USD $)	0 Months Ended		12 Months Ended			1 Months Ended	0 Months Ended
	Feb. 28, 2013	Oct. 28, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2014	Nov. 23, 2011	Apr. 27, 2012	Jan. 31, 2015	Feb. 20, 2015
		renewal_options					settled_cases			sqft	Pending_Cases
		sqft
Commitments And Contingencies [Line Items]
Reserve for loss contingencies			$1,710,000,000				$1,710,000,000
Current portion of legal settlement accrual			1,443,114,000	215,644,000			1,443,114,000
Change in estimate of litigation liability			0	50,400,000	0
Lawsuit filing period	45 days		45 days
Stay of approval period, Hatch-Waxman Act	30 months		30 months
Lease agreement, area of office space (in square feet)		300,000
Lease Agreement, Duration of Option to Lease Additional Area Under Lease Agreement		4 years
Maximum Additional Area Under The Lease Agreement		150,000
Term Of Lease agreement		12 years
Lease Agreement, Number Of Renewal Options		3
Additional Period Of Renewal For Lease Agreement		60 months
Direct Financing Lease, Monthly Rent Expense					500,000
Increase In Lease Rate During Subsequent Years, Percentage		2.25%
Direct Financing Lease Obligations			49,900,000				49,900,000
Operating Leases, Rent Expense, Net			8,500,000	18,700,000	14,200,000
Accounts Payable
Commitments And Contingencies [Line Items]
Direct Financing Lease Obligations			3,900,000				3,900,000
Other Liabilities
Commitments And Contingencies [Line Items]
Direct Financing Lease Obligations			46,000,000				46,000,000
Subsequent Event
Commitments And Contingencies [Line Items]
Area of Real Estate Property										60,000
Vaginal mesh cases
Commitments And Contingencies [Line Items]
Reserve for loss contingencies			1,655,195,000	520,000,000			1,655,195,000
Loss Contingency, Reduction Factor, Percentage			20.00%				20.00%
Current portion of legal settlement accrual			1,390,000,000				1,390,000,000
Settlement Funds			485,229,000	11,518,000			485,229,000
Watson Settlement Agreement
Commitments And Contingencies [Line Items]
Estimated litigation liability			0				0
Change in estimate of litigation liability			0	50,400,000
MCP cases | Subsequent Event
Commitments And Contingencies [Line Items]
Pending claims, number											600
Propoxyphene cases | Subsequent Event
Commitments And Contingencies [Line Items]
Pending claims, number											47
Testosterone Cases | Subsequent Event
Commitments And Contingencies [Line Items]
Pending claims, number											230
Department of Health and Human Services Subpoena and Related Matters
Commitments And Contingencies [Line Items]
Litigation settlement, amount						1,400,000
AMS | Vaginal mesh cases
Commitments And Contingencies [Line Items]
Product liability accrual, period expense			1,660,000,000				1,660,000,000
Loss contingency, claims settled, number							45,400
Ventiv Agreement
Commitments And Contingencies [Line Items]
Costs and Expenses, Related Party				15,100,000	37,200,000
Grunenthal Agreement
Commitments And Contingencies [Line Items]
License And Supply Payment Period			45 days
Additional milestone payment recognized			32,900,000	35,300,000	35,700,000
Voltaren Gel Agreement
Commitments And Contingencies [Line Items]
Amount Of Purchase Made Pursuant To Long Term Purchase Agreement			55,000,000	50,200,000	34,000,000
Teikoku Seiyaku Co Ltd
Commitments And Contingencies [Line Items]
Amount Of Purchase Made Pursuant To Long Term Purchase Agreement			45,100,000	167,000,000	179,500,000
Japanese Facilities For Commercial Sale in the United States			2
Termination Of Agreement Notice Period			45 days
License Agreement, Royalty Rate, Percentage of Net Sales								6.00%
Payments for royalties			19,100,000	35,000,000	55,700,000
Royalty payable			19,100,000				19,100,000
Noramco, Inc.
Commitments And Contingencies [Line Items]
Long Term Purchase Commitment Renewal Period			1 year
Long Term Purchase Commitment Term									4 years
Automatic Renewal Provision For Unlimited Successive Periods									1 year
Purchased Amount			76,000,000	66,100,000	52,900,000
Sharp Corporation [Member]
Commitments And Contingencies [Line Items]
Termination Of Agreement Notice Period			90 days
Long Term Purchase Commitment Renewal Period			1 year
Purchased Amount			2,000,000	7,800,000	9,500,000
Ups Supply Chain Solutions
Commitments And Contingencies [Line Items]
Initial Term Of Agreement Extended Date			31-Mar-15
Watson Laboratories, Inc
Commitments And Contingencies [Line Items]
Percentage of royalty rate of gross sales (percent)			25.00%
Royalty revenue			$51,300,000	$58,700,000

Commitments_And_Contingencies_2

Commitments And Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Qualified Settlement Funds
Cash distributions to Qualified Settlement Funds	$585,165,000	$54,500,000	$0
Product Liability
Ending Balance	1,710,000,000
Net gain included in Other income, net	0	50,400,000	0
Vaginal mesh cases
Qualified Settlement Funds
Beginning Balance	11,518,000
Cash distributions to Qualified Settlement Funds	585,165,000
Cash distributions to settle disputes from Qualified Settlement Funds	-111,454,000
Ending Balance	485,229,000
Product Liability
Beginning Balance	520,000,000
Additional charges	1,273,358,000
Cash distributions to settle disputes from Qualified Settlement Funds	-111,454,000
Cash distributions to settle disputes	-26,709,000
Ending Balance	1,655,195,000
Watson Settlement Agreement
Product Liability
Litigation settlement liability relieved during the year		85,123,000
Cost of product shipped to Watson’s wholesaler affiliate		-11,093,000
Estimated gross-to-net liabilities on product shipped to Watson’s wholesaler affiliate		-29,162,000
Rebate on product shipped to Watson’s wholesaler affiliate		5,532,000
Net gain included in Other income, net	$0	$50,400,000

Commitments_And_Contingencies_3

Commitments And Contingencies (Summary Of Minimum Future Rental Payments Required Under Operating Leases and Capital Leases) (Details) (USD $)	Dec. 31, 2014
Capital Leases
2015	$6,526,000
2016	6,640,000
2017	6,875,000
2018	7,072,000
2019	7,270,000
Thereafter	39,025,000
Total minimum lease payments	73,408,000
Less: Amount representing interest	8,041,000
Total present value of minimum payments	65,367,000
Less: Current portion of such obligations	6,526,000
Long-term capital lease obligations	58,841,000
Capital Leases, Future Minimum Sublease Rentals	23,000,000
Operating Leases
2015	15,292,000
2016	9,320,000
2017	6,677,000
2018	4,310,000
2019	1,697,000
Thereafter	2,918,000
Total minimum lease payments	$40,214,000

Other_Comprehensive_Loss_Incom2

Other Comprehensive (Loss) Income-Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized (losses) gains arising during the period, Before-Tax Amount	($1,646)	$1,233	$1,441
Less: reclassification adjustments for loss realized in net loss, Before-Tax Amount	17	0	0
Net unrealized (losses) gains, Before-Tax Amount	-1,629	1,233	1,441
Foreign currency translation (loss) gain, Before-Tax Amount	-121,417	682	2,104
Fair value adjustment on derivatives designated as cash flow hedges arising during the period, Before-Tax Amount	0	853	-1,892
Less: reclassification adjustments for cash flow hedges settled and included in net loss, Before-Tax Amount	0	-232	436
Net unrealized fair value adjustment on derivatives designated as cash flow hedges, Before-Tax Amount	0	621	-1,456
Other comprehensive (loss) income, Before-Tax Amount	-123,046	2,536	2,089
Unrealized (losses) gains arising during the period, Tax (Expense) Benefit	547	-458	-38
Less: reclassification adjustments for loss realized in net loss, Tax (Expense) Benefit	0	0	0
Net unrealized (losses) gains, Tax (Expense) Benefit	547	-458	-38
Foreign currency translation (loss) gain, Tax (Expense) Benefit	28	32	60
Fair value adjustment on derivatives designated as cash flow hedges arising during the period, Tax (Expense) Benefit	0	-307	680
Less: reclassification adjustments for cash flow hedges settled and included in net loss, Tax (Expense) Benefit	0	84	-157
Net unrealized fair value adjustment on derivatives designated as cash flow hedges, Tax (Expense) Benefit	0	-223	523
Other comprehensive (loss) income, Tax (Expense) Benefit	575	-649	545
Unrealized (losses) gains arising during the period, Net-of-Tax Amount	-1,099	775	1,403
Less: reclassification adjustments for loss realized in net loss, Net-of-Tax Amount	17	0	0
Less: reclassification adjustments for loss realized in net loss	-1,082	775	1,403
Foreign currency translation (loss) gain, Net of tax amount	-121,389	714	2,164
Fair value adjustment on derivatives designated as cash flow hedges arising during the period, net of tax amount		546	-1,212
Less: reclassification adjustments for cash flow hedges settled and included in net loss, net of tax amount	0	-148	279
Less: reclassification adjustments for cash flow hedges settled and included in net income (loss)	0	398	-933
OTHER COMPREHENSIVE (LOSS) INCOME	($122,471)	$1,887	$2,634

Other_Comprehensive_Loss_Incom3

Other Comprehensive (Loss) Income-Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net unrealized (losses) gains	($484)	$598
Foreign currency translation loss	-123,604	-5,193
Fair value adjustment on derivatives designated as cash flow hedges	0	-320
Accumulated other comprehensive loss	($124,088)	($4,915)

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	Dec. 31, 2014	Feb. 11, 2014	Dec. 31, 2013	Aug. 31, 2012
Equity [Abstract]
Common stock, shares authorized	350,000,000		350,000,000
Common stock, par value (in dollars per share)	$0.01		$0.01
Ordinary shares, shares authorized	1,000,000,000
Ordinary shares, par value (in dollars per share)	$0.00
Euro deferred shares, shares issued	4,000,000	4,000,000
Euro deferred shares, par value (in dollars per share)	$0.01	$0.01
2012 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount				$450,000,000

Sharedbased_Compensation_Narra

Shared-based Compensation (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 15, 2011
Shareholders Equity [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	13,000,000
Stock-based compensation expense	$32,700,000	$39,000,000	$59,400,000
Unrecognized compensation cost	57,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in dollars per share)	$11.91
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit (in dollars per share)	$79.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	41,400,000	97,100,000	19,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,063,352	4,245,789	8,824,705	8,115,467
Stock Issued During Period, Shares, Treasury Stock Reissued	75,450	188,374
Issuance of ordinary shares related to the employee stock purchase plan	4,617,000	5,310,000	6,062,000
Employee Stock Purchase Plan
Shareholders Equity [Line Items]
Stock-based compensation expense	600,000	2,500,000
Percentage Of Contribution By The Employees	10.00%
Percentage Of Price Per Common Stock	90.00%
Share-Based Compensation, ESPP Contribution, Amount Numerator	25,000
Percentage Of Common Shares Outstanding					1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					1,200,000
Nonvested Stock Options
Shareholders Equity [Line Items]
Unrecognized compensation cost	14,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$20.28	$9.37	$10.50
Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options	2 years
Performance Stock Units
Shareholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Performance Cycle Period	3 years
Performance Stock Units | Minimum
Shareholders Equity [Line Items]
Share-based Compensation, Award Adjustment Rate	0.00%
Performance Stock Units | Maximum
Shareholders Equity [Line Items]
Share-based Compensation, Award Adjustment Rate	300.00%
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)
Shareholders Equity [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 10 months 24 days
Nonvested Restricted Stock Units And Performance Stock Units
Shareholders Equity [Line Items]
Unrecognized compensation cost	$27,100,000	$16,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in dollars per share)	$73.70	$31.55	$34.76
Nonvested Restricted Stock
Shareholders Equity [Line Items]
Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options		0 years 3 months 18 days

Sharedbased_Compensation_Sched

Shared-based Compensation (Schedule Of Allocation Of Stock-Based Compensation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$32,671	$38,998	$59,395
Discontinued operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	5,832	9,276	18,592
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	21,690	24,982	35,482
Research and development expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	3,670	4,740	5,321
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$1,479	$0	$0

Sharedbased_Compensation_Summa

Shared-based Compensation (Summary Of Activity Under Stock Incentive Plans) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Outstanding, Number of Shares, Beginning Balance	4,245,789	8,824,705	8,115,467
Granted, Number of Shares	736,948	593,709	2,237,081
Exercised, number of shares	-1,528,295	-3,836,560	-853,794
Forfeited, Number of Shares	-371,410	-1,291,043	-613,613
Expired, Number of Shares	-19,680	-45,022	-60,436
Outstanding, Number of Shares, Ending Balance	3,063,352	4,245,789	8,824,705
Vested and expected to vest, end of period, Number of Shares	2,929,508
Exercisable, end of period, Number of Shares	1,477,631
Weighted Average Exercise Price
Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)	$29.30	$27.93	$25.79
Granted, Weighted Average Exercise Price (in dollars per share)	$75.13	$30.81	$34.58
Exercised, Weighted Average Exercise Price (in dollars per share)	$27.09	$25.32	$22.66
Forfeited, Weighted Average Exercise Price (in dollars per share)	$39.76	$32.73	$31.31
Expired, Weighted Average Exercise Price (in dollars per share)	$24.56	$30.06	$27.61
Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$40.15	$29.30	$27.93
Vested and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$39.23
Exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$28.30
Weighted Average Remaining Contractual Term [Abstract]
Outstanding, ending balance, Weighted Average Remaining Contractual Term	5 years 3 months 25 days
Vested and expected to vest, end of period, Weighted Average Remaining Contractual Term	5 years 3 months 0 days
Exercisable, end of period, Weighted Average Remaining Contractual Term	4 years 6 months 22 days
Outstanding, end of period, Aggregate Intrinsic Value	$103,208,779
Vested and expected to vest, end of period, Aggregate Intrinsic Value	101,160,091
Exercisable, end of period, Aggregate Intrinsic Value	$65,901,298

Sharedbased_Compensation_Stock

Shared-based Compensation (Stock Option Assumption) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Average expected term (years)	4 years	5 years	5 years
Risk-free interest rate	1.30%	0.80%	0.90%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	32.00%	33.00%	33.00%

Sharedbased_Compensation_Summa1

Shared-based Compensation (Summary Of Restricted Stock Units and Performance Stock Units Activity) (Details) (Restricted Stock Units (RSUs) and Performance Stock Units (PSUs), USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)
Number of Shares
Outstanding, Number of Shares, Beginning Balance	2,262,428	2,423,612	2,629,782
Granted, Number of Shares	609,357	1,543,221	1,087,171
Forfeited, Number of Shares	-374,463	-899,954	-362,682
Vested, number of shares	-842,569	-804,451	-930,659
Outstanding, Number of Shares, Ending Balance	1,654,753	2,262,428	2,423,612
Vested and expected to vest, end of period, Number of Shares	1,444,957
Aggregate Intrinsic Value
Outstanding, Aggregate Intrinsic Value, end of period	$120,623,231
Vested and expected to vest, Aggregate Intrinsic Value, end of period	$99,516,485

Other_Income_Net_Schedule_Of_C

Other Income, Net (Schedule Of Components Of Other (Income) Expense, Net) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Component of Operating Income [Abstract]
Watson litigation settlement income, net	$0	($50,400)	$0
Net gain on sale of certain early-stage drug discovery and development assets	-5,200	0	0
Foreign currency (gain) loss, net	-10,054	-21	0
Equity earnings from unconsolidated subsidiaries, net	-8,325	-1,482	-386
Other miscellaneous	-8,745	-1,156	-235
Other income, net	($32,324)	($53,059)	($621)

Income_Taxes_Components_Of_Inc

Income Taxes (Components Of Income Before Income Tax By Geography) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Domestic	($33,459)	$385,366	($12,049)
International	133,334	0	0
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$99,875	$385,366	($12,049)

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Current, Federal	$30,385	$93,212	$102,695
Current, Foreign	-2,550	0	0
Current, State	16,270	10,980	14,098
Current, Total	44,105	104,192	116,793
Deferred, Federal	-31,922	36,369	-79,313
Deferred, Foreign	-620	0	0
Deferred, State	-7,740	-1,336	-4,474
Deferred, Total	-40,282	35,033	-83,787
Excess tax (shortfall) benefit of stock options exercised	33,501	4,315	2,530
Valuation Allowance	943	202	3,286
INCOME TAX	$38,267	$143,742	$38,822

Income_Taxes_Schedule_Of_Recon

Income Taxes (Schedule Of Reconciliation Of Income Tax At Federal Statutory Income Tax Rate To Total Income Tax Provision) (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal income tax at the statutory rate		$34,956	$134,878	($4,218)
State income tax, net of federal benefit		10,095	5,554	10,697
Research and development credit		-2,535	-6,002	0
Uncertain tax positions		2,494	2,779	13,741
Tax effect of foreign operations		-52,246	0	0
Change in valuation allowance		-952	0	0
Effect of permanent items:
Branded prescription drug fee	25,000	16,336	12,060	6,108
Domestic production activities deduction		5,468	-6,835	-2,859
Transaction-related expenses		5,889	2,643	0
Fines and penalties		0	17	11,176
Excise tax		15,398	0	0
Executive compensation limitation		3,590	417	1,286
Extinguishment of convertible debt		5,802	0	0
Share based compensation		2,227	0	0
Audit settlements		-1,875	0	0
Other		3,320	-1,769	2,891
INCOME TAX		$38,267	$143,742	$38,822

Income_Taxes_Schedule_Of_Defer

Income Taxes (Schedule Of Deferred Tax Assets And Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Accrued expenses	$644,858	$410,750
Compensation related to stock options	15,415	20,685
Net operating loss carryforward	108,823	71,544
Loss on capital assets	10,642	9,112
Research and development credit carryforward	13,085	13,905
Uncertain tax positions	6,574	8,659
Prepaid royalties	5,190	0
Tax credit carryforwards	12,249	110
Other	23,299	40,943
Total gross deferred income tax assets	840,135	575,708
Deferred tax liabilities:
Depreciation and amortization	-894,714	-556,086
Non-cash interest expense	-6,012	-5,427
Other	-9,492	0
Total gross deferred income tax liabilities	-910,218	-561,513
Valuation allowance	-40,646	-17,854
Net deferred income tax liability	($110,729)	($3,659)

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	($943,000)	($202,000)	($3,286,000)
Deferred Tax Assets, Valuation Allowance	40,646,000	17,854,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	952,000	0	0
Undistributed Earnings of Foreign Subsidiaries	111,800,000
Percentage of tax benefit likelihood to be realized upon examination	50.00%
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense (Benefit)	-4,600,000	900,000	-500,000
Total Unrecognized Tax Benefits Including Interest And Penalties	115,804,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		109,200,000
Income Tax Expense
Operating Loss Carryforwards [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	22,800,000
Other Expense
Operating Loss Carryforwards [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	21,900,000
Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	431,600,000
Canada Revenue Agency
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	45,200,000
Tax Credit Carryforward, Amount	$25,300,000

Income_Taxes_Schedule_Of_Recon1

Income Taxes (Schedule Of Reconciliation Of Change In Uncertain Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized Tax Benefits, Beginning Balance	$58,629	$58,917	$40,628
Gross additions for current year positions	6,008	2,076	24,088
Gross additions for prior period positions	873	4,618	285
Gross reductions for prior period positions	-6,647	-2,390	-632
Decrease due to lapse of statute of limitations	-5,067	-4,592	-5,452
Decrease due to settlements	-597
Additions related to acquisitions	54,750
Currency translation adjustment	-2,619
Unrecognized Tax Benefits, Ending Balance	105,330	58,629	58,917
Accrued interest and penalties	10,474
Total UTB balance including accrued interest and penalties	115,804
Current portion (included in accrued expenses)	0
Non-current portion (included in other liabilities)	$115,804

Net_Loss_Income_Per_Share_Reco

Net (Loss) Income Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net (Loss) Income Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
INCOME (LOSS) FROM CONTINUING OPERATIONS	$19,481	$48,953	$40,575	($47,401)	$10,596	$91,680	$80,688	$58,660	$61,608	$241,624	($50,871)
Less: Net (loss) income from continuing operations attributable to noncontrolling interests									-399	0	0
Income (loss) from continuing operations attributable to Endo International plc ordinary shareholders									62,007	241,624	-50,871
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	-72,724	-301,002	-20,189	-385,877	-772,339	-37,065	-32,577	-32,057	-783,326	-926,963	-689,466
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	($53,483)	($252,084)	$21,160	($436,912)	($775,910)	$40,223	$34,999	$15,349	($721,319)	($685,339)	($740,337)
For basic per share data—weighted average shares	153,772	153,309	152,368	128,135	115,105	114,327	112,531	111,216	146,896	113,295	115,719
Dilutive effect of ordinary share equivalents									2,600	2,453	0
Dilutive effect of 1.75% Convertible Senior Subordinated Notes and warrants									7,234	4,081	0
For diluted per share data—weighted average shares	159,213	158,975	163,369	128,135	128,644	120,261	117,221	113,189	156,730	119,829	115,719

Net_Loss_Income_Per_Share_Narr

Net (Loss) Income Per Share (Narrative) (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 09, 2008	Jul. 31, 2014	30-May-14	Sep. 17, 2013
Short-term Debt [Line Items]
Antidilutive shares excluded from calculation	7.4	21.9	26
1.75% Convertible Senior Subordinated Notes due 2015
Short-term Debt [Line Items]
Interest Rate (percent)	1.75%
Convertible notes, maturity date	15-Apr-15
Initial conversion price (in dollars per share)	29.2						$29.20
1.75% Convertible Senior Subordinated Notes due 2015 | Warrants
Short-term Debt [Line Items]
Share issued for repurchase of senior note (shares)	3.4			13	1.4	8.2

Savings_And_Investment_Plan_An1

Savings And Investment Plan And Deferred Compensation Plans (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Savings And Investment Plan And Deferred Compensation [Line Items]
Contributions towards defined contribution Savings and Investment Plan	$7.50	$11.40	$12
Deferred Compensation Plan | Deferred bonus
Savings And Investment Plan And Deferred Compensation [Line Items]
Deferral percentage for employees		50.00%
Deferred Compensation Plan | Deferred restricted stock units
Savings And Investment Plan And Deferred Compensation [Line Items]
Deferral percentage for employees		100.00%
401(k) Restoration Plan | Deferred salary and bonus
Savings And Investment Plan And Deferred Compensation [Line Items]
Deferral percentage for employees		50.00%
Directors Deferred Compensation Plan | Meeting fees, retainer fees, and restricted stock units
Savings And Investment Plan And Deferred Compensation [Line Items]
Defined Contribution Plan Maximum Contribution By Non Employee Directors Percent		100.00%
Endo 401(k) Plan
Savings And Investment Plan And Deferred Compensation [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match		100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		6.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%
Endo 401(k) Plan, Matching Tier One
Savings And Investment Plan And Deferred Compensation [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%
Endo 401(k) Plan, Matching Tier Two
Savings And Investment Plan And Deferred Compensation [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2.00%

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Feb. 24, 2015	Jan. 27, 2015	Jan. 29, 2015	Feb. 10, 2015	Dec. 31, 2014
Subsequent Event | AMS
Subsequent Event [Line Items]
Disposal Group, Expected Sale Price	$1,650,000,000
Expected Proceeds from Divestiture of Businesses	1,600,000,000
Subsequent Event | Maximum | AMS
Subsequent Event [Line Items]
Disposal Group, Expected Milestone Payment	50,000,000
Subsequent Event | 6.00% Senior Notes Due 2025
Subsequent Event [Line Items]
Face value of debt instrument		1,200,000,000
Interest Rate (percent)		6.00%
Debt Instrument, Redemption Price, Percentage		101.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | From February 1, 2020 to and including January 31, 2021
Subsequent Event [Line Items]
Redemption Percentage		103.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | From February 1, 2021 to and including January 31, 2022
Subsequent Event [Line Items]
Redemption Percentage		102.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | From February 1, 2022 to and including January 31, 2023
Subsequent Event [Line Items]
Redemption Percentage		101.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | From February 1, 2023 and thereafter
Subsequent Event [Line Items]
Redemption Percentage		100.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | Prior To February 1, 2018
Subsequent Event [Line Items]
Debt Instrument, Redemption Price, Percentage		106.00%
Subsequent Event | 6.00% Senior Notes Due 2025 | Prior To February 1, 2018 | Maximum
Subsequent Event [Line Items]
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed		35.00%
Auxilium Pharmaceuticals, Inc. | Subsequent Event
Subsequent Event [Line Items]
Total acquisition consideration			3,000,000,000
Payments to acquire business			790,800,000
Shares, Outstanding			54.97
Business Combination, Termination Fee			28,400,000
Auxilium Pharmaceuticals, Inc. | Subsequent Event | 1.50% Convertible Senior Notes Due 2018
Subsequent Event [Line Items]
Face value of debt instrument			350,000,000
Interest Rate (percent)			1.50%
Convertible notes, convertible amount per share (in dollars per share)			$9.88
Debt Instrument, Convertible, Conversion Ratio			0.343
Auxilium Pharmaceuticals, Inc., Consideration Option One | Subsequent Event
Subsequent Event [Line Items]
Percentage Of Common Shares Outstanding			94.90%
Business combination, consideration, equity, ratio			0.488
Auxilium Pharmaceuticals, Inc., Consideration Option One, Prorated For Oversubscription [Member] | Subsequent Event
Subsequent Event [Line Items]
Business combination, consideration, equity, ratio			0.3448
Business acquisition, share price (in dollars per share)			$9.75
Auxilium Pharmaceuticals, Inc., Consideration Option Two | Subsequent Event
Subsequent Event [Line Items]
Percentage Of Common Shares Outstanding			0.40%
Business combination, consideration, cash, percent			100.00%
Business acquisition, share price (in dollars per share)			$33.25
Auxilium Pharmaceuticals, Inc., Consideration Option Three | Subsequent Event
Subsequent Event [Line Items]
Percentage Of Common Shares Outstanding			4.70%
Business combination, consideration, equity, ratio			0.244
Business acquisition, share price (in dollars per share)			$16.63
Litha Healthcare Group Limited | Paladin Labs Inc.
Subsequent Event [Line Items]
Percentage of equity method of investments in subsidiaries					70.30%
Escrow deposit					40,200,000
Litha Healthcare Group Limited | Subsequent Event | Paladin Labs Inc.
Subsequent Event [Line Items]
Total acquisition consideration				$40,100,000
Business acquisition, share price (in dollars per share)				$0.24

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Schedule Of Quarterly Financial Data) (Details) (USD $)	3 Months Ended								12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Data [Abstract]
Total revenues	$662,877,000	$654,116,000	$592,848,000	$470,842,000	$452,587,000	$550,075,000	$586,177,000	$535,842,000
Gross profit	288,697,000	312,923,000	289,403,000	258,163,000	239,860,000	328,174,000	351,547,000	318,497,000
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	19,481,000	48,953,000	40,575,000	-47,401,000	10,596,000	91,680,000	80,688,000	58,660,000	61,608,000	241,624,000	-50,871,000
Discontinued operations, net of tax	-72,724,000	-301,002,000	-20,189,000	-385,877,000	-772,339,000	-37,065,000	-32,577,000	-32,057,000	-783,326,000	-926,963,000	-689,466,000
Net loss attributable to Endo International plc ordinary shareholders	-53,483,000	-252,084,000	21,160,000	-436,912,000	-775,910,000	40,223,000	34,999,000	15,349,000	-721,319,000	-685,339,000	-740,337,000
Continuing operations, basic (usd per share)	$0.13	$0.32	$0.27	($0.37)	$0.09	$0.80	$0.72	$0.53	$0.42	$2.13	($0.44)
Discontinued operations, basic (usd per share)	($0.48)	($1.96)	($0.13)	($3.04)	($6.83)	($0.45)	($0.41)	($0.39)	($5.33)	($8.18)	($5.96)
Basic (usd per share)	($0.35)	($1.64)	$0.14	($3.41)	($6.74)	$0.35	$0.31	$0.14	($4.91)	($6.05)	($6.40)
Continuing operations, diluted (usd per share)	$0.12	$0.31	$0.25	($0.37)	$0.08	$0.76	$0.69	$0.52	$0.40	$2.02	($0.44)
Discontinued operations, diluted (usd per share)	($0.46)	($1.90)	($0.12)	($3.04)	($6.11)	($0.43)	($0.39)	($0.38)	($5)	($7.74)	($5.96)
Diluted (usd per share)	($0.34)	($1.59)	$0.13	($3.41)	($6.03)	$0.33	$0.30	$0.14	($4.60)	($5.72)	($6.40)
Weighted average shares—Basic (shares)	153,772	153,309	152,368	128,135	115,105	114,327	112,531	111,216	146,896	113,295	115,719
Weighted average shares—Diluted (shares)	159,213	158,975	163,369	128,135	128,644	120,261	117,221	113,189	156,730	119,829	115,719
Inventory Step Up Cost	25,500,000	17,400,000	19,100,000	3,600,000					65,582,000	0	880,000
Revenue Recognition, Milestone Method, Revenue Recognized	16,800,000	13,400,000	10,400,000	11,200,000	18,600,000	3,100,000	5,400,000	2,600,000
Business Combination, Acquisition Related Costs	9,800,000	2,700,000	19,600,000	45,300,000	4,100,000	1,500,000	1,600,000	500,000	77,384,000	7,614,000	18,432,000
Asset impairment charges	22,500,000				27,300,000	800,000	2,800,000	1,100,000	22,542,000	32,011,000	72,551,000
Amortization of Intangible Assets	70,900,000	55,400,000	52,800,000	39,700,000	26,500,000	29,500,000	35,600,000	32,000,000	218,712,000	123,547,000	146,898,000
Severance costs	8,700,000	7,500,000	11,400,000	-1,900,000	15,300,000	20,800,000	41,600,000	13,700,000	14,400,000	35,200,000	20,000,000
Legal Fees	35,000,000	3,100,000	4,000,000		9,000,000	-14,600,000	-16,500,000	-18,800,000
Branded prescription drug fee		25,000,000							16,336,000	12,060,000	6,108,000
Excise and Sales Taxes		-1,000,000	-4,700,000	60,000,000
Intangible Asset Amortization And Inventory Step-Up	$9,200,000

SCHEDULE_IIValuation_and_Quali1

SCHEDULE II--Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$5,594	$5,533	$5,255
Additions, Costs and Expenses	165	1,358	2,817
Deductions, Write-offs	-1,840	-1,297	-2,539
Balance at End of Period	$3,919	$5,594	$5,533